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Abstract 
Background 
Dementia is a serious health problem showing an increasing prevalence rate with increasing 
age. It is the main reason for institutionalizing elderly people. Disruptive and agitated 
behaviour affect 30 to 50% of all individuals with dementia at some point in the course of the 
illness. Such behaviour decreases the quality of life of patients and carers, puts heavy strains 
on relatives and professional carers and poses a diagnostic, therapeutic and economic 
challenge. There is a need for new psychopharmacological and non-psychopharmacological 
treatments, because the existing drugs have limited benefits and are associated with poor 
tolerance and serious side effects. Furthermore, there is a need for validated assessment tools 
to evaluate patients before therapy and during follow-up. Given the daily routine in nursing 
homes with many competing demands brief instruments are preferable.  
 
Aims 
The thesis had three aims: 
1) To evaluate the effect of oxcarbazepine (OXC) in the treatment of severe agitation 
and aggression in patients residing in nursing homes with Alzheimer‘s disease or 
vascular dementia or a mixture of both.  
2) To study the psychometric properties of the Norwegian version of the Brief 
Agitation Rating Scale (BARS) by performing a factor analysis on a large sample of 
Norwegian nursing-home patients and testing the reliability and validity on another 
sample. 
3) To test the reliability and validity of the Norwegian version of the Neuropsychiatric 
Inventory, Nursing-home Version (NPI-NH). 
 
Methods 
Ad 1) We conducted an eight-week, multicentre, randomised, double-blind, placebo-
controlled trial carried out independently of the pharmaceutical industry, randomizing 103 
patients in 35 nursing homes (NH) either to placebo or OXC. The change in agitation and 
aggression sub-scores on the NPI-NH was the primary outcome. The secondary outcomes 
were the change in the carers‘ total burden score measured by the NPI-NH and change in the 
BARS total score. 
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Ad 2) The BARS is a short form of the Cohen-Mansfield Agitation Inventory (CMAI) that 
measures agitation in dementia. For the study of the reliability and validity of the BARS we 
investigated the test-retest reliability and internal consistency of the BARS on 56 nursing-
home patients, and the validity of the BARS on 138 patients. In the validity study, we 
compared the BARS scores with the NPI-NH sub-scale Agitation/Aggression (NPI-NH/AA) 
and the Cornell Scale for Depression in Dementia sub-scale Agitation (CSDD/A). 
 Data used to perform a factor analysis came from a study that investigated the use of 
restraints and surveillance in Norwegian nursing-homes, published by Øyvind Kirkevold et al. 
(2004). 1,870 nursing-home patients were included in the analyses. 
 
Ad 3) The psychometric properties of the NPI-NH were tested by establishing inter-rater 
reliability using kappa statistics. Fifty patients were included and examined by a physician, 
who also rated the patients‘ behaviour using BEHAVE-AD and the Cornell scale. Concurrent 
validity of the NPI-NH and BEHAVE-AD was analysed. 
 
Results 
Ad 1) After eight weeks, no statistically significant differences were found between the two 
groups for all outcomes. The placebo group showed a 36.3% reduction in agitation and 
aggression score on the NPI-NH compared to 39.0% in the OXC group. A trend was observed 
in favour of the OXC group in the reduction of the score on the BARS (p = 0.07).  
 
Ad 2) In the reliability study, the mean BARS score was 24.2 (SD 12.6), Cronbach‘s alpha 
was 0.76; the test-retest reliability showed a Spearman‘s rho of 0.64, and increased to 0.86 
when we deleted the item ‗complaining‘. Mean score in the validation study was 19.7 (SD 
11.5). The BARS score correlated with the NPI-NH/AA and the CSDD/A scores, Spearman‘s 
rho 0.55 and 0.52 respectively. These correlations changed when controlling for the Clinical 
Dementia Rating Scale (CDR) stages. The highest correlations between the BARS and the 
NPI-NH/AA and the BARS and the CSDD/A were found among patients with CDR score 2. 
Using an eigenvalue of ≥1, the exploratory factor analysis of the BARS revealed 
clusters in three dimensions of agitation. The first factor was named ‗physically aggressive 
behaviour‘, the second ‗physically non-aggressive behaviour‘ and the third ‗verbal agitation‘. 
Cronbach‘s alpha was 0.70, 0.78 and 0.46 respectively. Linear regression analysis showed 
that less able functioning in the activities of daily living (ADL) was positively associated with 
physically aggressive behaviour and verbal agitation, whereas increased severity of dementia 
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and better ADL functioning were associated with physically non-aggressive behaviour. In 
addition, verbal agitation had a positive relationship with a higher number of drugs taken per 
day.  
 
AD 3) Internal consistency of NPI-NH, as measured by Cronbach‘s alpha was above 0.8. 
Inter-rater reliability was, except for one item, between kappa 0.85 and 1.0 across assessors 
with different levels of health education. All correlations between the NPI-NH and the 
BEHAVE-AD items were significant, ranging from 0.38 to 0.72. The weakest correlations 
were between items assessing affective and anxiety symptoms. 
 
Conclusions 
We could not find any statistically significant difference between the OXC group and the 
placebo, but, interestingly, the outcomes for reduction of agitation measured with the NPI-NH 
and the BARS differed. The Norwegian version of the BARS is a reliable and valid 
instrument to measure agitation in dementia and it measures three dimensions of agitation: 
physically aggressive behaviour, physically non-aggressive behaviour and verbal agitation. 
The Norwegian version of the NPI-NH is a reliable and valid instrument for assessing the 
syndromes of behavioural and psychological symptoms in nursing-home residents, but it is 
not a specific instrument for the measurement of agitation. 
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Sammendrag (Norwegian summary) 
 
Bakgrunn 
Forekomst av demens øker med alderen. Demens er et alvorlig helseproblem og den 
hyppigste årsaken til innleggelse på sykehjem. Omtrent 30 til 50% av alle som får en 
demenssykdom utvikler en eller annen form av uro (agitasjon) i sitt sykdomsforløp. Dette 
bidrar til redusert livskvalitet hos pasientene, pårørende og helsepersonell som har omsorg for 
dem. Det kan bli til en stor belastning for pårørende og pleiepersonell og en diagnostisk, 
terapeutisk og økonomisk utfordring. Vi trenger psykofarmakologiske og ikke-
farmakologiske behandlingsalternativer til de eksisterende medikamentene, fordi de har 
begrenset effekt, tåles dårlig og kan føre til alvorlige bivirkninger.  
Det er behov for gyldige verktøy som måler agitasjon for å kunne bedre evaluere 
pasientene før behandling og følge dem opp under behandling, ikke bare i klinisk praksis men 
også i forskningssammenheng. De daglige rutinene på sykehjem med sine mange 
konkurrerende krav fører til at kortversjoner av slike instrumenter foretrekkes.  
 
Formål 
Avhandlingen har tre formål: 
1) Evaluere effekten av okskarbazepin (OXC) i behandling av alvorlig agitasjon og 
aggresjon hos pasienter på sykehjem med Alzheimers sykdom eller vaskulær 
demens eller en blandingsform av begge.  
2) Studere de psykometriske egenskapene av den norske versjonen av Brief Agitation 
Rating Scale (BARS): Vi testet påliteligheten/repeterbarheten (reliabiliteten) og 
gyldigheten (validiteten) i et utvalg av norske sykehjemspasienter og gjennomførte 
en faktoranalyse av BARS it et annet utvalg. 
3) Teste reliabilteten og validiteten av den norske versjonen av Neuropsychiatric 
Inventory, Nursing-home Version (NPI-NH). 
 
Metoder 
Ad 1) Vi gjennomførte en dobbelblind, placebokontrollert multisenterstudie uavhengig av 
farmakologisk industri ved å randomisere 103 pasienter i 35 sykehjem enten til placebo eller 
OXC. Forandringen i agitasjons- og aggresjonsskårene på NPI-NH var det primære 
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endepunktet. De sekundære endepunktene var forandringen på pleiernes total belastning målt 
med NPI-NH og forandringen i sum skåren av BARS. 
 
Ad 2) BARS er en kortversjon av Cohen-Mansfield Agitation Inventory (CMAI) som måler 
agitasjon ved demens. Vi undersøkte test-retest reliabiliteten og den indre konsistensen hos 56 
sykehjemspasienter. Validitetsundersøkelsen utførte vi hos 138 pasienter. I 
validitetsundersøkelsen sammenliknet vi BARS skårene med NPI sub skala 
agitasjon/aggresjon og med Cornell Scale for Depression in Dementia: sub skala agitasjon. 
 Dataene som vi brukte for å gjennomføre en faktoranalyse kom fra en studie som 
undersøkte bruken av tvang og overvåkning i norske sykehjem og som ble publisert av 
Øyvind Kirkevold et al. (2004). 1,870 sykehjemspasienter ble inkludert i analysen. 
 
Ad 3) De psykometriske egenskapene av NPI-NH ble testet. Vi undersøkte inter-rater 
reliabiliteten mellom fagpersoner med forskjellige nivåer av helseutdannelse. Til dette 
formålet brukte vi kappa-statistikk. Femti pasienter ble inkludert og undersøkt av en lege som 
også skåret pasientenes atferd med BEHAVE-AD- og depresjonen med Cornell-skalaen. NPI-
NH ble validert mot BEHAVE-AD. 
 
Resultater 
Ad 1) Etter åtte uker fant vi ingen statistisk signifikant forskjell mellom placebo- og OXC-
gruppen. Placebogruppen viste en 36.3% reduksjon av agitasjons- og aggresjonsskåren på 
NPI-NH sammenliknet med 39.0% i den OXC-gruppen. Man kunne observere en trend til 
fordel for OXC- gruppen ved reduksjon av BARS-totalskåret (p = 0.07).  
 
Ad 2) I reliabilitetsstudien var den gjennomsnittlige BARS-skåren 24.2 (SD 12.6), 
Cronbach‘s alpha var 0.76. Test-retest reliabiliteten målt med Spearman‘s rho var 0.64, og 
økte til 0.86 når vi slettet symptomet ‖klaging‖. Gjennomsnittsskåren av BARS i 
validitetsstudien var 19.7 (SD 11.5). Spearman‘s rho mellom BARS og NPI-NH, subskåren 
agitasjon/aggresjon, og agitasjonsspørsmålet i Cornell-skalaen var henholdsvis 0.55 og 0.52. 
Disse korrelasjonsverdiene forandret seg når vi kontrollerte for demensgraden målt med 
kliniske demensvurderinsgskalaen (KDV). Høyest korrelasjonen fant vi mellom BARS og 
NPI-NH/AA og mellom BARS og CSDD/A hos pasienter med KDV-skåre 2. 
I faktoranalysen av BARS fant vi at skalaen består av tre komponenter. Den første 
faktoren kalte vi fysisk aggressiv atferd, den andre fysisk ikke-aggressiv atferd og den tredje 
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verbal agitasjon. Cronbach‘s alpha var henholdsvis 0.70, 0.78 og 0.46.  En lineær 
regresjonsanalyse viste at dårligere fungering i dagliglivets aktiviteter (ADL) var relatert til 
fysisk aggressiv atferd og verbal agitasjon, mens økt alvorlighetsgrad av demens og bedre 
ADL-funksjon var assosiert med fysisk ikke-aggressiv atferd. I tillegg fant vi en positiv 
sammenheng mellom verbal agitasjon og mer bruk av legemidler. 
 
Ad 3) Cronbach‘s alpha, som mål for den interne konsistensen av NPI-NH var 0.8. 
Kappaverdiene var, med unntak for en variabel, mellom 0.85 og 1.0 når man sammenliknet 
evalueringen utført av personer med forskjellig helseutdanning. Korrelasjonene mellom 
leddene i NPI-NH og BEHAVE-AD var mellom 0.38 og 0.72. De svakeste korrelasjonene 
fant vi mellom symptomer på depresjon og angst.  
 
Konklusjoner 
Vi fant ingen statistisk signifikant forskjell mellom OXC- og placebogruppen, men interessant 
var det at resultatene målt med NPI-NH og BARS var så forskjellige. Den norske versjonen 
av BARS er reliabel og valid og måler tre dimensjoner av agitasjon: fysisk aggressiv atferd, 
fysisk ikke-aggressiv atferd og verbal agitasjon. NPI-NH er også reliabel og valid når man 
undersøker atferds- og psykologiske symptomer hos sykehjemspasienter, men er ikke et 
verktøy som spesifikt måler agitasjon. 
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AD  Alzheimer‘s Disease 
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1. Introduction 
Dementia is a devastating illness with an increasing prevalence, mainly because of the aging 
of the population 
1-4
. Dementia has emerged as the most potent risk factor for 
institutionalisation in a 12-year community-based epidemiological study 
5
. Besides the impact 
of dementia on the health and quality of life (QoL) of patients and their relatives and carers 
6-
11
, which is a hidden cost, many countries are confronted with rising actual costs of dementia 
care 
12
. 
  Syndromes of behavioural and psychological symptoms are very common in dementia 
13-17
. Agitation is highly prevalent in nursing-home patients 
13 18 19
, is highly disabling for the 
patient, is one of the most distressing aspects of dementia, and is one of the main causes of 
institutionalisation of elderly people 
18 20-23
. Different scales for the assessment of 
psychological and behavioural symptoms have evolved, such as the Cohen-Mansfield 
Agitation Inventory (CMAI) 
24
, the Behavioural Pathology in Alzheimer‘s Disease 
(BEHAVE-AD) rating scale 
25
 and the Neuropsychiatric Inventory (NPI) 
26
 as the ones most 
used in research. The mentioned scales measure different aspects of agitation as reflected in 
the choice of items. This could also be seen in our study investigating the effect of 
oxcarbacepine (OXC), where NPI scores and BARS scores differed widely (see Paper I, 
figure 2a and 2b). 
  Agitation and other neuropsychiatric symptoms lead frequently to the use of 
psychotropic drugs and, in Norwegian nursing homes, especially antipsychotics 
27-29
. 
Antipsychotics have only a modest benefit, and patients treated with such drugs run a definite 
risk of serious and even irreversible side-effects and higher mortality 
30
. Therefore, treatment 
with antipsychotics is not an ideal solution for treating behavioural and psychological 
symptoms of dementia 
31-34
. 
  A review of pharmacological treatment of agitation and aggression concluded that no 
treatment may be preferable and the effect sizes have been modest at best 
35
. Carbamazepine 
was effective in treating agitation and aggression in one study 
36
, whereas no effect was found 
in another study 
37
. Studies investigating the efficacy of other anti-epileptic drugs, such as 
valproate and divalproex sodium, have reported conflicting and inconclusive results 
38-42
. 
  To find a better tolerated alternative to the existing psychopharmacological 
medications, we conducted a study to evaluate whether OXC is effective in the treatment of 
agitation and aggression in institutionalized patients with Alzheimer‘s disease or vascular 
dementia. 
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2. Dementia 
2.1. Prevalence, incidence and survival 
2.1.1. Prevalence     
The study by Plassman et al. 
4
 stated that the prevalence rate of dementia in the USA 
increased with age, from 5.0% of those aged 71-79 years to 37.4% of those aged 90 and older. 
A meta-analysis of different prevalence studies in Europe came to the conclusion that the 
overall European prevalence for the five-year age groups from 60 to 94 years, were 1.0, 1.4, 
4.1, 5.7, 13.0, 21.6 and 32.2%, respectively 
43
. A study conducted in England and Wales 
(Table 2.1.1), the ―MRC CFA Study‖ (1998), included 10,377 persons aged 65 and above, 
and one in Canada, ―Canadian Study of Health and Aging‖ (1994), included 10,263 persons 
aged 65 and above. These large-scale studies reported prevalence data that are generalizable 
for England, Wales and Canada. Results from the British study are quite similar to the results 
of the Canadian study. The overall prevalence of dementia in persons 65 years and over was 
6.6% in England and Wales. The figures for Canada are pooled to 8% for all individuals over 
age 65 and 35% of those older than age 85. Lobo et al. 
44
 undertook a collaborative study 
(EURODEM) of 11 population-based cohorts carried out in eight European countries and 
found that there were no important differences in the age-specific prevalence between the 
studies or between the countries. 
 
Table 2.1.1.  Results of the prevalence study from England and Wales (MRC CFA Study,  
                      1998). 
 
Prevalence of dementia by age and sex (%)  (Pooled results from five centres of the 
Medical Research Council Cognitive Function and Ageing Study) 
Age-group Men (%) Women (%) 
65-69 1.4 1.5 
70-74 3.1 2.2 
75-79 5.6 7.1 
80-84 10.2 14.1 
85+ 19.6 27.5 
 
 Estimates of the prevalence of dementia in Norway are based on extrapolation from 
international studies 
45-47
 as well as results from a Norwegian study 
48 49
. Table 2.1.2 presents 
the prevalence data for Norway (Oslo) compared with Rotterdam and the mean of the eight 
European countries that participated in the EURODEM study. 
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Table 2.1.2.  Prevalence of dementia in Norway (Oslo) compared to Rotterdam and  
                      European countries (adapted from Engedal et al. 2004)    
                  
Age 
(years) 
Rotterdam 
(%) 
EURODEM 
  ♂    (%)    ♀ 
Oslo 
(%) 
65-69  0.9 1.6 1.0  
70-74 2.1 2.9 3.1  
75-79 6.1 5.6 6.0 10.1 
80-84 17.6 11.0 12.6 16.7 
85-89 31.7 12.8 20.2 26.2 
90+ 40.7 22.1 30.8 28.3 
 
2.1.2. Incidence 
The incidence and risk for dementia were assessed in a large community-based prospective 
cohort study in Rotterdam with an average follow-up period of 2.1 years 
47
. Overall, the
 
incidence rate per 1,000 person-years was 7.7 for Alzheimer's
 
disease and 1.5 for vascular 
dementia. The age-specific incidence rates were similar in men and women, continued to 
increase after the age of 84 years, and remained stable over time for both dementia and AD 
50
. 
Incidence rates for dementia and AD increase across the 5-year age groups; AD rates rise 
from 2.8 per 1000 person-years (age group, 65-69 years) to 56.1 per 1000 person-years in the 
older than 90-year age group 
51
. 
2.1.3. The number of patients with dementia worldwide in the years to come 
Wimo et al. 
52
 estimated a considerable increase in the number of elderly patients with 
dementia worldwide from 25 million in the year 2000 to 63 million in 2030 (41 million in less 
developed regions) and to 114 million in 2050 (84 million in less developed regions). Ferri et 
al. 
3
 reported that 24.3 million people have dementia today, with 4.6 million new cases of 
dementia every year (one new case every 7 seconds). Wancata et al. 
53
 calculated the 
prevalence of dementia in Europe for the period 2000-2050. The number of dementia cases in 
the year 2000 was 7.1 million. Within the next 50 years, this number is expected to rise to 
about 16.2 million dementia sufferers. The number of new dementia cases per year is 
expected to increase from about 1.9 million in the year 2000 to about 4.1 million in the year 
2050.  
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2.1.4. Survival 
Xie et al. 
54
 used the same cohort from England and Wales, as already reported, to investigate 
the median survival time: ―Estimated median survival time from onset of dementia to death 
was 4.1 years for men and 4.6 years for women. There was a difference of nearly seven years 
in survival between the younger old and the oldest people with dementia: 10.7 for ages 65-69; 
5.4 for ages 70-79; 4.3 for ages 80-89, and 3.8 years for ages > or=90. Significant factors that 
predicted mortality in the presence of dementia during the follow-up included sex, age of 
onset, and disability.‖  
  The Cardiovascular Health (CHS) Cognition Study showed a more differentiated 
picture, making the distinction in survival time dependent on what kind of dementia the 
patients had. Adjusted accelerated life models estimated median survival time from the onset 
of dementia to death as 3.9 years for those with vascular dementia (VaD), 7.1 years for AD, 
5.4 years for mixed dementia, and 11 years for matched controls with normal cognition 
55
. 
Mild Cognitive Impairment (MCI), see chapter 2.4., in the CHS-Cognition Study had a 
prevalence rate of 22% among the participants aged 75 years or older 
56
.  
 2.2. Risk factors for dementia 
2.2.1. Demographic risk factors    
Old age is the most important risk factor for AD. A meta-analysis of incidence studies 
showed that both AD and dementia continue to increase with increasing age up to the age 98, 
although the rate of acceleration slows down 
57
. However, it looks as though dementia is an 
inevitable disorder as a person gets older 
58
. 
Whether or not gender is an independent risk factor has been discussed. One meta-
analysis found women had a higher incidence of AD than men, but not a higher incidence of 
dementia in general 
57
. Another study found that the risk of getting AD was not essentially 
higher for women than men 
59
. 
Is ethnicity a risk factor? Jorm and Jolley 
60
 found in a meta-analysis that dementia has 
a higher incidence in Europe than in Far East. East Asia also tended to have a lower incidence 
of AD. Whether that is due to ethnicity, genetics or other factors, like the environment, 
differences in nutrition or socio-cultural aspects, is not clear.  
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2.2.2. Vascular risk factors 
Among others, the Honolulu-Asia Aging Study (HAAS) 
61-63
 and a prospective study in 
Sweden 
64
 found good evidence that hypertension in middle-age increases the risk for AD 10 - 
15 years later. A prospective, population-based study from Finland 
65
 showed that middle-
aged people with raised systolic blood pressure or high serum cholesterol concentration had a 
significantly higher risk of Alzheimer's disease in later life, even after adjustment for age, 
body mass index, education, vascular events, smoking status and alcohol consumption, than 
those with normal systolic blood pressure (odds ratio 2.3) or serum cholesterol (odds ratio 
2.1). Participants with both of these risk factors in midlife had a significantly higher risk of 
developing Alzheimer's disease than those with either of the risk factors alone (odds ratio 
3.5). Diastolic blood pressure in midlife had no significant effect on the risk of Alzheimer's 
disease. 
  A systematic review and meta-analysis 
66
 found a significantly increased risk of 
Alzheimer's disease with current smoking and a likely but not significantly increased risk of 
vascular dementia, unspecified dementia and cognitive decline. Neither review found clear 
relationships with former smoking.  
  From the Framingham study 
67
, it could be concluded that the risk for stroke is equal 
to or greater than the lifetime risk (LTR) of AD. The LTR of AD at age 65 approximated 1 in 
5 for women and 1 in 10 for men. Women had a higher risk because of their longer life 
expectancy. Schneider et al. 
68
 investigated the effect of sub-cortical infarcts on the 
development of dementia. After controlling for cortical infarcts and AD pathology, sub-
cortical infarcts, present in 39 of 53 (73.6%) subjects with infarcts, increased the odds of 
dementia almost 4-fold and reduced cognitive function by more than a third of a unit. It may 
be hypothesised that there are two main pathways to AD 
69
: in one, the vascular disease is an 
essential contributor, and in the other it is a multi-domain, but mainly genetic, pathway. In a 
general community-dwelling population, those with dementia most often have multiple brain 
pathologies, which greatly increases the odds of dementia. Knopman et al. 
70
 found in a 
fourteen-year longitudinal study that the vascular risk factors diabetes and hypertension, a 
history of stroke itself, and apolipoprotein E epsilon 4 (APOE ε4) genotype independently 
contribute to cognitive decline in late middle age and the early years of old age. 
 Hypercholesterolemia in midlife has been associated with an increased risk for 
dementia in cohort studies 
65 71
. Midlife serum total cholesterol was associated with an 
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increased risk of AD and VaD 
72
. Even moderately elevated cholesterol increased the risk of 
dementia.  
 Diabetes, especially type II (DM), has also been found to increase the risk for 
dementia in general and, more specifically, in AD 
73
. Kopf and Frölich 
74
 reviewed 11 studies 
that investigated diabetes as a risk factor for AD. They concluded that DM is likely to 
increase the risk of Alzheimer's disease. The association of Alzheimer's disease and DM is 
more clear-cut, if mild cases of DM are included in the analysis. Also, biologically there is a 
connection between DM and AD through an enzyme called ‗glycogen synthase kinase 3‘ 
(GSK-3) that mediates the addition of phosphate molecules to certain proteins 
(phosphorylation) and thus inactivates glycogen synthase. This enzyme is ubiquitous in all 
organisms and all body cells and is a factor in regulating insulin signalling. GSK-3 also plays 
a pivotal and central role in the pathogenesis of both sporadic and familial forms of AD. In 
the GSK-3 hypothesis of AD, GSK-3 is central in the (hyper)phosphorylation of the tau-
protein and thus intervenes in the essential transport function of the microtubules, leading 
from the nerve body through the nerve axons to the synapses. Over-activity of GSK-3 
accounts for memory impairment, tau hyper-phosphorylation, increased beta-amyloid 
production and local plaque-associated microglial-mediated inflammatory responses 
75
. 
Interestingly, memory training and physical exercise decrease GSK-3 and, thereby, tau-
phosphorylation. 
   Risk factors may be additive, for example, combining obesity with hypertension and 
high cholesterol led to an OR of 6.2 
76 77
. Luchsinger et al. 
78
 found that the risk of AD 
increased with the number of risk factors (diabetes + hypertension + heart disease + current 
smoking).  
It has also been shown that higher homocystein levels contribute to faster cognitive 
decline 
79-81
. 
  In summary, Lutz Frölich presented an overview of the strength of association 
between risk factors and dementia as representative of the Working Group of the European 
Collaboration on Dementia (EuroCoDe, Alzheimer Europe) at the IPA 2009 in Montreal: 
OR=25 for age, OR=3-4 for genetic risk factors and OR=1.8-2.3 for cardiovascular risk 
factors or lifestyle risk factors, with strong, strong and moderate/insufficient evidence, 
respectively. Coley et al. 
82
 reviewed the epidemiological data and concluded that even if 
there are consistent findings from large observational studies regarding preventive or risk 
factors for dementia, few randomised controlled trials have been designed specifically to 
prove the protective effects of interventions based on such factors for the incidence of 
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dementia. Because of the multi-factorial origin of dementia, it appears that multi-domain 
interventions could be suitable for preventive interventions, but designing such trials remains 
very challenging for researchers. It is possible to estimate the risk relative to other individuals 
using variables derived from a population study and adding up to a midlife ‗dementia risk 
score‘ 83, which identifies some excellent treatment targets for prevention, such as 
hypertension, obesity, hypercholesterolemia and lack of physical activity. 
2.2.3. Head injuries  
Head injuries may be a risk factor, but the studies are inconclusive. However, it is interesting 
to note that Mayeux et al. 
84
 found that head injuries are only a risk factor for AD in people 
with the APOE ε4 allele. 
2.2.4. Genetic risk factors  
Some key genes have been identified, which are causal in some early onset cases of AD, i.e., 
producing a higher amount of presenilin-1 (Chromosome 14), presenilin-2 (Chromosome e1), 
and amyloid precursor protein (Chromosome 21). The genetic influence of APOE-ε4 85 is a 
known risk factor for AD 
86
. Age-related memory decline in APOE-ε4 carriers diverges from 
that of non-carriers before the age of 60 years, despite ongoing normal clinical status 
87 88
. A 
meta-analysis found age-adjusted odds ratios for AD of 2.6 for ε2/ε4 heterozygotes, 3.2 for 
ε3/ε4, and 14.9 for ε4/ε4 homozygotes 89. However, these striking findings need to be put in 
context. Up to 50% of those who are homozygous for ε4 and who live beyond 90 do not 
develop AD and about two-thirds of those who develop AD have no ε4 allele 90.  
  The largest ever Alzheimer‘s genome-wide association study (GWAS) 91 involved 
16,000 individuals, including 6,000 Alzheimer‘s patients. This study replicated the 
established association with the APOE locus and observed two loci not previously associated 
with the disease: the CLU (also known as APOJ) gene and the PICALM gene. These 
associations were replicated in stage 2 (2,023 cases and 2,340 controls), producing 
compelling evidence for association with Alzheimer's disease in the combined dataset. The 
results were compared  to a similar French study of more than 7,000 individuals (2,032 with 
Alzheimer's disease and 5,328 controls), carried out at the National Institute of Health and 
Medical Research in Lille, France, by Philippe Amouyel and colleagues 
92
, which not only 
confirmed the two recently discovered genes but identified a third, CR1.  
Furthermore, Down‘s syndrome is a well-established risk factor causing AD via 
amyloid precursor protein. 
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 2.3. Protective factors 
 
Different preventive or protective factor hypotheses are under scrutiny: genes 
93
, toxic 
hypothesis, psychosocial hypothesis, vascular hypothesis, oxidative stress hypothesis. Many 
different protective factors have been discovered. 
  A higher level of work complexity 
94 95
, education and social relationships 
96 97
 have 
been shown to be protective. The association between low education and dementia is probably 
not explained only by the unhealthy lifestyles of the less educated compared with higher 
educated persons. Higher educated persons may have a greater cognitive reserve that can 
postpone the clinical manifestation of dementia. With appropriate training and practice, adults 
over the age of 65 can significantly improve their memory, concentration, and problem-
solving capacity, according to the findings of the Advanced Cognitive Training for 
Independent and Vital Elderly (ACTIVE) clinical trial 
98
.  
  Mental, physical and social components of leisure activities equally contribute to 
decreasing the risk of dementia 
99-101
. Rovio et al. 
102
 showed that leisure-time physical 
activity in middle-age, at least twice a week, was associated with a reduced risk of dementia 
and AD. They could also show that these associations were even more pronounced among the 
APOE-ε4 carriers and that regular physical activity, especially among genetically susceptible 
individuals, may reduce the risk or delay the onset of dementia and AD. The Framingham 
study 
61 103
 and new findings from the Finnish population-based CAIDE study 
104 105
, and 
some others showed that there may be possibilities of preventing AD and VaD, through 
intervention to reduce cardiovascular risk factors. Aerobic fitness and exercise are effective at 
preventing cortical decay and cognitive impairment in older adults 
106
; altogether 16 studies 
have produced moderate to high evidence of this. A study of adults with subjective memory 
impairment with a 6-month programme of physical activity provided a modest improvement 
in cognition over an 18-month follow-up period 
107. A study published in ‗Nature‘ showed a 
positive relationship between exercise and cognitive functioning 
108
. Erickson et al. 
109
 used a 
region-of-interest analysis on magnetic resonance images and found a triple association such 
that higher fitness levels were associated with larger left and right hippocampi after 
controlling for age, sex, and years of education. Larger hippocampi and higher fitness levels 
were correlated with better spatial memory performance. Cognitive training 
110
, in particular 
reasoning training resulted in less functional decline in self-reported instrumental activities of 
daily living (ADL). Compared with the control group, cognitive training resulted in improved 
cognitive abilities five years after the initiation of the intervention. 
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  Longitudinal observations of dietary habits could show that a high intake of 
unsaturated, unhydrogenated fats may be protective against AD, whereas an intake of 
saturated or trans-unsaturated (hydrogenated) fats may increase risk, especially among 
APOE-ε4 carriers 111-114. Combining all the evidence related to dietary interventions to 
prevent dementia (poly-unsaturated fatty acids – PUFA – 6 studies; fish consumption, 4 
studies; Mediterranean diet 1 study; moderate alcohol, 5 studies) resulted in insufficient 
evidence 
115
. 
   Personality traits, such as low neuroticism in combination with high extraversion are 
associated with the lowest dementia risk. However, among socially isolated individuals even 
low neuroticism alone seems to decrease dementia risk 
116
. 
  A 21-year follow up study showed that treatment of midlife vascular risk factors is 
effective in the prevention of AD in later life 
65
. Haag et al. 
117
 evaluated prospectively the 
data from the Rotterdam Study and could show that treating hyperlipidemia with statins helps: 
compared with life-long non-use of cholesterol-lowering drugs, statin use was associated with 
a decreased risk of AD (HR 0.57), but non-statin cholesterol-lowering drug use was not (HR 
1.05). HRs were equal for lipophilic (HR 0.54) and hydrophilic statins (HR 0.54). Haag et al. 
118
 investigated in the same cohort the association between the duration of antihypertensive 
use and the risk of dementia. They observed an 8% risk reduction per year of antihypertensive 
drug use for persons of under 76 years of age, whereas for persons over 75 years this was 4%. 
Equivalent estimates were observed for AD. No apparent differences were observed among 
different types of antihypertensive drugs. Finally, one can summarise that everything that 
works well in the prevention of coronary heart disease may be also effective in the prevention 
of dementia. 
2.4. Different types and stages of dementia 
 
Many of the prevalence studies report specific prevalence rates for different dementia 
disorders. The Rotterdam study 
46
, as an example, showed a prevalence of AD of 72%. The 
lowest rate of AD is 60% 
119
. Next is vascular dementia (VaD) that shows a prevalence of 20-
25%. The third and fourth most prevalent types of dementia are dementia with Lewy bodies 
(DLB) and Frontal / frontotemporal lobe dementia (FTLD), respectively. There are many 
patients who have elements of different dementias at the same time (mixed cases), and this is 
illustrated in Figure 2.4.1. Cerebrovascular disease is now believed to represent a continuum 
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of relevance for AD as well as for VaD 
120-123
. Similarly, AD is frequently noted to be 
accompanied by pathological findings typical for DLB 
124
.                                        
 
 
Figure 2.4.1. Different types of  
dementia, presenting in 
individual patients (+,*, ¤). 
                                                                                                                                                                                                                                                                                              
 
There are many other types of dementia, such as alcohol induced dementia, and different 
types of dementia in later stages of degenerative neurological diseases, such as Parkinson‘s 
disease, where 30-75% of patients are affected 
125, Pick‘s disease, Huntington‘s disease and 
the late stages of infectious diseases, such as Creutzfeld-Jacob‘s disease, herpes, syphilis, 
AIDS, Borrelia, and some endocrinological diseases, such as phenylketonuria, and genetic 
diseases, such as Down‘s syndrome. Other causes may be brain tumours, normal-pressure 
hydrocephalus and traumatic lesions of the brain. This list is by no means complete; it shows 
only that there may be many different reasons for dementia, but 95% of all cases of dementia 
are AD, VaD, DLB, FTLD, and alcohol-related dementias.  
  Besides the different types of dementia, there is a consensus about grading dementia 
in mild, moderate and severe stages, dependent on the performance in the ADL. Long before 
a patient fulfils the criteria for a diagnosis of dementia, there is a preclinical phase or an 
asymptomatic prodromal. This may last as long as 20 years or more (Figure 2.4.2).  
2.4.1. Preclinical AD and MCI 
In recent years, there has been a strong focus on diagnosing the preclinical stages of AD. The 
preclinical phase is characterised by mild impairment in verbal memory, which probably 
reflects damage of the hippocampus, with later involvement of areas governing language, 
spatial orientation, attention, concentration, and psychomotor speed 
126
. In one study, nuns 
who had poor linguistic abilities in their 20s had more senile plaques and neurofibrillary 
tangles in old age 
127
. It is unclear whether these impairments reflect very early manifestations 
of the disease or risk factors for the disease 
128
. Subjective cognitive impairment (SCI) or 
subjective memory impairment (SMI) and mild cognitive impairment (MCI) manifesting itself 
with different types of recognisable deficits, without any decline in functional abilities,
AD PDD
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Figure 2.4.2.  Progression to Alzheimer‘s disease (AD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
may constitute precursors of dementia. There are difficulties with terminology in this area. In 
collaboration with the International Psychogeriatric Association and the World Health 
Organization, a concept of ―ageing associated cognitive decline‖ (AACD) was proposed 129, 
defined as being the normal course of cognitive decline in ageing. As a more specific 
pathological decline with recognizable degrees of objective cognitive impairment, Petersen 
and colleagues described MCI and focused on the amnestic (or memory) form of MCI as 
precursor mostly of AD 
130 131
, see Figure 2.4.3. It has become a generally accepted term (see 
definition in Abbreviations & Definitions). However, it is important to note that there are as 
yet no internationally agreed single sets of diagnostic criteria for MCI, though the broad 
criteria were recommended for use by an international consensus group 
132
. The International 
Psychogeriatric Association‘s Expert Conference on Mild Cognitive Impairment summarized 
the research on MCI in a review, saying that the prevalence in population-based 
epidemiological studies ranges from 3% to 19% in adults older than 65 years. Some people 
with mild cognitive impairment seem to remain stable or return to normal over time, but more 
than half progress to dementia within 5 years. Mild cognitive impairment can thus be 
regarded as constituting a risk for dementia, and its identification could lead to secondary 
prevention by controlling risk factors such as systolic hypertension. The amnestic subtype of 
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mild cognitive impairment has a high risk of progression to Alzheimer's disease, and it could 
constitute a prodromal stage of this disorder. 
 
Figure 2.4.3.  Criteria for MCI (from Petersen, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other definitions and subtypes of mild cognitive impairment need to be studied as potential 
prodromes of Alzheimer's disease and other types of dementia 
133
. 
 
2.5. Diagnosing dementia 
 
The term dementia describes a syndrome characterised by memory impairment, intellectual 
deterioration, decline in performance of the ADL, changes in personality and behavioural 
abnormalities. These symptoms have to be of such severity as to interfere with social 
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activities and occupational functioning. Distinct subtypes of dementia syndromes are 
identifiable from the etiologic factors, clinical presentation, and the pattern of impairment, the 
natural course of the dementia and laboratory or neuroimaging tools. The International 
Classification of Diseases (ICD-10) 
134
 Diagnostic Criteria for Research (DCR-10) 
135
 has 
represented one way of describing dementia (Table 2.5.1).  
 
Table 2.5.1.  Dementia ICD-10. Diagnostic criteria for research (DCR-10).1993.  
                     General criteria for dementia. Shortened version. 
 
The primary requirement for diagnosis is evidence of a decline in both memory and thinking 
that is sufficient to impair the personal activities of daily living. The impairment of memory 
typically affects the registration, storage, and retrieval of new information, but previously 
learned and familiar material may also be lost, particularly in the later stages. The Mini 
Mental State Examination (MMSE) may be of some help in describing the different cognitive 
deficits and offers modest accuracy, and best value for ruling-out a diagnosis of dementia in 
community and primary care 
136
. Dementia is more than problems with memory: there is also 
impairment of thinking and of reasoning capacity, a reduction in the flow of ideas, etc. The 
I    Decline in cognitive function, objectively verified 
 (1) Decline in memory, especially new information 
(2) Decline of at least one other cognitive function as 
  judgment, planning, thinking, abstraction, calculation, orientation, 
 language… 
Mild: Interferes with everyday activities; complicated daily tasks cannot be 
 undertaken 
Moderate: Serious handicap to independent living, needs assistance from another  
            person 
Severe: Continuous care necessary 
 
II   Awareness of the environment (i.e. absence of clouding of consciousness) is preserved.   
   When there are superimposed episodes of delirium, the diagnosis of dementia 
 should  be deferred.  
 
III  Decline in emotional control or motivation, or a change in social behaviour manifest as 
 at least one of the following:  
(1) emotional instability 
(2) irritability 
(3) apathy 
(4) coursing of social behaviour 
 
IV   The symptoms in criterion (I) should have been present for at least 6 months; if the  
            period since the manifest onset is shorter, the diagnosis can be only tentative. 
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processing of incoming information is impaired, in that the individual finds it increasingly 
difficult to attend to more than one stimulus at a time, such as taking part in a conversation 
with several persons, and shifting the focus of attention from one topic to another. If dementia 
is the sole diagnosis, evidence of clear consciousness is required. However, a double 
diagnosis of delirium superimposed upon dementia may be seen. The above symptoms and 
impairments should have been evident for at least 6 months to make a confident clinical 
diagnosis of dementia.  
   
Differential diagnoses: A depressive disorder (F30-F39) has to be considered, which may 
exhibit many of the features of an early dementia, especially memory impairment, slower 
thinking, and lack of spontaneity; delirium (F05); mild or moderate mental retardation (F70-
F71); states of subnormal cognitive functioning attributable to a severely impoverished social 
environment and limited education; iatrogenic mental disorders due to medication (F06). 
 Diagnosing dementia is no longer done only by testing and clinical examinations of 
the patient, as was originally recommended by the National Institute of Neurological and 
Communicative Disorders and Stroke – Alzheimer‘s Disease Related Disorders Association 
(NINCDS-ADRDA), ICD-10 (DCR-10) or the Diagnostic and Statistical Manual of Mental 
Disorders-IV-Text Revision (DSM-IV-TR) 
137
 criteria for AD, the prevailing diagnostic 
standards in research.  Distinctive and reliable biomarkers of AD are now available through 
structural MRI 
138 139
, molecular neuroimaging with PET, and cerebrospinal fluid analyses. 
Consequently, Dubois et al. suggested a revision of the research criteria for the diagnosis of 
Alzheimer's disease. These new criteria are centred on a clinical core of early and significant 
episodic memory impairment in addition to abnormal biomarkers like structural neuroimaging 
with MRI, molecular neuroimaging with PET, and cerebrospinal fluid analysis of beta 
amyloid or tau proteins 
140
. However, much work lies ahead to find criteria that can be proven 
pathologically and will generally be accepted as clinically sound 
141
. The dilemma can be 
exemplified, when comparing different diagnostic criteria for VaD 
142 143. Wetterling‘s group 
144
 compared the criteria for the diagnosis of VaD in an unselected sample of 167 elderly 
patients with probable dementia using different criteria, and as a result they found poor 
concordance. Gold et al. 
145
 reported similar poor results comparing different diagnostic tools.  
   Bringing down the time from onset of the first symptoms until a diagnosis can be 
given, is still a challenge. Indeed, in Europe only about 45% of sufferers get a diagnosis of 
dementia  
146
. Moreover, there is a lack of trained professionals to diagnose and manage the 
disease, a lack of human and financial resources to provide care and services for people with 
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AD (as well as their families) and a lack of infrastructure to deliver the required services. 
These difficulties are compounded by inadequate education of both the general public and 
physicians, which also has implications for the treatment recommendations given at the time 
when a dementia is diagnosed 
147
. Waldemar et al. 
148
 reviewed and discussed existing 
barriers to diagnosis and treatment for patients with dementia in Europe as well as 
approaches to overcome these barriers. The barriers to care are manifold, being present at all 
levels in each society and every country in Europe. Multilevel and multifaceted strategies are 
needed to improve diagnosis and treatments for all patients with cognitive complaints. A 
multidisciplinary approach based on close collaboration between GPs and specialised memory 
clinics may be the ideal model for accurate early diagnosis and subsequently early 
pharmacological and psychosocial interventions. For all healthcare professionals, there should 
be specialised training in dementia and frequently updated practice guidelines to provide the 
framework for standards of care. Culture-sensitive strategies to promote public knowledge 
and destigmatise dementia are essential. Policy makers and authorities should be made aware 
of the benefits of early access to diagnosis and treatment. Green et al. 
149
 measured symptoms 
of anxiety, depression, and test-related distress 6 weeks, 6 months, and 1 year after disclosure 
or non-disclosure. The disclosure of APOE genotyping results to adult children of patients 
with Alzheimer's disease did not result in significant short-term psychological risks. Test-
related distress was reduced among those who learned that they were APOE ε4-negative. 
Persons with high levels of emotional distress before undergoing genetic testing were more 
likely to have emotional difficulties after disclosure. 
2.6. Quality of life in dementia 
The WHO Quality of Life (QoL) working party defined the QoL as individuals‘ perception of 
their position in life in the context of the culture and value systems in which they live, in relations 
to their goals, expectations, standards and concerns. To define the QoL is a difficult task, 
especially in dementia care 
150-154
. Research interest in the field of the QoL in dementia has 
been increasing over at least the past decade. A unifying theme is the influence that Lawton's 
model of the QoL in dementia had on conceptualization of the QoL 
155
. Lawton identified four 
main dimensions that contribute to the QoL: (1) psychological well-being (e.g., positive and 
negative affect), (2) behavioural competence (e.g., cognitive and functional abilities), (3) the 
objective environment (e.g., carers and living situation), and (4) perceived QoL 
156-159
. 
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Whitehouse and Rabins 
160
 argued that the QoL
 
of persons with dementia is not an 
isolated concept to be included
 
as one of many measurements of the benefits of our care, but
 
rather that it is the central goal of our professional activity. 
 
Health-related quality of life (HR-QoL) scales are particularly important in older 
people as global outcome measures for interventions as shown in a systematic literature 
review and a meta-analysis of intervention effectiveness 
161
. Improvement of the QoL in 
dementia should have a high priority in care, treatment and research, as has been stated in a 
position paper from the International Working Group on Harmonization of Dementia Drug 
Guidelines 
162 163
. Addressing well-being has also been highlighted in a Norwegian study 
164
. 
As in other diseases, so in dementia, QoL outcomes have not been prioritised in the past. In 
our OXC study, unfortunately, we did not use a scale measuring QoL outcomes either.  
Needs that are not met lessen the QoL and may be associated with psychological 
problems, such as anxiety and depression. Worse orientation, greater physical dependency, 
pain, depression, and anxiolytic treatment are associated with a worse QoL 
165
. Sensory or 
physical disability (including mobility problems and incontinence), mental health needs, and 
social needs, such as company and daytime activities, were often unmet 
166
. A study
167
 that 
assessed the QoL used as a proxy measure the Alzheimer‘s Disease Related Quality of Life 
(ADRQL) 
168
 and correlated it with the Neuropsychiatric Inventory (NPI) 
169
. They found 
significant negative correlates with delusions, hallucinations, agitation or aggression, 
dysphoria or depression, anxiety, apathy, disinhibition, irritability, and aberrant motor 
behaviour. Agitation and aggression were the neuropsychiatric symptoms that best predicted a 
poor QoL, accounting for 19% of the variance.  
People with dementia can experience a positive QoL throughout the disease, with 
about 50% experiencing no decrease in the QoL, although dementia‘s disabling course 
continues. The QoL can be improved in dementia. Interventions to treat neuropsychiatric 
symptoms, physical health problems and pain may serve to improve or slow the decline in the 
QoL for individuals with dementia. There is no evidence that psychopharmacotherapy 
improves the QoL, but some evidence that psychosocial interventions improve the QoL in 
AD. In a number of studies, the carer‘s QoL is improved by interventions like education and 
long-term emotional support.  
35 
 
3. Behavioural and psychological symptoms in dementia  
    (BPSD) 
3.1. Description  
For some time, behavioural and psychological symptoms, including psychotic symptoms 
170-
173
, have been known to be part of dementia. In Alois Alzheimer‘s classic case description of 
Auguste D, he noted that his patient believed ―that people were out to murder her‖, ―seems to 
have auditory hallucinations‖, ―dragged objects here and there and hid them‖, and that ―often 
she screams for many hours in a horrible voice.‖ Therefore, Alzheimer identified delusions, 
hallucinations, activity disturbances, and aggression, as part of the clinical presentation. John 
Zeisel described it as the four ‗A‘ of AD: agitation, aggression, anxiety and apathy. 
  The International Psychogeriatric Association (IPA) coined the non-cognitive 
symptoms in dementia as ‗Behavioural and Psychological Symptoms in Dementia‘ (BPSD). 
BPSD constitute a major clinical component of AD and other dementia types 
171
. They 
include delusions, hallucinations, activity disturbance (e.g., agitation and aggression), 
affective disturbances, anxieties, diurnal rhythm disturbances and apathy 
169 174 175
. There is a 
growing interest in BPSD as they are responsible for a large share of the suffering of patients 
and carers, and they strongly determine the patients‘ and family carers‘ life situation, QoL and 
management 
21 176 177
. Various studies have characterized these emotional changes in detail 
25 
178-191
. BPSD do not provide a diagnosis or a unitary concept, but a description of a multitude 
of symptoms that occur in persons with dementia, often clustered together in behavioural 
or/and psychological syndromes 
192
 (see Table 3.1.1). Some have presented these syndromes 
as three domains: psychosis/agitation, mood disorders and apathy. Specific behavioural 
disturbances in dementia may be associated
 
with underlying disorders such as the presence of 
psychosis and depression 
193
. In Kunik et al.‘s study psychotic symptoms were associated 
with aggressive behavioural symptoms, and
 
depressive symptoms were associated with 
constant requests for help,
 
complaining, and negativism. Therefore, a search for underlying 
treatable psychiatric disorders should be considered when exploring the BPSD symptoms. 
  Lyketsos 
194
 summarised that BPSD are central features of dementia and an important 
treatment target. They should be assessed in future studies of emerging dementia therapies, 
using appropriate measures matched to the purpose of each study. Several significant issues 
remain regarding (1) the classification of these symptoms into syndromes, 
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Table 3.1.1.  BPSD symptoms as listed by the International Psychogeriatric Association 
  Task Force on BPSD, 1996 (adjusted). 
 
Psychological or psychiatric symptoms  
assessed at patient/relative interview   
Behavioural symptoms assessed by behavioural 
observation or by patient/relative   
Anxiety Aggression 
Depressed mood Screaming 
Hallucinations Restlessness 
Delusions Agitation 
 Wandering 
 Culturally inappropriate behaviour 
 Sexual disinhibition 
 Hoarding 
 Cursing 
 Shadowing 
 
and (2) the development of better clinical measures for their quantification. Empirical 
characterization of clinically meaningful change in the BPSD by examining their relationship 
with the burden of dementia care, disability, the quality of life, carer distress, and resource 
utilization would be an important advance. 
3.2. Scales measuring BPSD 
3.2.1. Some methodological challenges related to scales  
There are some methodological challenges common to all clinical scales: they are non-linear, 
have a floor and ceiling effect, they are biased by examiners‘ attitudes, perceptions and 
subject to unreliable recall. In addition, these clinical instruments have the disadvantage that 
they require quite a large number of participants when used as outcome measures in clinical 
trials to get enough power for the statistical analyses. Biomarkers, however, are not prone to 
so much subjective evaluation, and, used as endpoints in trials, do not require as many 
participants 
195
.   
 Appropriate and sensitive use of the instruments is critical for the delivery of 
improved quality of care. The use of tests in psychiatry has always been widespread in 
research, as they are the main method of measuring outcome in clinical trials. Tests are also 
increasingly common for screening and diagnostic purposes in clinical practice; for example, 
neuropsychological testing in the diagnosis of dementia 
196
. Scales differ according to the 
source of information (e.g., carer versus patient), type of behaviour assessed (e.g., mood, 
agitation, or delusions), origin of the scale (i.e., imported from psychiatry, adapted from 
psychiatric scales, adapted from scales for neurologic conditions, or developed specifically 
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for dementia), and anticipated application of the tool (e.g., behavioural characterization, 
longitudinal follow-up, or differential diagnosis). Investigators have rarely articulated the 
theoretical framework on which their scales are based, and in most cases, theories were 
eschewed in favour of empirically based assessments of observed behaviour. Theoretical 
assumptions, however, can be inferred from the structure of the scales 
197
. 
  On principal, it is necessary to discuss the limitations of a tool. There is always a 
compromise between the bandwidth of a tool and its fidelity, a trade-off between depth vs 
breadth, between specificity and sensitivity. Important aspects are the informant interviewer 
interaction and the interpretation of the outcomes, the setting of the evaluation and the range 
and background of the health care professionals. Scores have to be seen in the context of the 
patients‘ education, social-cultural background, physical and mental health, sensory 
disabilities and last but not least the willingness to cooperate. No scale will be suitable for 
application with all individuals or in all contexts. Therefore, instruments have to be selected 
for specific purposes. There are so-called ‗omnibus tools‘, global assessment scales, designed 
for example to screen many domains simultaneously. Another possible approach is to compile 
different scales into a comprehensive assessment battery. 
 The complexity and importance of behavioural and psychopathological phenomena in 
dementia require that they can be differentially assessed in the course of the disease and 
quantified for research purposes 
198
. This holds particularly true for the measurement of 
therapeutic responses in drug efficacy studies. However, the lack of a clear definition and 
boundaries between entities automatically creates problems of measurement 
199
 (see also 
chapter 4.1). 
Using rating scales in nursing-homes leads generally to special challenges: carers are 
not always present, the residents‘ behaviour challenges them in very different ways, an 
observation interval of two or more weeks may reduce the accuracy by more variance in 
individual recall. Assessment of the spectrum of different BPSD is necessary to improve the 
understanding of the individual patient‘s total picture. The assessment of BPSD is often 
complicated both by communication difficulties and by the complexity of the manifested 
behaviour. 
  In clinical settings and research, the following scales are those commonly used to 
assess the whole spectrum of the BPSD symptoms: The Neuropsychiatric Inventory (NPI) 
169
 
or NPI-Nursing-home Version (NPI-NH) 
200
, the Behavioural Pathology in Alzheimer's 
Disease Scale (BEHAVE-AD) 
25
, along with the Behavioural Rating
 
Scale for Dementia 
(BRSD) 
201
.  
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3.2.2. The Neuropsychiatric Inventory  
The primary purpose of the measure is to provide a rapid assessment of a wide variety of 
behaviour encountered in dementia. The NPI is a fully structured interview in which all 
questions are provided and read verbatim. It is based on observations made by family or 
professional carers over the previous two weeks. A screening question is asked first, followed 
by sub-questions if the response to the screening questions suggests the presence of 
abnormalities involving that neuropsychiatric domain. Each of 12 items is rated by severity 
(1=mild, 2=moderate, 3=severe) and frequency (1=occasionally, 2=often, 3=frequently, 
4=very frequently). The NPI also assesses the amount of carer distress engendered by each of 
the neuropsychiatric disorders. A total NPI score and a total carer distress score are 
calculated, in addition to the scores for the individual symptom domains. The frequency score 
and severity score get combined together by multiplication, consequently, the lowest score is 
0 and the highest 12 for each item. The sum score for the whole scale ranges from 0 to 120 
(NPI) and to 144 (NPI-NH) for the neuropsychiatric symptom items and from 0 to 50 (NPI) 
and to 60 (NPI-NH) for the carer burden. Three modified versions of the original 10-item NPI 
have been developed: the NPI-Nursing-Home version (NPI-NH) 
200
, the NPI-Questionnaire 
(NPI-Q) 
202
, a brief clinical questionnaire form of the NPI intended for use in routine clinical 
practice, and the Carer-Administered NPI (CGA-NPI) 
203
, in which carers complete the 
written form of the brief NPI-Q. The NPI-Q assesses the same 12 items as the NPI-NH, 
though only the severity and not the frequency of the symptoms, with scores ranging from 0 
to 36. A carer distress score is also rated on a scale from 0-5 points ranging from 0 to 60. The 
CGA-NPI resembles the original NPI more closely than does the NPI-Q, with inclusion of 
both severity and frequency scales for each of the 12 items. Minor modifications were made 
to the NPI, such as excluding medical terms that may confuse carers. There is also good 
agreement between the CGA-NPI and the original NPI for prevalence (κ=.62), frequency 
(r=.69), severity (r=.64) and carer burden (r=.61) of anxiety. 
 The NPI is applied more and more frequently in clinical trial settings 
204-213
. These 
quotations represent not a complete list, but an example of studies using the NPI. Having two 
different scores for severity and frequency for each domain potentially increases the utility of 
the NPI in drug efficacy studies. 
  After its introduction in 1994, the scale was translated into several languages and 
validated in various cultural settings 
16 214-227
. The concurrent validity of the NPI was tested 
against relevant sub-scales of the BEHAVE-AD 
25
. The correlations between the sub-scales of 
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the BEHAVE-AD and the sub-scales of the NPI were between 0.54 and 0.78 (frequency) and 
0.47 and 0.80 (intensity). These studies suggest that the NPI is psychometrically sound, 
comprehensive and sensitive to change. We have evaluated the reliability and the validity of 
the Norwegian version of the NPI-NH in an unselected nursing-home sample.  
There is an ongoing discussion that NPI-NH has shown a lower efficacy in 
intervention trials than other instruments. Also our study of oxcarbazepine‘s effect on 
agitation and aggression in severe dementia has shown a clear difference between the NPI-
NH and the BARS results. Besides that which has already been mentioned, some argue that 
this discrepancy may be caused by registering a ―lot of noise‖ (S.Gauthier, IPA 2009), 
because the NPI registers 12 variables with 6 to 8 items each. The difference between 
frequency and intensity of the sub-items is often not clearly understood and may be too 
complex.  
3.2.3. Behavioural Pathology in Alzheimer's Disease Scale (BEHAVE-AD) 
This scale was developed more than 20 years ago 
25 228
. Its predecessor was the Symptoms of 
Psychosis in Alzheimer‘s Disease (SPAD) scale. The items were taken from a chart review 
which indicated that seven broad categories of BPSD are responsive to intervention with the 
antipsychotic medication thioridazine. Reisberg called these categories of BPSD the 
‗Psychosis of AD Syndrome‘ which contained the following domains: (1) Paranoid and 
delusional ideation; (2) Hallucinations; (3) Activity disturbances; (4) Aggressiveness; (5) 
Diurnal rhythm disturbances; (6) Affective disturbances, and (7) Anxieties and phobias. 
Reisberg et al. developed the BEHAVE-AD as a semi-structured interview to measure 
behaviour disturbances in patients with AD. An informant assesses these seven categories of 
symptoms on a 25-item scale, and rates each of these symptoms on a 4-point severity scale 
from 0 (not present) to 3 (most severe). The BEHAVE-AD rates the patient‘s behaviour 
occurring during the previous two weeks and a brief period of observing the patient. The 
second part of the BEHAVE-AD contains a global assessment of severity, the degree to 
which these symptoms are troubling to the carer and/or dangerous to the patient: from 0 (not 
at all) to 3 (severely troubling or intolerable to the carer or dangerous to the patient). The total 
possible score on the BEHAVE-AD ranges from 0 to 75. Adequate reliability and validity 
data have been reported 
229
. BEHAVE-AD was moderately correlated to the BARS; Pearson‗s 
r was 0.44, 0.35 and 0.27 measured on day shift, evening and night shift, respectively 
230
. 
Cummings et al. 
169
 tested the validity of the NPI by using the BEHAVE-AD sub-scales and 
compared them with the NPI sub-scales. They found correlation values (Spearman‘s rho) for 
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the frequency scores between 0.54 and 0.78, and for the severity between 0.47 and 0.80. A 
modified version of the BEHAVE-AD, the BEHAVE-AD-FW, includes a frequency 
component for each of the 25 symptoms assessed 
231
. Subsequent studies supported 
Patterson‘s findings that the reliability of the BEHAVE-AD is excellent and similar to that of 
the most reliable cognitive dementia assessments 
175 229 232
. A multicentre trial 
233
 has 
indicated that each of the BEHAVE-AD symptomatic categories responds statistically 
significantly to even minimal, non-specific psychological support; in response to the 
psychological effects associated with being in a trial and being on placebo treatment, total 
BEHAVE-AD decreased by 25% (the single categories decreased by 18% to 45%). The 
BEHAVE-AD has been found to be useful with outpatients and in NH settings, and appears 
particular useful for identifying behavioural disturbances in patients who are moderately to 
severely demented 
234
. It appears to be appropriate for use in both outpatient and NH settings 
and has demonstrated sensitivity to change (i.e., significant improvement with active 
treatment in comparison to placebo) in both institutional and outpatient settings and in 
subjects with diverse dementia diagnoses 
233 235
. Several studies have used the BEHAVE-AD 
as a kind of gold standard to validate other scales, as we did 
227
. It may be a disadvantage that 
such important items as apathy and irritability are not included in the BEHAVE-AD. A reason 
may be that it was designed by empirical review of only 57 patients with AD with the main 
focus on psychosis.   
3.2.4. Behavioural Rating
 
Scale for Dementia (BRSD or CERAD-BRSD) 
The BRSD was developed by the Consortium to Establish a Registry
 
for Alzheimer‘s Disease 
(CERAD). It was designed to assess behavioural symptoms in
 
persons with dementia. The 
original version 
201
 has 48 items, and the revised version 46 items 
236
. The CERAD-BRSD 
was developed based on existing instruments (BEHAVE-AD, the Columbia University Scale 
for Psychopathology in Alzheimer‘s Disease 237, the Cornell Scale for Depression in 
Dementia 
238
) and clinical experience. The CERAD-BRSD is administered in an interview 
with the patient‘s primary carer, and rates the frequency of occurrence of items under code A 
on a scale of 0 (not occurred since illness began), 1 (1 to 2 days in past month), 2 (3 to 8 days 
in past month, up to twice a week), 3 (9 to 15 days in past month), and 4 (16 days or more in 
past month), 8 (occurred since illness began, but not in past month), 9 (unable to rate). Items 
with the code B are rated 0 (not occurred since illness began), 1 (Yes, has occurred in past 
month), 8 (Occurred since illness began, but not in past month), 9 (Unable to rate). If the 
frequency score is rated 1 to 4 then for 11 items severity is also rated. The CERAD-BRSD has 
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been demonstrated to have good inter-rater reliability. It consists of eight factors: depressive 
features, psychotic features, defective self-regulation, irritability/agitation, vegetative features, 
apathy, aggression, and affective instability 
201
. The 46-item, revised version produced 6 
factors/sub-scales 
236
 in mild to moderate dementia: depressive symptoms (7 items), psychotic 
symptoms (6 items), apathy (3 items), vegetative symptoms (4 items), irritability/aggression 
(5 items), and behavioural disturbances (5 items). The rating results in 6 sub-scores and two 
total scores for the psychopathological symptoms. One total score is weighted (0 to 4 for 26 
items, 0 to 5 for 11 items, and 0 to 1 for 8 items) and is the sum of all individual item scores, 
except the one unspecific item (that comprises all other symptoms that are not part of the 
scale). This total score reflects the total psychopathological burden, based on the number of 
symptoms and the frequency of them. This total score may be 0 to 167. The other total score, 
―number of items rated 1 to 4‖ is the sum of items that have been registered as present during 
the past month, except the one unspecific item. The second total score ranges from 0 to 45.  
 Patterson et al. 
239
 examined, as part of the Alzheimer's Disease Cooperative Study 
(ADCS) Instrument Development Project, the CERAD-BRSD for its sensitivity to degree of 
cognitive impairment, its test-retest reliability, and its sensitivity to longitudinal change. The 
internal consistency, measured by Cronbach‘s alpha score, was 0.87. The Cronbach‘s alpha 
value for the sub-scales ranged from 0.48 (apathy) to 0.80 (psychotic symptoms). The inter-
rater reliability (n=104) showed a kappa from 0.77 to 1.0, the vast majority being over 0.9. 
The test-retest reliability (one month) showed a Spearman‘s rho value ranging from 0.70 to 
0.89. The convergent validity has been tested by Weiner et al. 
240
 by comparing the BRSD 
with the CMAI. Pearson‘s r was 0.76 when comparing the total scores of both scales. 
  Because the most frequent rating on the CERAD-BRSD is ―16 or more times in the 
past month‖, it does not distinguish between behaviour that occurs very frequently (several 
times a day) and those that occur once every 1 to 2 days. This may limit its usefulness in 
detecting subtle changes of treatment effects. Weiner et al. 
240
 tested the sensitivity for change 
during a period of 12 months and could not show any significant change. These results have 
been confirmed by Patterson et al. 
239
. 
3.2.5. Other scales   
There are some other scales like the non-cognitive sub-scale of the Alzheimer‘s Disease 
Assessment Scale (ADAS-noncog) 
241
 and the Comprehensive Psychopathological Rating 
Scale (CPRS) 
242
 for patients with a dementia of the Alzheimer‘s type and multi-infarct 
dementia.  
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  Supplementary to the scales which measure the whole spectrum of the BPSD, there are 
more specific scales that explore single symptoms or syndromes like the Cornell Scale for 
Depression in Dementia (CSDD), the Cohen-Mansfield Agitation Inventory (CMAI), the 
Brief Agitation Rating Scales (BARS), to mention only a few. This issue will be revisited 
more specifically in connection with the assessment of agitation. 
3.3. Prevalence of BPSD 
3.3.1. BPSD in MCI 
Hwang et al. 
243
 compared the neuropsychiatric features of the amnestic-type MCI with those 
of mild AD patients and normal controls. The Neuropsychiatric Inventory (NPI) was used for 
this purpose. They found significant differences in apathy, dysphoria, irritability, anxiety, 
agitation, and aberrant motor behaviour between the MCI and control groups. Delusions were 
less common in MCI compared with mild AD.   
3.3.2. BPSD in AD vs VaD  
Fuh et al. 
244
 explored the neuropsychiatric manifestations in patients with AD, cortical and 
subcortical VaD, and mixed cortical and subcortical VaD. There were few differences 
between the patients with AD, subcortical VaD and cortical VaD. The most consistent 
difference was the high sleep disturbance scores in those with cortical VaD.  
3.3.3. BPSD in FTD vs AD  
Liu et al. 
245
 took volumetric measurements of the frontal, anterior temporal, ventromedial 
frontal cortical (VMFC), and amygdala regions of the brain in patients with FTD and normal 
control subjects, as well as patients with AD. Both the temporal and frontal variants of the 
FTD showed significant increases in rates of elation, disinhibition, and aberrant motor 
behaviour compared with AD. The frontal variant of FTD (fvFTD) group also showed more 
anxiety, apathy, and eating disorders, and the temporal variant of FTD (tvFTD) showed a 
higher prevalence of sleep disturbances than AD. The only behaviour that differed 
significantly between fvFTD and tvFTD were apathy, greater in fvFTD, and sleep disorders 
more frequent in tvFTD. Mendez et al. 
246
 found in analyses of SPECT results in FTD patients 
that early temporal involvement is associated with frivolous behaviour and right temporal 
involvement is associated with emotional disturbances. In contrast, those with right frontal 
disease may present with alterations in non-verbal behaviour. 
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3.3.4. BPSD in out-patients with dementia   
Mega et al. 
23
 compared consecutive outpatients with AD with normal age-matched control 
subjects and reported the prevalence of all forms of BPSD together of 88% in AD patients. 
All 10 items of aberrant behaviour of the NPI-scale were significantly increased in the AD 
patients compared with normal subjects. The most common item was apathy, which was 
exhibited by 72% of patients, followed by agitation (60%), anxiety (48%), irritability (42%), 
dysphoria and aberrant motor behaviour (both 38%), disinhibition (36%), delusions (22%), 
and hallucinations (10%). Piccininni et al. 
17
, Ritchie 
247
 and Holtzer et al. 
248
 found similar 
prevalence data in ambulatory care settings. 
3.3.5. BPSD in nursing homes 
In NH BPSD are frequent 
13 14 249-254
. Approximately 80% of the patients in Norwegian 
nursing homes have dementia and 84% of these exhibit at least one behavioural or 
psychological symptom. Table 3.3.1 lists all the BPSD with a prevalence of nearly 75% in the  
whole nursing-home population, included those who do not have dementia. 
 
Table 3.3.1.  Frequency of psychiatric and behavioural symptoms at different levels of 
  severity among nursing-home patients (n=1,163), Selbæk 2007. 
 
Psychiatric and 
behavioural symptoms 
N
a
 Any symptoms 
(%)
b
 
Clinically significant 
Symptom (≥4) (%)b 
Serious symptom 
(≥9) (%)b 
Delusions 1,112 31.1 20.7 8.8 
Hallucinations 1,127 21.6 12.2 3.9 
Depression 1,140 40.8 21.4 5.9 
Anxiety 1,148 29.4 20.5 6.4 
Euphoria 1,155 8.4 5.5 1.0 
Aggression/agitation 1,156 34.9 22.8 6.7 
Apathy 1,150 33.0 25.7 7.3 
Disinhibition 1,146 30.1 19.5 6.1 
Irritability 1,159 43.2 26.5 5.6 
Aberrant motor behaviour 1,147 20.0 17.6 7.2 
Any NPI-symptom 1,162 73.8 65.2 29.2 
 
a
Number of patients with complete data. 
b
Percentage of patients with complete data (prevalence of the various symptoms and clusters of symptoms). 
 
  Irrespective of the severity of the AD, many studies have shown that apathy is the 
most frequent symptom, followed by depression, anxiety and agitation. In the pre-dementia 
phase of the disease, apathy and depression are the earliest neuropsychiatric symptoms 
255
. In 
the dementia stage, numerous symptoms are present in over 80% of patients, as emphasised 
by various European studies 
192
. The co-occurrence of symptoms is frequent and can, 
44 
 
according to Savva et al. 
256
, be explained by clustering of symptoms. By the use of a factor 
analysis of the NPI a four-factor solution was found, corresponding to psychosis/apathy, 
depression/anxiety, irritability/persecution and wandering/sleep problems. 
 Psychosis occurred more frequently with declining cognition. Anxiety and depression 
were more common in younger individuals and in those with poor self-reported health. Aalten 
et al. 
257
 analysed NPI-factors from cross-sectional data of 2,354 patients with AD from 12 
centres from the European Alzheimer's Disease Consortium. In Aalten et al.‘s analyses the 
sub-syndrome apathy was the most common, occurring in almost 65% of the patients. The 
factors hyperactivity/agitation and affective symptoms were present in all sub-analyses, but 
the presence of the factors apathy and psychosis was dependent on use of cholinesterase 
inhibitors and the severity of dementia, respectively 
258
. Data from the Cache County Study 
259
, a population-based phenomenological study, showed that the spectrum of 
neuropsychiatric symptoms in AD can be empirically classified into three groups: an affective 
syndrome, a psychotic syndrome and other neuropsychiatric disturbance. A syndromic 
grouping may be useful for understanding the aetiology and, consequently, to improve 
treatment and care. 
3.3.6. The course of BPSD 
Steinberg et al. 
260
 examined the longitudinal course of BPSD in the community. He estimated 
a point and 5-year period prevalence of neuropsychiatric symptoms in an incident sample of 
408 dementia participants from the Cache County Study. The NPI was used to assess 
symptoms at baseline and at 1.5 years, 3.0 years, 4.1 years, and 5.3 years. Point prevalence, 
period prevalence and mean symptom severity at each time point were estimated. Point 
prevalence for delusions was 18% at baseline and 34 to 38% during the last three visits; 
hallucinations, 10% at baseline and 19 to 24% subsequently; agitation / aggression fluctuated 
between 13% and 24%; depression 29% at baseline and 41 to 47% subsequently; apathy 
increased from 20% at baseline to 51% at 5.3 years; elation never rose above 1%; anxiety 
14% at baseline and 24 to 32% subsequently; disinhibition fluctuated between 2% and 15%; 
irritability between 17% and 27%; aberrant motor behaviour gradually increased from 7% at 
baseline to 29% at 5.3 years. Point prevalence for any symptom was 56% at baseline and 76 
to 87% subsequently. Five-year period prevalence was greatest for depression (77%), apathy 
(71%), and anxiety (62%); lowest for elation (6%), and disinhibition (31%). 97% experienced 
at least one symptom. Symptom severity was consistently highest for apathy. Steinberg et 
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al.‘s results gave converging evidence that syndromal definitions may more accurately 
capture neuropsychiatric co-morbidity in dementia.  
  Selbaek et al. 
261
 (see Table 3.3.1) found in their study of a large Norwegian nursing 
home sample similar results: clinically significant BPSDs (defined as NPI item scores ≥4) 
were exhibited by 84% of patients with dementia at the baseline or follow-up interviews. 
Overall persistence of symptoms was 79%. Individual symptoms, such as depression (58%), 
delusions (56%), and agitation/aggression (47%) had resolved at a high rate. Ryu et al. 
262
 
investigated a smaller sample. In all 93.8% had BPSD at baseline; 75.0% had at least one 
clinically significant symptom, 80.4% of whom had persistent significant symptoms at 6-
month follow-up. BPSD were highly persistent overall, there was no significant change in 
mean BPSD score for any symptom over 6 months, but many individuals became better or 
worse; 61.2% of those with at least one significant baseline symptom in any domain 
improved. 
3.3.7. Predictors of BPSD 
Zuidema et al. 
253
 examined predictors of neuropsychiatric symptoms in a large sample of 
nursing-home residents. For grading of the stage of dementia they used the Global Detoriation 
Scale for Assessment of Primary Degenerative Dementia (GDS): stage 1 to 4 cognitive 
decline without dementia, stage 5= mild stage of dementia, stage 6=moderate stage of 
dementia, stage 7=severe stage of dementia. While physically aggressive behaviour was more 
common in patients with very severe cognitive deterioration GDS stage 7, disinhibition, 
irritability, physically non-aggressive and verbally agitated behaviour were more common in 
patients in GDS stage 5 or 6. Physically aggressive behaviour was more common in men, 
whereas female patients demonstrated more verbally agitated behaviour. With respect to other 
neuropsychiatric symptoms, delusions and depression were also more common in patients in 
GDS stage 5 and 6, while the prevalence of anxiety and apathy further increased in severely 
demented patients, GDS stage 7. Apathy was more prevalent in male patients, while 
depression and anxiety were more common in females. 
3.3.8. Recurrence rate of BPSD  
Recurrence rates of neuropsychiatric symptoms during a 1-year period were 85% for 
depression, 93% for agitation, and 95% for psychosis 
184
. 
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3.4. Impact of dementia and BPSD  
3.4.1. Patients 
Neuropsychiatric symptoms have been found to be predictive for several outcomes like the 
course of the disease 
248 263
, institutionalisation 
18 177 263-266
, costs of dementia care 
12
, use of 
psychotropic drugs 
261 267
, increased risk of mortality, decreased QoL for patients and carers 
6 
176 268
, and higher rates of carer and staff burnout. Hurt et al. 
6
 found that BPSD symptoms 
relating to a lower quality of life differed between patient and carer ratings: depression and 
irritability were found to predict lower carer ratings of quality of life, whilst delusions and 
apathy indicated lower patient ratings. Agitated behaviour such as wandering and physical 
aggression are a leading cause of transfer from assisted living to NHs 
269 270
. 
3.4.2. Family and carers 
Dementia and BPSD impose enormous burdens on the patients‘ families 10 271-273. Carers are 
generally the spouses or the children of the patients. There is a transition from having a 
reciprocal relationship to one of being a carer. Family members and other carers experience 
psychological distress, physical ill health, social isolation and financial hardship 
235 273-275
. The 
ability of carers to provide emotional support is reduced if they are distressed emotionally or 
overwhelmed by competing demands. BPSD complicate the course of the disease and 
increase the stress on the carers. A newly performed review 
276
 to identify the predictors of 
nursing-home admission (NHA) identified 782 relevant studies; 80 were selected for review 
based upon eligibility criteria. The most consistent predictors of NHA of persons with 
dementia included severity of cognitive impairment, Alzheimer disease diagnosis, 
dependencies in the activities of daily living, behavioural symptoms, and depression. Carers 
who indicated greater emotional stress, a desire to institutionalize the care recipient, and 
feelings of being "trapped" in care responsibilities were more likely to admit persons with 
dementia to nursing homes. Levels of depression and exhaustion are higher than in non-carers 
of similar age in the general population. Predictors of carer stress, related to the patient, are 
BPSD, lack of knowledge about dementia and its care on the part of the carer, immature 
coping mechanisms like avoidance and denial 
275
, previous poor psychological or physical 
health and a poor relationship between the patient and his relatives. Carers were found to be 
poor at identifying the antecedents and consequences of BPSD. 
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  Support of carers should be adjusted to their needs. These may differ depending on the 
stage of dementia. The Relative Stress Scale (RSS) may be useful in identifying these needs 
and in facilitating individualised intervention. In multiple regression analysis, total NPI as a 
measure of BPSD, the carer being a wife and the hours spent caring per week, contributed to 
the explanation of total RSS with a quite high explanatory power of 48% 
277
. Kaufer et al. 
278
 
developed a scale corresponding to the NPI, the Neuropsychiatric Inventory Carer Distress 
Scale (NPI-D). They concluded that NPI-D ratings for 9 of 10 NPI symptom domains 
correlated most strongly with either NPI symptom severity or total (frequency x severity) 
scores. Agitation, dysphoria, irritability, delusions, and apathy were the symptoms most often 
reported to be severely distressing to carers. There is increasing evidence that the features of 
neuropsychiatric symptoms may be influenced by carers‘ characteristics. Sink et al. 279 found 
that, after adjusting for patient characteristics, carers who were younger, less educated, more 
depressed, more burdened, or spent more hours per week giving care, reported more BPSD in 
care recipients, independent of patient characteristics, including dementia severity.  
    Interventions on behalf of the carer showed diverging results. Studies including family 
carers of patients with dementia have shown that psycho-educative programmes and long- 
term emotional support reduce distress and postpone institutionalisation 
280-282
. These studies 
underline the importance of long- term, individually tailored, interventions to help the carers 
cope with the many challenges they face.  
3.4.3. Staff  
The term ‗staff‘ describes professional and paraprofessional health-care personnel in a variety 
of settings [e.g. day care, assisted living, nursing home (NH) with regular care units (RU) and 
special care units (SCU)]. Nursing homes have been described as a complex adaptive system 
283
. This system theory may open up new insights, lead to new management approaches, and 
result in a more efficient and better quality of care. This again will have positive effects on the 
patients‘ QoL and the severity and frequency of their symptoms.  
  Distress caused by BPSD, experienced by staff carers, is similar to that faced by 
family carers 
9
, often arising from disrupted interaction with and responses to residents and 
their family members. 
There is a growing movement toward less restrictive care settings, such as assisted 
living facilities 
284
, not least because care costs are 21 to 30% lower (in the USA) than in 
skilled nursing facilities 
285
.  
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An increasing number of profoundly cognitively impaired and more physically 
disabled patients are nowadays referred to NHs 
13 286 287
, which has potential cost and policy 
implications. In Norwegian NHs more than 80% of the patients have dementia. In Selbæk et 
al.‘s 13 study in Norwegian NHs, only 3 per cent had no sign of cognitive decline. One out of 
three had a severe stage of dementia, 72% of the patients with dementia had clinically 
significant psychiatric and behavioural symptoms (NPI-NH item score ≥4), 40% had 
symptoms of psychosis, and from the total NH population 41% had symptoms of depression 
and 23% clinically significant aggression or agitation. An elderly person in a Norwegian NH 
has on average six diagnoses that need treatment. Consequently, NHs nowadays have 
acquired many new tasks like specialised medical treatment and individualised psychosocial 
interventions, and can no longer be seen as just a residence for the elderly. On one hand, these 
changes create a need for providing higher standards of qualified care services in NHs; on the 
other hand, the staff are not prepared to meet the increasing needs. Contrary to the big 
challenges caused by BPSD and physical co-morbidities in NHs, over 40% of the staff in 
Norwegian NHs have no formal health education. Not being educated well enough for the 
challenges arising in their daily work, staff in NHs experience higher stress, probably 
reflected in higher percentages of sick leave (11% in the years 2004 – 2008, Statistics 
Norway, 2009. http://www.ssb.no/pleie/tab-2009-07-02-09.html) as one easy-to-measure 
consequence. There are not enough physicians working in Norwegian NHs. Taking into 
consideration all these facts, the time spent for individual contact with the patients is limited 
by the daily routine in nursing-homes, which presents many competing demands. Cohen-
Mansfield et al. 
180
 could show that time spent together with the patients contributed to 
reducing agitation in NHs. 
 The consequences of distress may also be experienced when aspects of the nursing-
home environment, often caused by financial gaps and educational deficits, fail to meet the 
expectations of staff carers. Staff members report that they are frequently burdened by the 
repetitious, sometimes frightening and unpredictable behavioural problems, such as 
aggression and agitation displayed by the residents, without the ability to correct or change 
them. This kind of behaviour can lead to frustration, guilt, and emotional and physical 
exhaustion, and may result in feelings of failure and inadequacy or being overwhelmed by 
care and responsibilities on part of staff members. Antisocial behaviour of the residents may 
cause embarrassment and resentment for staff members as well as family carers.  
  In addition, attempts by family members to continue to participate in caring are often 
discouraged by staff members. This perspective can result in family-staff role conflicts 
288 289
. 
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However, systematic implementation of family involvement in institutional care settings can 
yield positive outcomes for the job satisfaction of the formal carers 
290 291
. In Norway, a study 
292
 showed that most of the patients in NHs get good basic care and that acceptable quality of 
care (QoC) had a strongly negative association with such patient characteristics as low 
function in mental capacity, low function in activities of daily living and aggressive 
behaviour. In most of the measured areas of QoC, ward characteristics, such as type of ward, 
size of ward and staffing ratio, do have an influence on QoC. 
There is little research documenting the work situation of the enrolled nurses and 
nursing assistants who make up the majority of carers for older people today. Edvardsson et 
al. 
293
 showed that in settings where staff reported high job strain, the prevalence of 
behavioural symptoms was significantly higher than in settings where staff reported low job 
strain. Furthermore, settings characterized by staff having a more positive caring climate had 
significantly less prevalence of escape, restless and wandering behaviour compared to settings 
having a less positive caring climate. The attitudes that staff members bring with them and the 
procedures that they use in interacting with the residents are crucial factors in achieving 
positive relationships with the residents and creating an environment that imparts trust and a 
feeling of safety on the residents‘ part. In another study, Edvardsson et al. 294 pointed out 
predictors of job strain perceived by staff members: perceived caring climate of the unit, staff 
education level, the chance to discuss difficulties and ethics at work and the age of the staff. 
These predictors had a statistically significant association with job strain. Focus on training 
and administrative interventions can produce desired staff outcomes 
280 295-299
.  
There has been a trend in long-term care in the last decades to move from a traditional 
medical model towards a holistic approach. New models of care address more and more 
individual needs of the aging population 
300 301
.  
3.4.4. Finances 
Hemels et al. 
302
 reported the clinical and economic factors in the treatment of BPSD and 
could show that BPSD was remarkably costly, because it involves more health-care 
professionals and early institutionalisation. As the costs for institutional long-term care rise, 
the public and private health service providers are more and more determined to find solutions 
for the increasing challenges. Therefore, they promote research into the QoC 
303
, also into 
NHs. One example of that is an international collaboration to create standards of care and the 
measurement of outcomes. It started with creating the Residents Assessing Instrument (RAI). 
Today it is a collaborative network of researchers (www.InterRAI.org) in over 30 countries 
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committed to improving health care for persons who are elderly, frail, or disabled. Their goal 
is to promote evidence-based clinical practice and policy decisions through the collection and 
interpretation of high quality data about the characteristics and outcomes of people served 
across a variety of health and social service settings. As Harriet Finne-Soveri (personal 
communication) has stated, there are five nuts to crack: (1) Who is the client in a NH? (2) 
Who has the right to define ―expensive‖? (3) What is ‗quality‘ when the patient has dementia, 
several incurable diseases, multiple medication, persistent symptoms, unknown distance to 
death? (4) How do we measure quality? (5) What is the influence of structure and process on 
outcomes? The term ‗structure‘ includes architecture, furniture, aids, instruments, staffing, not 
only the number of staff but also their qualifications. The ‗process‘ of care means data 
gathering, examinations, diagnostics, care procedures, and service procedures, such as 
leadership and management.  
Briefly, the challenges of financing the costs of dementia care, with focus on the 
situation in Norway, will be described here. Since 1994, the Husbanken and other 
governmental incentives [Handlingsplan for eldreomsorgen (St.meld. nr.50 (1996-1997)] 
have supported the counties in building assisted-living homes for the elderly, so as to get a 
more differentiated and at the same time cheaper care system. These apartments are rented by 
the residents; care services are provided as individually needed by the counties‘ mobile home-
care teams. Between 1996 and 2003, the number of this type of care facilities has increased 
four times to 23,000. At the same time, the places in NHs were reduced, as has already been 
mentioned. In 2003, about 40,800 persons over 49 years were long-term residents in care 
facilities. 
 The future population structure may contribute to an explosive need for care services. 
In 2060, the number of persons over 65 years old in Norway will be more than double those 
of today – from 617,000 in 2009 to 1.5 millions in 2060. The percentage of those aged 80 
years or more will increase from 4.6 to 9.1 per cent – from 219,000 to 635,000 (Statistics 
Norway, 2009, http://www.ssb.no/emner/02/03/folkfram/). This implies that the number of 
persons with physical illnesses and dementia who will need a place in NHs will increase and, 
consequently, the health-care expenses will rise. Consumers prefer assisted living to NHs, and 
state agencies interested in controlling the escalating costs of long-term care also favour 
assisted living. Table 3.5.1 gives an overview of what kind of care services the counties in 
Norway provided in 2008 (provisional numbers): 
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Table 3.5.1.  Care service recipients and type of services provided in Norway in 2008 
                   (not final numbers).  
 
 Percentage 
Age No. of 
recipients 
Only 
practical 
assistance 
Only home 
services 
Practical 
assistance 
& Home services 
Other 
services 
Short term 
care in NH 
Long term 
care in NH 
Total 260.604 18 24 23 20 3 13 
0-17 14.990 3 7 0 83 7 1 
18-49 44.285 20 41 16 21 1 1 
50-66 31.660 20 34 25 16 1 4 
67-79 45.355 20 25 23 16 3 12 
80-89 91.163 19 19 26 15 3 18 
≥90 33.149 12 12 30 10 4 32 
 
 
   Use of formal services and the associated costs of caring for people with dementia will 
not only be driven by increasing numbers of people 85 years of age and older, but also by 
general economic inflation and the annual increases in health costs exceeding the inflation 
rate in industrialised countries. We also may face a decrease of informal (unpaid) carers who 
provide the vast majority of long-term care to disabled people today 
304-309
, because the 
number of adults in single-person housholds is rising steadily and more couples have no 
children. The most rapid growth in persons living alone for all age groups occurs in the 
oldest-old age group, creating an increased need for long-term assistance 
310 311
. Formal 
service use and costs also may increase because of changes in the employment structure of the 
economy, such as the increasing number of women in paid employment 
312
. In a study of the 
future need for long-term care (LTC) in the UK the calculation 
313
 was as follows: 
Expenditure on LTC services for older people with cognitive impairment is projected to rise 
from 0.60% of Gross Domestic Product (GDP) (£5.4 billion) in 2002 to 0.96% of GDP (£16.7 
billion) in 2031, assuming no other changes. Varying the assumptions, the projection for 2031 
ranges from 0.83% to 1.11% of GDP. These figures do not include the opportunity costs of 
informal care. 
 Estimates of both the direct and indirect costs of care for individuals with AD in the 
United States vary from a high of US$67.3 billion (1991 dollars) to a low of US$52 billion 
(1990 dollars) 
314
. Wimo et al. 
315
 calculated the costs for dementia care for Sweden and 
estimated the increase in the number of patients from 1991 to 2025 and the respective costs 
from Swedish Crowns (SEK) 74 billion to SEK 110 billion. The costs for dementia care in 
Norway today are calculated to be over 18 billion Norwegian crowns and will increase in the 
future as in Sweden, if essential progress in the prevention of dementia does not occur 
316
. 
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Jonsson et al. 
317
 found that costs of care in patients with AD are high and related to the 
severity of the dementia as well as the presence of behavioural disturbances.   
4. Agitation in dementia 
4.1. Description 
Agitation is a common neuropsychiatric phenomenon of dementia. The term ‗agitation‘ 
encompasses a wide variety of behaviour: restlessness, wandering, cursing, screaming, 
repetitive motor activities, irritability, hostility, resistance and aggression… 
     Historically, prior to the research of Jiska Cohen-Mansfield, the literature did not 
specify a definition for agitation in dementia. Cohen-Mansfield and Billig 
176
 searched all the 
literature available at that time and as a result of that defined agitation as ―inappropriate 
verbal, vocal or motor activity that is not explained by needs or confusion per se.‖  Jiska 
Cohen-Mansfield has spearheaded this field and found in an observational study that agitated 
behaviour (in particular ‗strange noises‘, ‗requests for attention‘, ‗repetitious mannerisms‘, 
‗picking at things‘, ‗strange movements‘, and ‗pacing‘) were manifested at very high 
frequencies 
318
. They created the Cohen-Mansfield Agitation Inventory (CMAI) on a NH 
patient sample 
21 24 176
 
319
. The original factor analyses by Cohen-Mansfield et al. 
24
 and Finkel 
et al. 
320
 yielded three syndromes of agitation labelled as aggressive behaviour (items: hitting, 
kicking, pushing, tearing things, cursing/verbal aggression, grabbing, biting and spitting), 
physically non-aggressive behaviour (pacing, disrobing, wandering and repetitious 
mannerisms), and verbally agitated behaviour (complaining, negativism, repetitious sentences 
and screaming). Later on, Cohen-Mansfield described the factor structure of agitation as 
measured by the CMAI in outpatients as comprising four sub-types and conceptualised 
agitation along two axes: aggressive-nonaggressive and physical-verbal 
321 322
. In 1989, Taft 
323
 described two components of agitation: 1) excessive motor or vocal activity and 2) the 
inappropriateness of the behaviour. 
  Agitation can also be grouped into disruptive but non-aggressive physical and verbal 
behaviour (e.g., pacing, handling things repeatedly, restlessness, or repeated requests for 
attention), socially inappropriate behaviour (such as undressing or urinating in public), or 
verbal or physical aggression. Some authors have operationalised all behavioural symptoms in 
dementia as agitation 
324. The conceptual difficulty arises because the term ‗agitation‘ can 
include many different kinds of behaviour, but according to Cohen-Mansfield‘s definition, the 
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behaviour must be inappropriate and not clearly the sole outcome of cognitive impairment or 
better explained by some other condition, such as delirium. For example, repetitive screaming 
due to obvious pain would not be considered a manifestation of agitated behaviour but would 
be seen as an appropriate means of communicating the need for pain relief 
325
. Because 
agitated behaviour is context-dependent and a given behaviour may be classified as agitated 
for one individual and not another, the objective measurement of such behaviour is difficult 
20
. There is still considerable confusion in the psychiatric community as to how aggression 
and agitation are to be specifically defined and best distinguished 
326
. 
    The four-fold typology of Jiska Cohen-Mansfield is, however, not universally 
accepted, and other typologies have been suggested. One such typology is based on a factor 
analysis performed by Devanand et al. 
327
, who found factors such as disinhibition, apathy or 
indifference, catastrophic reactions, sundowning, and denial. One reason for these disparate 
findings is the use of different assessment instruments that encompass different domains.   
    There are also classification systems for subtypes of agitation, such as aggressive 
behaviour focusing on the following dimensions: 1) the nature of the behaviour, such as 
physical aggression, verbal aggression, or sexual aggression 
328
; 2) the target of the behaviour 
(i.e., disturbing or endangering the self or others) 
329
; 3) the degree of disruption (i.e., 
disturbing versus endangering) 
330
; or 4) the environmental conditions under which the 
behaviour occurs (e.g., night time or during intimate care) 
331
.  
  Factor analytic studies of aggressive behaviour revealed three factors that are thought 
to describe aggression among the demented elderly; these are: verbal aggression, physical 
aggression and antisocial behaviour 
332
. For a pragmatic therapeutic approach, Lesser et al. 
333
 
suggested dividing agitation into three subtypes: spontaneous (episodic, no obvious 
precipitant, frequently accompanied by disorientation and sometimes hallucinations), reactive 
(preceded by an identifiable precipitant), and disinhibited (chronic and unrelenting, with no 
clear periodicity or trigger). 
  Nonetheless, there is still a debate going on as to whether agitation and aggression in 
dementia are unitary concepts or not, and which aspects of agitation we should focus on when 
designing intervention trials so as to maximise outcome effects. In two out of eight factor 
analyses of the CMAI, Zuidema et al. 
19
 and Rabinowitz et al. 
334
, found the 3-factor solution 
of physical aggression, physically non-aggressive behaviour and verbally agitated behaviour. 
Zuidema‘s conclusion was that ―the robustness of these findings across different care settings 
suggests that agitated behaviour have a common basis.‖ Also our factor analysis of the BARS, 
a short version of the CMAI, confirms the existence of these three factors; we labelled them 
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physically aggressive, physically non-aggressive and verbally agitated behaviour. However, 
this may only reflect the basic assumptions of agitation incorporated into the CMAI and the 
BARS, by that looking through the same spectacles, while blinded to other aspects of the 
agitation spectrum.  
  Lastly, Poole et al. 
335
 reviewed 80 articles and found 47 types of behaviour classified 
as agitation. This shows that problem behaviour is a complex phenomenon affected by an 
interaction of the type of degenerative brain diseases, the grade of cognitive impairment, 
physical health, mental health, past habits and personality, unmet needs and environmental 
factors 
336
. Caused by the many-faceted aetiology, agitation is individually shaped and 
difficult to define. The lack of a precise definition and the complexity of the problem may 
lead to research difficulties in terms of defining research questions and relevant outcome 
measures. 
4.2. Scales measuring agitation 
The core of all assessment in dementia care is careful enquiry and attentive listening, and 
there is no substitute for a clinical interview by a trained doctor, nurse, psychologist, 
occupational therapist or social worker. However, having acknowledged this, there is a 
special and important role for the use of formal scales in dementia assessment. Although this 
has to be balanced by a clinical and ‗holistic‘ approach, the provision of a number allows 
measurement of change and ready comparison of the patient to others and to a population 
norm. Furthermore, measurements can encourage full and more objective assessment of, for 
example, behaviour problems in dementia rather than relying on the carers‘ complaints.  
  Assessment and management of agitation is challenging and confronts carers and 
doctors with tasks that are sometimes frustrating and overwhelming 
337 338
.  
  Many instruments have been devised to measure aggressive and agitated behaviour in 
different patient populations and in a variety of settings, but up to now no single scale has 
emerged as the ‗gold standard‘. Some are global scales, such as the NPI and the BEHAVE-
AD, measuring the whole spectrum of psychological and behavioural problems in dementia as 
described in chapter 3.2, others measure single domains like agitation and aggression, e.g., the 
CMAI and the BARS. 
4.2.1. The Cohen-Mansfield Agitation Inventory (CMAI)      
The CMAI provides extensive coverage of an undifferentiated agitation domain in dementia. 
It was developed using the following definition of agitation: ―agitation is defined as 
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inappropriate verbal, vocal or motor activity that is not explained by apparent needs or 
confusion per se‖ 176. The CMAI is a 29 to 36 item observational instrument, completed by 
nursing staff, measures agitation in nursing-home residents on a 7-point Lickert-type scale per 
item according to frequency of occurrence during the preceding 2 weeks (1=never; 7=several 
times an hour). This scale yields three factors physically aggressive behaviour, physically 
non-aggressive behaviour and verbally agitated behaviour. The CMAI has good internal 
consistency, inter-rater reliability and concurrent validity 
19 319 320 334 339-346
. There is also a 
CMAI Short Form (CMAI-SF) 
20 322
 that has been used in some trials 
347-349
. It reflects the 
three factors of the original CMAI and includes 14 types of aggressive behaviour that carers 
may rate on a 5-point frequency scale. The items are based on the factor structure of the 
original inventory. 
  The factor structure of the CMAI enables clinicians and researchers to avoid global 
scores and obtain sub-scale scores. It is thereby possible to relate different behavioural 
symptoms to medical, cognitive, and demographic variables in order to understand and 
manage them better. 
  Weiner et al. 
240
 made a longitudinal comparison of two carer-administered assessment 
tools, the CMAI and the CERAD-BRSD, among community-dwelling patients with AD with 
baseline and 12-month follow-up data. Among the AD subjects, the correlation between total 
CMAI at baseline and 1 month re-administration was 0.83. In the same subjects, stratified into 
5 groups by MMSE scores, the correlations between BRSD baseline and 1-month scores 
ranged from 0.70 to 0.89. There was high correlation between total scores of both instruments 
at baseline and 12 months. In addition, all CMAI sub-scales, except ‗verbally aggressive‘, 
correlated significantly with total BRSD score at both time points. At baseline BRSD sub-
scales for irritability/aggression, behavioural dysregulation and psychotic symptoms and at 12 
months, irritability/aggression and behavioural dysregulation correlated with total CMAI 
scores. Neither scale changed significantly over 1 year, but there was wide individual 
variation. CMAI and BRSD scores correlated with 1-year change in the FAST, but not with 
MMSE or CDR (which weight cognition heavily), suggesting that behavioural disturbance 
may be more strongly related to ability to manage the activities of daily living (executive 
function) than to other aspects of cognition. The CMAI and the CERAD-BRSD appear to be 
interchangeable as measures of agitation, with the CMAI possibly more useful for patients 
who lack language and the CERAD-BRSD more sensitive to apathy and depression.  
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4.2.2. Scale for Aggressive Behaviour in the Elderly (RAGE) 
The Scale for Aggressive Behaviour in the Elderly (RAGE) 
332
 measures the quantity and 
severity of aggressive behaviour, and gives a score on a four-point scale (0 to 3) for each of 
the 21 items and a total score. The RAGE scale was derived using the following definition of 
aggressive behaviour: ―Aggressive behaviour is an overt act, involving the delivery of 
noxious stimuli to (but not necessarily aimed at) another organism, object or self, which is 
clearly not accidental‖. This scale was developed for use by nursing staff on psychogeriatric 
inpatients with dementia, but it has since then also been used in nursing homes for all patients. 
It has excellent reliability and validity 
331 350-352
. The scale has three components: verbal 
aggression, physical aggression and antisocial behaviour.  
4.2.3. Pittsburgh Agitation Scale (PAS) 
The Pittsburgh Agitation Scale (PAS) 
353
 is a brief screening instrument for agitation in 
dementia; however, unlike the CMAI and the BARS, it measures the severity but not the 
frequency of agitation. The PAS is based on the following definition of agitation: ―Agitation 
is vocal or motor behaviour that is either disruptive, unsafe, or interferes with the delivery of 
care in a particular environment.‖ The PAS is designed as an observational instrument for use 
in NH or in psychogeriatric wards. The scale takes only one minute to administer and is rated 
by direct observation by clinical staff over a period of 1 to 8 hours (one shift) or also one 
week. It is very flexible because the observer himself or herself may choose the period that 
should be rated. The quantification of the severity of the disruptive behaviour is provided 
within four general behaviour groups (items): aberrant vocalization, motor agitation, 
aggression and resisting care, on a scale ranging from 0 to 4. The score reflects the most 
severe behaviour within each behaviour group. The maximum total score is 16, which 
indicates very severe agitation problems. Therefore, an improvement in PAS score, as in other 
scales, may represent an improvement in particularly severe behaviour, but other symptom 
domains of agitation may still exist. Inter-rater reliability exceeded 0.80. Validity was 
assessed by comparing the PAS score with the number of clinical interventions required. The 
PAS has been used in clinical trials 
354
. 
4.2.4. Staff Observation Aggression Scale (SOAS) and revised version (SOAS-R) 
This scale is designed as an observational instrument 
355
 for monitoring the nature and 
severity of aggressive incidents in a psychiatric ward. By filling in a form of this scale at 
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every incident of aggression, it may also be used to monitor the frequency of aggression. The 
SOAS severity scoring system was refined on the basis of the staff severity estimates. The 
revised scoring method and other refinements in the contents of the instrument led to the 
construction of the SOAS-R. The validity of the SOAS-R was tested by comparing a visual 
analogue scale (VAS), on which the staff member marked the severity of the aggression on a 
continuous 100-mm scale ranging from ―not severe at all‖ (at the 0-end of the VAS) to 
―extremely severe‖ (at the 100-end of the VAS).  The SOAS-R seems to be a promising tool 
for monitoring a wide range of (self-) destructive acts in psychiatric wards 
356
. The SOAS-R 
scale is built up of five columns: (1) Provocation (0 to 2 points), (2) Means used by the 
patient (0 to 3 points), (3) Target of aggression (0 to 4 points), (4) Consequence(s) for the 
victim(s) (0 to 3 points), (5) Measure(s) to stop aggression (0 to 2 points). The total severity 
score of the SOAS-R can vary from 0 (least severe form of aggression, mostly verbal 
aggression) to 22 (most severe form of aggression). Nijman et al. 
357
 reviewed the correlations 
between the SOAS and SOAS-R and found that the SOAS-R severity scores were more 
closely related to clinical judgements of aggression severity than the original ones (SOAS). 
The correlation of the original SOAS total scores between observers was 0.87 and the kappa 
was 0.61, indicating fair to good agreement 
358
. Furthermore, the scale is quick to complete 
and there is no need for staff to be trained to use it. In their review of papers on violence 
among psychiatric patients, Shah et al. 
359
 described the SOAS as an instrument ―of particular 
interest . . . with evidence of good reliability and validity‖ (p.307). As a result of another 
study investigating the RAGE and the SOAS, Shah et al. 
360
 recommended a "run in" period 
of at least 4 weeks in intervention studies using the SOAS to reduce contamination by 
spontaneous decline. The RAGE and all its sub-items did not spontaneously decline, but the 
total number of aggressive incidents on the SOAS, the SOAS total score, and the sub-item 
scores, spontaneously declined after week 4 and became stable by week five. The SOAS 
focuses exclusively on aggression and is not constructed especially to validate patients with 
dementia. 
4.2.5. Ryden Aggression Scale (RAS) 
This scale was designed to assess agitation in patients with dementia who live in the 
community with family carers  
328. It is based on the modified Lanza‘s aggression model 361 
where aggressive behaviour is defined as: ―hostile action directed towards other persons or 
objects or towards the self.‖ The RAS was created by reviewing the literature and taking the 
consensus of five registered nurses on the different items. It is a 25-item scale that rates the 
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frequency of occurrence of aggressive behaviour from 0 (less than once a year) to 5 (one or 
more times daily) and is composed of three sub-scales: ‗physically aggressive behaviour‘ 
(PAB, 16 items), ‗verbal aggressive behaviour‘ (VAB, 4 items), and ‗sexually aggressive 
behaviour‘ (SAB, 5 items). It is designed as a questionnaire to be completed by carers about 
their dementia patient. The RAS was used in a pilot study by Ryden 
328
 where he investigated 
a sample of 183 patients with dementia living at home. It showed good internal consistency 
(Cronbach‘s alpha: RAS=0.88; PAB=0.84; VAB=0.90; SAB=0.74) and test-retest reliability 
(Pearson‘s r=0.86). The validity data are not as good.  
 4.3. Brief Agitation Rating Scale (BARS) 
Finkel et al. 
230
 developed the BARS to allow nurses and other carers in a nursing-home to 
assess the level of agitation in a patient rapidly. It was developed as a subset of the Cohen-
Mansfield Agitation Inventory (CMAI) after the CMAI was administered to 232 NH residents 
by interviewers who had been trained by a psychiatrist. The BARS was developed in a three-
stage process. First, correlations of individual items against the total score were rated, with 
those having a high correlation selected for possible inclusion. Secondly, inter-rater reliability 
was assessed. Thirdly, items were selected to be representative of the original CMAI factor 
structure. The BARS captures the following ten agitation items on a 7-point scale from 1 
(=never) to 7 (=several times an hour) looking back over the last two weeks. 
 
Items included in the BARS: 
(1) hitting    (2) grabbing    (3) pushing  
(4) pacing or aimless wandering (5) repetitious mannerisms  (6) restlessness 
(7) screaming    (8) repetitive sentences or questions  
(9) making strange noises  (10) complaining 
 
  In the light of the desire to keep the rating scale even simpler and easy to do by busy 
clinicians, some have streamlined the scoring system and reduced the point range from 0 
(=never) to 3 (=often or continuous), reporting agitation during only one week.  
 This scale‘s performance data, as reported by Finkel et al. 230, are listed in the 
following: the Cronbach alpha for the 3 daily shifts ranged from 0.74 to 0.82. The intra-class 
correlation between rater pairs was 0.73. The scores correlated well with a CMAI done on the 
same patient group. Shah et al. 
362
 compared three scales that measure agitation in dementia: 
the CMAI, the RAGE and the BARS. They found that the internal consistency, measured by 
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Cronbach‘s alpha, was greater than 0.8 on all three scales. The test-retest and inter-rater 
reliability correlations were 0.75 or greater for all three scales, but the BARS showed some 
weaker results.  
4.3.1. Studies using BARS as outcome measure 
Although the BARS has been used in studies in Norway 
27 210 363 364
 and other countries 
40 276 
365-369
, no study, besides that on the developing sample, has been carried out to explore the 
factor structure. The aim of our study was to examine the extent to which the BARS is a 
homogeneous scale, measuring shared underlying constructs, and whether the dimensions 
Finkel et al. 
230
 found, would be revealed in an exploratory factor analysis on a large 
Norwegian sample. The BARS has been recommended for use in the ―Agitation Decision-
Making Framework‖ for nurses and care staff, developed by Dr.John Bidewell at the 
University of Western Sydney, Australia. 
 4.4. Prevalence and correlates of agitation 
Already in the early 1980s, Rabins et al. 
7
 described the prevalence of catastrophic reactions 
and physical violence as very high, 87% and 47% respectively, and 75% of the carers 
reported this as the most serious problem they face in patients with dementia. Burns et al. 
179
 
found that out of a sample of 178 patients with AD, aggression was observed in 20%, 
wandering in 19%, binge-eating in 10%, hyperorality in 6%, urinary incontinence in 48%, and 
sexual disinhibition in 7%. Behavioural abnormalities were greater in those with more severe 
dementia. Temporal lobe atrophy correlated with aggression. Later research confirmed that 
behavioural symptoms, such as aggression, agitation and psychosis, are common in moderate 
to severe stages of dementia 
16 23 339 370 371
.  
 McShane et al. 
372
 investigated over a four-year follow-up, whether individuals who 
experience psychiatric symptoms early in dementia are more prone to develop behavioural 
problems later in the illness. They found that physical aggression was predicted by a sad 
appearance. Motor hyperactivity was predicted by ideas of persecution. These associations 
were robust, remaining significant over 2, 3 and 4 years of follow-up time and were 
independent of cognitive function, age, sex and duration of the illness. They concluded that 
there may be two distinct longitudinal syndromes of non-cognitive symptoms in dementia and  
that important aberrant behaviour in late dementia may share pathophysiological mechanisms 
with psychiatric symptoms in early dementia. A study examining the longitudinal course of
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Table 4.3.1  Comparison of BARS with other scales measuring agitation in dementia. 
  
Scale Setting 
Observat. 
period 
(days) 
Informant 
No 
of items 
Factors* 
Agitation types assessed 
Other domains assessed 
 
Staff 
burden 
Freq. 
Sev. 
A V G D R I C U M PS AN DE O F S 
CMAI 
NH 
CI 
14 
Nurs. staff 
Carer 
29 A,M,V Y Y Y Y Y N Y N Y N N N Y N Y N 
NPI-NH NH 14 
Nurs. staff 
Carer 
12  Y Y Y N Y Y N Y Y Y Y Y Y Y Y Y 
BEHAVE-AD 
Out 
NH 
AD 
14 Carer 25+1 
PSx2, DE, 
AN,A,VE,M 
Y Y N N N N N N Y Y Y Y Y Y N Y 
CERAD - 
BRSD 
Out 
NH 
CI 
30 
modifiable 
Nurs. staff 
Carer 
48, 46 
A,DE, PS,U, 
I,VE, AP, EL 
Y Y Y N Y Y Y Y Y Y Y Y Y N Y Y 
RAGE 
In 
NH 
CI 
3 Nurs. Staff 21 V,A,AB Y Y Y Y N Y Y Y N N N N Y N Y Y 
PAS 
In 
CI 
1-8 hrs 
unto 7 days 
Nurs. Staff 4  Y Y N Y Y N Y Y Y N N N N N N 
Y 
RYDEN 
Out 
CI 
365 Family carers 25 A,V,SB Y Y N N N N N N N N N N Y N Y N 
OAS In 
One 
incident 
Nurs. Staff 4 
V,  
A (3 forms) 
Y Y N N N N N N N N N N N N N Y 
SOAS In 
One  
incident 
Nurs. Staff 
5  
Columns 
 Y Y N N N N N N N N N N N Y Y Y 
BARS 
NH 
CI 
14 Nurs. Staff 10 A,M,V Y Y Y N Y N Y N Y N N N Y N Y N 
 
*Factors are listed in order of their explanatory contribution 
A=Aggression (physical)   AB=Antisocial behaviour    AD=Alzheimer‘s disease  
AN= Anxiety    AP=Apathy    C=Complaining (critical) 
CI=Cognitively impaired patients  D=Demanding    DE= Depression 
EL= Emotional instability   F=Frequency    G= General restlessness 
I=Irritability     In=Inpatient (hospital ward)  M=Motor agitation 
NH=Nursing home    N=No      O=Other domains assessed 
Out= Outpatient     PS= Psychosis     R=Repetitive (motor and verbal) 
S=Severity     SB=Sexually aggressive behaviour  U=Uncooperative (resisting care) 
V=Verbal agitation (aggression)   VE=Vegetative functions (sleep…) Y=Yes 
 
6
0
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agitation in NHs was performed by Burgio et al. 
286
. This study used information from both 
staff ratings and direct observation of agitation. The design they used was longitudinal 
hierarchical linear modelling (with assessments every six months) to capture the dynamic 
nature of behaviour change as a function of the individual resident‘s characteristics and the 
progress of time. The severely cognitively impaired residents displayed more agitation than 
the moderately impaired group at baseline. Longitudinal analysis found a significant linear 
and quadratic trend only with the profoundly impaired residents. These residents showed 
slightly less agitation up to 12 months, with agitation increasing significantly from 12 to 18 
months.   
  Aarsland et al. could show that about a quarter of the variance in aggression could be 
attributed to psychosis 
373
. Gilley et al. 
374
 examined the relationship between psychotic 
symptoms and subsequent physically aggressive behaviour in outpatients with AD. The 
presence of delusions significantly predicted the presence and frequency of physical 
aggression. Of participants with high rates of physical aggression (> 1 episode/month), 80% 
had delusions. This effect was robust, even after controlling for the effects of other clinical 
variables. By contrast, hallucinations did not reliably predict episodes of physical aggression. 
Almost 50% of dementia
 
patients in NHs exhibit some form of agitation at any point in
 
time. Agitation, particularly wandering and physical aggression,
 
appears to be more common 
in NH populations, but agitation often
 
poses a much more serious management problem for 
carers
 
who live with a demented person at home. Agitation is perceived by the carers as more 
distressing than cognitive decline.
 
After incontinence, agitation is the second most cited 
reason
 
for NH placement. If carers
 
could be provided with better ways of dealing with 
agitation,
 
the benefits for them and for the health care system could be
 
substantial.  
The objective of Jiska Cohen-Mansfield‘s study in 2008 375 was to examine the 
relationship between type, frequency, and level of disruptiveness of physically aggressive 
agitated behaviour, physically non-aggressive agitated behaviour, verbally aggressive agitated 
behaviour, and verbally non-aggressive agitated behaviour in persons with dementia. The 
highest overall frequencies were reported for verbal non-aggressive behaviour and the highest 
average disruptiveness was correlated to verbal aggression. Frequency and disruptiveness of 
behaviour were highly correlated. When controlling for frequency of a certain type of 
behaviour, physically aggressive behaviour was the most disruptive across two nursing staff 
shifts. In understanding the impact of agitated behaviour, it is important to take into account 
both the type of behaviour and its frequency.  
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Engelborghs et al. 
376
 studied the profiles of neuropsychiatric symptoms in several 
degenerative dementias. In AD and mixed AD and VaD, activity disturbances and 
aggressiveness occurred in more than 80% of the patients. In FTD patients, with a prevalence 
of 70%, apathy was very common whereas delusions and hallucinations were rare. Frequently 
used behavioural assessment scales like the BEHAVE-AD systematically underestimated 
BPSD in FTD, whereas Rosen et al. 
377
 proposed a short version of the Neary criteria 
378
, a 
neuropathological validated set of five clinical features, which displayed high sensitivity for 
frontal lobe symptoms. Hallucinations discriminated DLB patients from other dementias. A 
high prevalence of disinhibition (65%) in DLB pointed to frontal lobe involvement. They 
concluded that behavioural assessment may help in differentiation between different forms of 
dementia and stressed the need for the development of new and more sensitive behavioural 
assessment scales. By means of the Middelheim Frontality Score (MFS), frontal lobe 
involvement was frequently observed in DLB. As 70% of FTD patients displayed apathy, 
prevalence was higher compared to the other disease groups, meanwhile indicating that 
apathy is frequently observed in dementia, irrespective of its aetiology. 
 4.5. Prevention of agitation and aggression 
There are some general principles that should be mentioned as means to prevent agitation and 
aggression in dementia: Analyse situations triggering agitation or aggression; try to find the 
patient‘s unmet needs and what he/she wants to communicate; relieve discomfort and pain; 
adjust care to the patient and not the patient to care; individualise the therapeutic approach to 
the single patient and to the stage of the dementia disease; make indoor architecture and 
outdoor spaces safe and easy to understand; contribute to helping the patient to understand the 
situation. Know the patient‘s life history and his/her likes and dislikes; think proactively – 
registering the moments the patient enjoys and introducing more of them, like relaxation with 
aroma-therapy, footbath, music therapy, massage, touch, walking, dancing, and good meals. 
Facilitate a good day-night rhythm by day light or light therapy and exercise, and a calm and 
warm place to sleep.  
 4.6. Aetiology of aggression and agitation in dementia 
Agitation is related to severity of dementia 
379
 and to specific types of associated 
psychopathology implicating frontal lobe dysfunction 
371
. With respect to the aetiology of 
aggression in demented patients, different approaches have been suggested. Raskind 
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described the interaction of three factors, which lead to aggression in this population:  
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(1) From a neurobiological perspective, greater neuronal loss 
380
 leads presumably to 
neurobiological dysregulation, e.g., cholinergic deficits 
381
, altered adrenergic function 
382 383
, 
and γ-aminobutyric acid disturbances in the substantia nigra, that may lower the threshold for 
the expression of aggression. (2) Cognitive impairment in patients with dementia increases 
the aggressive potential due to misperceptions, poor insight or disinhibition. 3) Factors like an 
unfamiliar environment might lead to an exacerbation of aggressive symptoms. In this 
respect, climate, noise level and general level of stimulation have to be balanced. Lehninger et 
al. 
384
 described the aetiology of agitation in dementia with the ‗Seven I‘s‘, illustrating what 
diagnosis and therapy should focus on: Iatrogenic (anticholinergics, sedatives, etc.), Infection 
(urinary tract infection, pneumonia…), Illness (acute and chronic with exacerbation), Injury 
(hip fracture, subdural hematoma, pain…), Impaction (fecal), Inconsistency in the 
environment (changes, different approaches…), Is the patient depressed? 
  Depending on which approach is chosen, many different models have been developed 
which try to explain agitation and aggression in dementia.  
4.6.1. Biological substrates  
4.6.1.1. Neurobiology or direct impact of dementia disease 
Psychological condition, progressive cognitive and functional losses in dementia influence the 
nature of BPSD. Lindenmayer 
385
 stated that, generally, agents that reduce dopaminergic or 
noradrenergic tone or increase serotonergic or GABAergic tone will attenuate agitation, often 
irrespective of aetiology. 
 The findings of Siegel et al. 
386
 will be presented in summary form. The various types 
of aggression may be reduced to two categories — defensive rage (affective defence), a 
reactive kind of aggression, and predatory attack or the proactive form of aggression. This 
approach helps explain the behavioural properties of aggression as well as the underlying 
neural substrates and mechanisms of aggression, both in animals and humans. Defensive rage 
behaviour is activated by a threatening stimulus that is real or perceived and is associated with 
marked sympathetic output. This yields impulsivity with minimal cortical involvement. 
Predatory attack behaviour in both animals and humans is generally planned, taking minutes, 
hours, days, weeks, months, or even years to produce action. In degenerative brain diseases 
aggression is mostly of a defensive nature and often driven by psychotic elements in 
perception 
373
.  
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Figure 4.6.1.  Brain structures involved in aggression, based on: Siegel and Victoroff (2009). 
 
  
 
 
  The limbic structures and the hypothalamus are involved in the control of aggression 
and rage in humans (Figure 4.6.1). The data is based upon studies involving neurological 
disorders in patients 
387
. These include behavioural correlates of temporal lobe epilepsy, 
sclerosis of the temporal lobe, tumours of the temporal lobe, other regions of the limbic 
system, and the hypothalamus. The limbic system powerfully modulates functions of the 
hypothalamus. Accordingly, damage or disruption of a limbic structure significantly disrupts 
the regulatory mechanisms modulating aggressive behaviour, resulting in loss of control over 
these functions.  
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  Gamma-amino butyric acid – A (GABA-A) receptors in the medial and lateral 
hypothalamus suppress defensive rage and predatory attack behaviour, respectively. GABA-A 
receptors in the medial hypothalamus are activated by GABA neurons projecting from the 
lateral hypothalamus, and likewise, GABA neurons arising in the medial hypothalamus 
activate these receptors in the lateral hypothalamus. There are striking similarities between 
the characteristics of defensive rage in animals and in humans. Defensive rage is associated 
with sudden, significant increases in sympathetic activation. The response is quite impulsive 
and clearly lacks cortical involvement (as shown from animal studies). This response remains 
intact in spite of ablation of the forebrain. In humans, many studies have reported a link 
between brain damage to the frontal cortex and increased aggressive behaviour 
388
. These 
findings are consistent with reports that individuals who rank highly on measures of reactive 
aggression show lower-than-average 
baseline activity in the frontal cortex 
389 390
. Defensive rage behaviour contains the following 
basic features: it is activated by a threatening stimulus (which may include self-generated 
emotions); it is associated with marked sympathetic output; it is impulsive; it does 
not require cortical involvement for its expression; and the attack response may be directed at 
a variety of targets present within the visual field. 
4.6.1.2. Neurobiological studies in dementia                  
Sharp et al. 
383
 studied the [3H]prazosin binding to alpha1-AdR in post-mortem brain tissue 
obtained from 24 patients with Alzheimer disease (AD) and 25 comparison cases. They found 
that aggressive behaviour was significantly correlated with the alpha1-adrenoceptor number 
in patients with AD. Furthermore, patients receiving ongoing antipsychotics had significantly 
higher density for [3H]prazosin than those who were not. They concluded that upregulation of 
alpha1-AdR is associated with aggressive behaviour and chronic treatment with antipsychotic 
medication. Aggression may also be facilitated by a dysbalance resulting from adrenergic 
system overactivity during a loss of serotonergic function.  
  Lai et al. 
391
 investigated the state of 5-HT(1A) receptors in the postmortem neocortex 
of 33 AD patients prospectively assessed for cognition and behavioural symptoms, together 
with 20 matched controls. 5-HT(1A) receptor binding affinity and density were unchanged in 
the overall AD group compared with the controls. Within the AD group, 5-HT(1A) receptor 
density in the temporal cortex inversely correlated with aggression and the severity of 
dementia. The 5-HT(1A) receptor density remained the best predictor for aggression, while 
temporal cortical neurofibrillary tangle grading was the best predictor for the severity of 
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dementia. This suggests that 5-HT(1A) receptor alteration is directly related to aggression in 
AD, while the severity of dementia is more strongly related to the neurodegenerative process. 
  Garcia-Alloza 
392
 assessed the cholinergic and serotonergic functions in post-mortem 
frontal and temporal cortex from 22 AD patients who had been prospectively assessed with 
the Mini-Mental State examination (MMSE) for cognitive impairment and a scale measuring 
BPSD. Not only cholinergic deficits, but also the cholinacetyltransferase/serotonin ratios, 
were significantly correlated with the final MMSE score both in the frontal and the temporal 
cortex. In addition, decreases in cholinergic function were correlated with the aggressive 
behaviour factor, supporting a dual role for the cholinergic system in cognitive and non-
cognitive disturbances associated to AD. The serotonergic system showed a significant 
correlation with overactivity and psychosis. An imbalance between cholinergic-serotonergic 
systems may be responsible for the cognitive impairment associated with AD.  
  Garcia-Alloza et al. 
393
 found in addition to cholinergic deficits, significant decreases 
in GABA content, with no changes in glutamate content, in the frontal and the temporal 
cortex. Both GABA levels and the glutamate/GABA ratio showed significant correlations 
with depression in AD. In the temporal cortex, higher densities of GABA(A)/benzodiazepine 
receptors also correlated with more severe depression. Consequently, it has been suggested 
that in a situation of cholinergic deficit, such as AD, an imbalance between the excitatory 
glutamatergic tone and inhibitory GABAergic tone may be responsible for non-cognitive 
behavioural disturbances. 
  Tekin et al. 
394
 identified 31 patients with a diagnosis of definite AD, on whom an 
autopsy had been carried out. Behavioural changes had been assessed with the NPI. Brain 
sections were collected from bilateral orbitofrontal and left anterior cingulate, superior 
temporal, inferior parietal, occipital, and hippocampal cortices for quantification of 
neurofibrillary tangles (NFTs) and diffuse neuritic plaques. The results suggest that agitation 
and aberrant motor behaviour are correlates of greater NFT pathology in the orbitofrontal 
cortex in AD, whereas increasing apathy may relate to greater NFT burden in the anterior 
cingulate. 
 Using Positron Emission Tomography (PET) examinations Sultzer et al. 
395
 
established relationships between non-cognitive symptoms and metabolic activity. They 
found that non-cognitive symptoms had regionally specific representations, with significant 
correlations between the agitation/disinhibition factor score and metabolism of the frontal and 
temporal lobes, between psychosis factor score and metabolism in the frontal lobe, and 
between anxiety/depression factor score and metabolism of the parietal lobe. These results 
67 
 
confirmed that psychiatric symptoms are fundamental expressions of the cortical dysfunction 
of AD. 
  Hirono et al. 
396
 studied the relation between regional brain perfusion and aggressive 
behaviour, using a Single Photon Emission Computed Tomography (SPECT) scan, in two 
groups of 10 patients with dementia with and without aggression, that were comparable for 
demographic factors, severity of cognitive impairments, and other behavioural symptoms as 
measured by the NPI. Patients who showed aggression revealed significant hypoperfusion in 
the left anterior temporal cortex; additional, bilateral dorsofrontal and right parietal cortex 
were also found to be significantly hypoperfused. 
4.6.1.3. Clinical neurobiological correlates 
Senanarong et al.s‘ study 371 is one of the largest and most comprehensive assessments of 
agitation reported. There was no difference in agitation sub-scale scores between patients with 
dementia of various aetiologies. The data suggest that agitation in AD is a frontal lobe 
syndrome. Frontal lobe dysfunction may predispose AD patients to agitation by exaggerating 
behavioural responses to many types of coexisting psychopathology or environmental 
provocations. 
  Herrmann et al. 
397
 examined in their review the role of norepinephrine (NE) on 
BPSD, including depression, aggression, agitation and psychosis. A number of lines of 
evidence suggest that NE dysfunction leading to BPSD may result from increased NE activity 
and/or hypersensitive adrenoreceptors compensating for loss of NE neurons with the 
progression of AD.  
  In a case control study Sukonick et al. 
398
 wanted to investigate the importance of the 
dysfunction of serotonin neurotransmission for aggressive behaviour in AD. Homozygosity 
for the long variant (*L) of an identified bi-allelic polymorphism of the serotonin transporter 
promoter region (5-HTTPR) is associated with increased expression of the transporter protein 
and increased speed of response to serotonin reuptake inhibitor treatment. Fifty-eight 
inpatients on a hospital geriatric psychiatry ward with AD and a history of aggressive 
behaviour and 79 never-aggressive patients with AD with comparable severity of cognitive 
impairment were studied. The *L/*L genotype was significantly associated with aggression in 
patients with AD.  
  Risperidone may be cited as an example of the clinical relevance of the 5-HT-system. 
Risperidone antagonises serotonin type 2 (5-HT2) and dopamine type 2 (D2) receptors. In 
many trials, risperidone has been investigated in use as therapy against aggression and 
68 
 
agitation in dementia. By decreasing serotonergic activity, reactive aggression in humans 
increases. That may be a reason for the modest efficacy of the drug against agitation in 
dementia. 
  At a clinical level, aggression has been shown to correlate very highly with psychosis 
373
. The presence of delusions is the best clinical indicator for the occurrence of aggressive 
features 
374 399
. 
4.6.2. Psychological and environmental factors  
Many different concepts and models have been discussed as possible explanations of the 
psychological aetiology of agitation and aggression in dementia. The available literature 
suggests that the various types of agitated behaviour have different meanings. Most seem to 
be associated with discomfort, which may include physical pain, external restraint, or feelings 
of depression or of loneliness. In contrast, some of the types of behaviour, especially in the 
physically non-aggressive category, may be adaptive and not an indication of discomfort. On 
the basis of these interpretations of the reasons for disruptive behaviour, several approaches 
for treatment follow logically.  
 Focusing on discomfort that the patient is not able to communicate verbally, Pelletier 
and Landreville 
400
 performed hierarchical linear multiple regression analyses controlling for 
the patients' characteristics (sex, severity of dementia, and disability). They could show that 
discomfort explains a significant share of the variance in overall agitation, non-aggressive 
physical behaviour and verbally agitated behaviour. No significant relationship was observed 
between discomfort and aggressive behaviour, but the power to detect this specific 
relationship was low.   
  Burgio et al.‘s work 286 included a small number of NH residents. The purpose was to 
examine aspects of 
401
 model of need-driven dementia-compromised behaviour. In this model, 
the authors hypothesized that background factors (e.g., age, gender, motor ability) combined 
with proximal factors (e.g., physical and social environment) determine the display of 
agitation. The model suggests that as the residents‘ cognitive and functional behaviour 
declines, residents become more vulnerable to ‗‗environmental stress‘‘ and more likely to 
display agitation because of their inability to meet their own needs. The profoundly 
cognitively impaired residents displayed more agitation than the moderately impaired group. 
In a longitudinal analysis they found a significant linear and quadratic trend only with the 
profoundly impaired residents. These residents showed slight reductions in agitation up to 12 
months, with agitation increasing significantly from 12 to 18 months.  
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  Schreiner et al. 
342
 studied agitated behaviour in elderly NH residents with dementia in 
Japan. From staff reports, it appeared that most physically aggressive behaviour occurred in 
relation to personal care. Other research has shown that dependency in personal care is related 
to aggressive behaviour 
402 403
 which probably relates to overall decline in cognitive 
functioning.  
  One of the most prominent models is that which explains agitation and aggression in 
dementia as an attempt to communicate unmet needs, a similar model to that of need-driven 
theory. In dementia, the patient has a decreased ability to meet his own needs because of his 
decreased ability to communicate his needs combined with his decreased ability to provide for 
himself (e.g., unable to use prior coping mechanisms). In addition, there are environmental 
limitations, because of a lack of understanding about what the patient wants to communicate 
or because the environment cannot provide his physical or psychosocial needs, e.g. the patient 
is residing in the wrong level of care. The behaviour may be a means of fulfilling needs, 
communicating needs or an outcome of frustration and other negative affects interacting with 
decreased inhibition. On the one hand, physical illnesses - including pain 
404
, inactivity, 
loneliness, insufficient staffing levels, cold or hunger at night - the reasons may be many that 
lead to problem behaviour caused by the environment or by the environment not meeting the 
patient‘s needs. On the other hand, structured activities, music, social interactions (creating 
the good moments of the day), and relaxing activities like a foot bath, aroma therapy, 
massage, touch, pets (visits with a dog) 
405
, family videotapes, walking in a garden and so on 
may be associated with decreased agitation. It should not be forgotten that agitation may also 
be related to sensory deprivation 
406
.  
  From a psychodynamic point of view, Hagberg 
407
 suggested that the organisation of 
the personality is affected, resulting in a reduction in ego resources, regressive behaviour, use 
of more primitive defence mechanisms to stave off painful emotions, and reactivation in 
conscious awareness of previously unconscious material. It may also be interesting to look to 
this issue from another perspective, the predictors of aggressive behaviour. Cognitive 
impairment and the poor quality of a relationship were the main predictors of physically 
aggressive behaviour. Verbally aggressive behaviour was predicted mainly by depressed 
mood, poor quality of relationships, and poor physical health. These results validated and 
expanded prior cross-sectional research on the correlates of aggression in other populations. 
Cohen-Mansfield and Werner 
408
 analysed in the same population the longitudinal predictors 
of physically and verbally non-aggressive inappropriate behaviour in 200 community-
dwelling elderly persons attending senior day care-centres. Models based on ratings obtained 
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from staff members and family carers were compared. Multiple factors contributed 
simultaneously to the prediction of non-aggressive behaviour. Similar to previous cross-
sectional results, physically non-aggressive behaviour was predicted mainly by good health 
and cognitive impairment. In addition, depression emerged consistently as a predictor of 
physically non-aggressive behaviour in all models. Verbally non-aggressive behaviour was 
predicted by a depressed mood and pain, confirming previous suggestions that these types of 
behaviour are related to discomfort. The relationship of these types of behaviour with 
cognitive functioning was relatively weak.  
  Summarising, it can be said that the most common unmet needs in verbally agitated 
patients are fears, pain, loneliness and depression, in physically non-aggressive behaviour the 
most common needs that are unmet are those for activity and stimulation, and in physically 
aggressive behaviour the need to evade discomfort, frustration after fruitless attempts to 
communicate needs, and need for more personal space, especially in psychosis 
409
. It is worth 
just mentioning that sheltered parks or gardens may have a positive effect on patients who 
pace or wander. 
 4.7. Diagnostic challenges of BPSD 
Multi-morbidity 
410
: advanced age, female gender, and education finishing at a lower level 
have been independently associated with a more than 50% increased risk for multi-morbidity. 
Multi-morbidity is the most common clinical description of the elderly and may be increased 
by unhealthy behaviour. In addition, neuropsychiatric symptoms, especially agitation, are 
linked to inadequate medical assessment and management of NH residents‘ other health 
conditions 
20 411
. In this way, agitation has the potential to be life threatening and reduces the 
quality of care the patient receives.  
4.7.1. Delirium 
Besides depression and dementia, the third of the three ―Ds‖ in old age psychiatry is delirium. 
It is a condition characterised by an acute onset and fluctuation in consciousness, memory, 
perception, behaviour and orientation (American Psychiatric Association 2000). In the context 
of our research, we have had to differentiate between agitation caused by dementia and a state 
of confusion like delirium. It occurs in hyperactive, hypoactive and mixed forms. The 
hyperactive and mixed form may present like agitation in dementia.  
Delirium affects up to 42% of older hospital inpatients 
412
, many with pre-existing 
dementia 
413
. The occurrence of delirium is associated with many poor outcomes, including 
71 
 
increased cognitive impairment and functional disability 
414
, increased length of hospital stay 
415 416
, and rates of institutionalisation 
414 416
; it is a marker of a higher risk of getting dementia 
and earlier death. In one study, it was reported that the incidence of dementia was 5.6% per 
year over 3 years for those without delirium and 18.1% per year for those with delirium 
417
. It 
could be shown that many symptoms of delirium persist over a long period and they often do 
not resolve at all: 
―Only five patients (4%) experienced resolution of all new symptoms of delirium 
before hospital discharge, and only 20.8% and 17.7%, respectively, had resolution of 
all new symptoms by 3 and 6 months after hospital discharge. These data suggest that 
delirium is a common disorder that may be substantially less transient than currently 
believed and that incomplete manifestations of the syndrome may be frequent.‖ 418  
A large meta-analysis showed that the combined proportions with persistent delirium (PerD) 
at discharge from hospital, 1, 3 and 6 months were 44.7%, 32.8%, 25.6%, and 21%, 
respectively. The outcomes (mortality rate, nursing-home placement, function, cognition) of 
patients with PerD were consistently worse than the outcomes of patients who had recovered 
from delirium 
419. Cole et al. also showed that even sub-syndromal delirium has bad outcomes 
420
.  
In clinical praxis, it may be quite a challenge to differentiate delirium from dementia 
with psychotic features. Often both conditions are present in the same individual, because 
physical illness in a patient with dementia may easily cause delirium. In addition, there are 
types of dementia, such as LBD, that characteristically show elements of delirium as 
fluctuating cognition with pronounced variations in attention and alertness. Further, other 
disorders like depression and acute psychosis may pose difficulties in differentiating the 
symptoms and finding the right diagnosis 
421
. A good medical history is the best tool in the 
performance of this task, including information collected from relatives and carers who have 
known the patient well over a long period of time. In our research project we asked a 
specialist in old age psychiatry or geriatric medicine to use the ICD-10 criteria (WHO 1992) 
for dementia and delirium as an approach to the differential diagnosis. The diagnosis of 
delirium is likely, if the medical history showed a rapid onset of clouding of consciousness 
and disturbance of cognition and behaviour, in contrast to the dementia criterion of a slow 
decline in memory and other cognitive abilities, which has been present for at least six 
months.     
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4.7.2. Comorbid psychiatric disorders 
Patients with AD have a three-fold higher risk of exhibiting psychopathology than controls, 
with depressive disorders being by far the most frequent type of comorbid psychiatric 
disorder (see chapter 3.3). In fact, depressive episodes are known to precede the ‗onset‘ of 
clinical AD. Multiple studies have demonstrated an increased history of depression in patients 
who go on to develop dementia, compared with those who do not 
422
. Data from a case-
register study of almost 23,000 patients with an affective disorder suggested that increasing 
severity, expressed as the number of major depressive episodes leading to an inpatient 
admission, increased the risk of developing dementia 
423
. On average, the rate of dementia 
tended to increase 13% with every episode leading to admission for patients with depressive 
disorder, and 6% with every episode leading to admission for patients with bipolar disorder, 
when adjusted for differences in age and sex. The presence of depression in individuals with 
MCI is predictive of a higher likelihood of developing AD; after three years 85% of the 
depressed patients had developed AD, in comparison with 32% of the non-depressed subjects.  
  While several studies failed to find any association between insight into AD and 
depression 
424
, others have found the opposite 
425 426
.  
  The potential pathogenetic mechanisms leading to the development of depression in 
dementia include psychosocial factors, prior psychiatric history, level of education, genetic 
risks, and biological changes associated with the process of dementia per se. These biological 
changes include inflammatory processes, abnormalities of monoaminergic transmission, and 
neuroanatomical pathology, like the presence of white matter hyperintensivities and 
hypometabolism in frontal lobes that has been associated with depression in dementia 
427 428
. 
Depression and AD may share common pathogenic mechanisms that would explain the higher 
prevalence of depression in AD patients. These include structural and functional 
abnormalities of common neuroanatomical regions, specifically atrophy of mesial temporal 
and mesial frontal structures, like the hippocampus 
429 430
. 
  Depression in AD very often differs symptomatically from primary depressive 
disorders. Its early recognition and treatment are important, as persistent depression may have 
a very negative impact on the QoL of patients and families, and may accelerate cognitive 
detoriation, or the need to transfer the patient to a NH. This is exemplified in a prospective 
study 
431
 with AD patients, who were evaluated annually. The presence of depression was, in 
addition to the cognitive impairment level, physical aggression and hallucinations, one of four 
predominant predictors of institutionalisation.    
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  Depression in AD may mimic major and minor depression seen in primary depressive 
disorders. Depression in dementia is more likely to have an atypical presentation. The patients 
are often unable to express symptoms of depressed mood (e.g., feelings of sadness or 
hopelessness, or suicidal ideation), as these require relatively unimpaired higher cognitive 
functions, the ability to recall recent events, and to think in the abstract. Furthermore, patients 
with AD are likely to exhibit a variety of physical and neurovegetative symptoms that are 
directly related to the underlying medical and neurological disorder, such as apathy, fatigue, 
disturbances of sleep and appetite, mood swings and crying attacks, all of which may also be 
present in non-depressed AD patients 
432
. In addition, often those symptoms that are elicited 
may not be present ‗most of the day, nearly every day‘ as required by the criteria of 
dysthymia or major depression.   
  Apathy is a particularly problematic symptom, as it may occur in depressed and non-
depressed AD patients. For example, in the Cache County Study, apathy was identified in 
almost one-third of AD patients; 40% of these patients were found to suffer from depression 
179
. Some of the other differences in depression between individuals with and without 
dementia include the presence of more ‗motivation‘ symptoms and fewer ‗mood‘ symptoms 
among people with dementia, despite a similar severity of depressive symptoms 
433 434
. 
Additionally, several studies have suggested that depressed patients with AD are more likely 
to exhibit psychotic, as well as aggressive, symptoms 
435-437
. Research studies fairly 
consistently report higher frequencies of depression in dementia with Lewy bodies, e.g. 
Ballard 
438
 and Klatka 
439
, and Parkinson‘s disease dementia (PDD) 440 than in AD. 
  There is some evidence that depression is one factor leading to aggression 
441
. The 
goal of Lyketsos et al.‘s study was to determine the frequency of physically aggressive 
behaviour in community-residing patients with dementia and its relationship to depression. 
They found that aggressive behaviour was closely associated with moderate to severe 
depression, male gender, and greater impairment in the performance of the activities of daily 
living, even after adjustment for delusions, hallucinations, sleep disturbance, and the severity 
of cognitive impairment. After adjustment for depression, gender, and impairment in 
performing the activities of daily living, there was no association between physically 
aggressive behaviour and the presence of either delusions or hallucinations. Lyketsos et al. 
442
 
stated that depressive features are associated with agitation and psychosis and may mediate 
the relationship between other forms of psychopathology and aggressive behaviour. Such a 
mediating role might explain contradictory findings of prior studies. Another study 
373
 has 
assessed the relationship between depression and physically aggressive behaviour, and it 
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showed no association between the two. However, the investigators in that study used a less 
systematic quantification of depressive symptoms and a broader definition of aggression. 
Furthermore, the number of subjects was much smaller.  
  The heterogeneity of depressive symptoms in AD may often preclude the recognition 
of depression. To overcome this problem, the National Institute of Mental Health has 
developed provisional diagnostic criteria for depression in AD 
443 444
.  
  
Anxiety, as an important and often overlooked part of BPSD, should be mentioned as a 
differential diagnostic challenge. Until recently, little attention has been paid to anxiety 
symptoms in dementia 
445
. However, anxiety is common in this population with a prevalence 
rate ranging from 5% to 21%, and associated with poor outcome and quality of life 
446-448
. The 
prevalence of anxiety symptoms ranges from 8% to 71% 
259 449
. The rate of anxiety disorders 
and symptoms in dementia varies dramatically from study to study, suggesting that there is a 
lack of consensus about how to define and conceptualize anxiety in this population. Several 
issues complicate this question, including the distinction between symptoms of anxiety and 
symptoms of dementia, the overlap between anxiety, depression, and agitation, and what 
constitutes the best source of information. Using revised diagnostic criteria for anxiety 
disorders in dementia, as has been proposed by Starkstein et al. 
450
, is a promising approach. 
Such an approach, however, should be based on consensus guidelines from experts in the field 
in addition to empirical data, as exemplified by the provisional diagnostic criteria for 
depression in AD 
444
. 
People with dementia must deal with significant changes - from threats to their 
physical and financial independence to loss of spouses and friends, home and the freedom to 
make their own decisions - at a time when they are often least equipped to deal with them. A 
state of anxious tension and frustration is built up caused by the feeling of losing control over 
life, losing orientation in time, by chaotic impressions, being exposed to stress and not able to 
use former coping strategies anymore, being dependent on unknown others, losing intimacy 
and privacy.  
 Anxiety disorders have been underestimated for several reasons. For example, older 
patients, and especially dementia patients, are less likely to report psychiatric symptoms and 
more likely to emphasize their physical complaints. There are only a few such studies, and 
some major epidemiological studies have excluded general anxiety disorders (GAD), one of 
the most prevalent anxiety disorders in older adults. However, an anxiety disorder should be 
considered in any patient with depressive symptoms or with physical symptoms that are not 
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explained by a physical problem, such as chest pain, palpitations, shortness of breath, 
diarrhoea or sleep problems, or behavioural disturbances like agitation or aggression, 
wandering and shouting. Though some question the "capacity" for anxiety in those with 
limited cognition, the same question has not been raised about children, who also have an 
underdeveloped nervous system. 
"What may be operating in both cases…are right-brain phenomena, such as the role of 
intuition, sensing, interpreting or misinterpreting something that seems not right… 
There are many examples in the case of anxiety where the diagnosis does not rely on 
what patients say, but rather on what they display. Overlooking the potential role of 
anxiety as clinically significant in AD is to overlook important intervention 
opportunities.‖ (Cohen, 1998) 451  
 Anxiety in AD is a frequent comorbid condition of major depression. GAD was present in 
26% with major depression and in 5% without depression 
450
. The authors validated a set of 
diagnostic criteria for anxiety in dementia. These criteria include restlessness, irritability, 
muscle tension, fears, and respiratory symptoms in the context of excessive anxiety and 
worry.  
  Another important question regarding anxiety symptoms in dementia is whether they 
should be considered as a separate clinical entity or as part of a broader syndrome. Some 
authors have suggested that there is a strong overlap between anxiety and agitation 
452
, and 
that perhaps agitation may be a symptom of generalized anxiety 
453
. To determine whether 
anxiety is distinct from other neuropsychiatric symptoms in dementia, Seignourel et al. 
454
 
reviewed six factor analyses pertaining to this question. Four studies used orthogonal 
rotations, constraining factors to be uncorrelated, which may result in the appearance of 
unreliable factors 
455
. The other two studies used oblique rotations. Regarding the overlap 
between anxiety and agitation, two studies 
456 457
 found anxiety and agitation to load on the 
same factor, while three others 
458-460
, including the two studies that used oblique rotations 
459 
460
, found them to load on separate factors. Moreover, one study that explicitly examined the 
relationship between anxiety and agitation found only a modest correlation, suggesting that 
the two constructs are not equivalent 
461
. Thus, the existing evidence provides more support 
for the distinctiveness of anxiety and agitation than for their equivalence. 
  Aggressive and non-aggressive agitation occur in about 20% of people with AD in 
contact with clinical services 
179
 or living in the community 
462
 and 40% to 60% of people in 
care facilities 
463
. A review of 55 studies, showed that psychosis was reported in 41% of 
patients with Alzheimer's disease, including delusions in 36% and hallucinations in 18% 
464
. 
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Aggressive behaviour was more frequent among patients with hallucinations than among 
those without. About a quarter of the variance in aggression could be attributed to psychosis 
373
. Psychotic phenomena in dementia do not have the same quality as those that occur in 
primary psychotic disorders such as schizophrenia. It is sometimes difficult to distinguish 
between true delusions and the overvalued ideas in someone with cognitive impairment. 
Often, delusions of patients with AD are of a paranoid nature and simple, probably because of 
cognitive impairment that precludes the elaboration of complex ideas. Hallucinations are 
slightly less common than delusions, and when they occur, they are usually visual. They may 
be striking and complex and lead to reactions, as for example a patient leaves the TV on so as 
not to disturb the others, whom she sees sitting there watching a programme. Visual 
hallucinations are a key symptom of DLB and PDD 
438 465
. The frequency of psychosis and 
agitation is similar in patients with VaD to people with AD, but delusions and visual 
hallucinations are significantly more frequent in DLB 
438
 and PDD 
440
. Psychotic symptoms 
are probably associated with the severity of the illness 
182
, and seem to occur more often in 
women than in men 
466
. Several studies report an association between delusions and the 
upregulation of muscarinic M1 or M2 receptors in DLB 
467 468
 and AD 
469
. Teaktong et al. 
summarised their results as follows: Impaired consciousness was significantly associated with 
increased M4 binding and delusions were significantly associated with increased M2 binding. 
Increased M2 and M4 receptor binding in DLB was also associated with visual hallucinations. 
Upregulation of M2 and M4 muscarinic receptors in the cingulate and adjacent cortex may 
thus contribute to the development of psychosis in DLB. Psychosis in general appears to 
increase in frequency with greater burden of neurofibrillary tangles 
470
. In DLB there is a 
well-established relationship between visual hallucinations and reduced cholinergic function 
467 471
, but the relationship is less clear in the context of AD 
381
. 
 4.8. Non-pharmacological therapy of agitation   
The treatment of agitation ideally entails identification and alteration of underlying causes as 
physical, environmental, social, and psychiatric factors 
472
. Most researchers and clinicians 
who treat agitated patients with dementia believe that behavioural and psychosocial treatment 
should be the primary approach 
473
. However, patients with aggressive agitated behaviour 
(either event or non-event related) may not respond to the behavioural treatment approach and 
will require the additional use of pharmacological agents. In 1996, Mintzer 
474
 proposed a 
clinical decision tree that is still helpful. We have adjusted it (Figure 4.8.1). Salzman et al. 
475
 
supported this procedure.  
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Figure 4.8.1. Clinical decision tree for the treatment of agitated patients with dementia,    
                        adjusted (Source: Mintzer, 1996). 
 
  Before looking at the different treatment options, it is useful to discuss the term 
‗efficacy‘, briefly. ‗Efficacy‘ in our context may mean that an intervention reduces the 
severity of agitation or number of symptoms, or improves the function in ADL and cognition; 
it may also mean that the therapy reduces the carer burden, or has a positive impact on the 
prevention of detoriation of cognition. Consequently, prevention of disability or reduction of 
the speed of decline may count as a positive outcome. Some newer studies have other efficacy 
outcomes, like the period of time the drug was taken as an indication, e.g., of how well 
patients tolerate the drug or if the treatment helps.  
Agitation 
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Pharmacological treatment 
Agitation 
still 
persists 
Side effects? Effect?  
Reevaluate – Withdraw 
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4.8.1. Behavioural and psychosocial interventions 
The ‘standard paradigm‘ for understanding dementia has been a medical or disease model. 
However, a number of findings indicate that causal mechanisms are far from straightforward, 
and a broader focus is needed 
476
. A more complete explanation requires consideration of 
psychosocial factors. An ‗alternative paradigm‘ to the pure biological view has been most 
clearly articulated by Kitwood 
477 478
 
479
 - a pioneer in the field of person-centred dementia 
care. He proposed a dialectical model of dementia, which is summarised in Figure 4.8.2. The 
term ‗dialectical‘ reflects the emphasis on interactions between variables operating at the 
biological and psychosocial levels.  
 
Figure 4.8.2.  Dialectical model of dementia (based on Kitwood, 1997). 
 
 
 
 
 
 
 
 
 
 
 
  Kitwood suggested that the manifestation and progression of AD in any individual are 
influenced by the interplay of neurological impairment, physical health and sensory acuity, 
personality, biographical experiences, and social psychology, in terms of environment, 
communication and interaction. Consequently, a therapeutic approach to agitation, and other 
behavioural disturbances in dementia, has to take into consideration each of these facets as a 
possible treatment approach. The brain has considerable potential for change (plasticity), 
some of which is retained in dementia. It was conceptualised that psychological experiences 
may affect the structure of the brain just as the brain structure may affect experience. This has 
clear implications for the provision of care, indicating a requirement for care that meets 
people‘s psychological needs and affirms personhood, sense of self and social value. These 
may have a positive impact on the QoL. Kitwood believed that a benign social psychology 
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coupled with an enriched environment might facilitate some regeneration or at least the 
maintenance of function for a period. While a malignant social environment might contribute 
to greater disability and speed up a decline (see Figure 4.8.2).  
 There is some evidence that supports this theory: Karlsson et al. 
480
 reported in an 
experimental study that environmental factors influenced biochemical markers of transmitter 
activity. Widerlov et al. 
481
 observed improvements in intellectual and motor functioning 
induced by integrity-promoting care and that somatostatin concentrations in cerebrospinal 
fluid were significantly elevated in an experimental group, but not in a control group. 
Conceptualising dementia within a bio-psycho-social framework encourages us to consider 
each of these levels and the interactions between them, in order to maximise well-being. 
Kitwood‘s dialectical model is consistent with this approach. Tom Kitwood developed 
innovative research projects and training courses, challenging the "old culture of care". His 
aim was to understand, as far as possible, what care is like from the standpoint of the person 
with dementia. One of his major innovations was Dementia Care Mapping (DCM), an 
observational method for evaluating the quality of care in formal settings. Kitwood described 
the DCM tool as based on ―a serious attempt to take the standpoint of the person with 
dementia, using a combination of empathy and observational skill.‖ The reasons for using 
DCM in practice can be listed as follows: driving forwards person-centred care through a 
developmental evaluation, assessing difficult situations with residents or at particular times of 
the day, staff training, to demonstrate the QoC, research and evaluation of interventions.  
Kitwood was always interested and involved in research with the aim of following it 
through to practice. His book ‗Dementia Reconsidered: The Person Comes First‘ (1997) 
brought together all his work, developments and discoveries. His philosophy is based on 
"person-centred care" (PCC), quite simply summarised as "treat others in the way you 
yourself would like to be treated".  
Edvardsson et al. 
482
 emphasised that PCC generally includes the recognition that the 
personality of the person with AD is increasingly concealed rather than lost, includes the 
tailoring of the person‘s care and their environment to their needs, offers shared decision-
making, interprets behaviour from the point of view of the patient, and prioritises the 
relationship as much as the care tasks.   
The Need-Driven Dementia-Compromised (NDB) Behaviour Model (see Figure 
4.8.3.) 
401
 has a similar approach to that of Kitwood. 
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Figure 4.8.3.  The Need-Driven Dementia-Compromised (NDB) Behaviour Model (Algase et 
  al., 1996). 
  
  Seemingly simple adjustments in care routines and approaches can make a significant 
difference to the experience of people with dementia 
483
. They suggested interventions that 
can help providers understand the "behavioural symptoms" of dementia, which are often 
considered a way of communicating unmet needs. By focusing on the person rather than on 
the disease, nurses promote comfort and functional autonomy in older adults whose cognitive 
impairments have progressed and yet who are very much alive and deserving of respectful, 
dignified care.  
  Brooker 
484
 developed the concept of PCC further to what she called VIPS, an 
acronym for the four key elements of PCC. ‗V‘ stands for ‗values people‘ with dementia and 
those who care for them, ‗I‘ for ‗treat people as individuals‘ – individualised care recognises 
the uniqueness of the person, ‗P‘ for ‗perspective of service users‘ – the experience of the 
person with dementia is the starting point, and ‗S‘ for ‗supportive social psychology‘ – 
relationships are paramount.   
Chenoweth et al. 
485
 conducted a cluster-randomised trial, the ‗Caring for Aged 
Dementia Care Resident Study (CADRES)‘ of PCC and DCM compared with the standard 
system of care in dementia. The primary outcome was agitation measured with the CMAI. 
The CMAI score was lower in sites providing DCM and PCC compared with the standard 
system of care. At 4 and 8 months, agitation had increased in the control group but decreased 
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in residents under the experimental care approaches. The CMAI proved to be more sensitive 
than the NPI-NH in detecting improvement in behaviour. The authors concluded that care that 
addresses residents' total human needs may mitigate cognitive and functional deterioration, 
supporting the need for individually tailored behavioural intervention. Ballard and Aarsland 
486
 commented on the study, saying that CADRES is of major importance in showing the 
value of DCM as an effective approach to reducing agitation in care-home residents with 
dementia. 
  Marte Meo supervision (MMS) is another method intended to support communication 
and interactions between the carer and a person with dementia. It was developed by the 
pedagogue Maria Aarts during the 1980s using videotape to help with diagnosis and treatment 
of the child-parent interaction. Later on, this method was also applied in dementia care. It uses 
short video recordings of an interaction, followed by staff training. It has not been possible to 
find a scientific article published either in an international journal, a meta-analysis or a 
Cochrane Review that evaluates this method in dementia care.   
 A Cochrane Review 
487
 evaluated music therapy as a therapy for behavioural, social, 
cognitive and emotional problems. Five studies were included. The methodological quality of 
the included studies was too poor to draw any useful conclusions. However, the evidence 
available suggests that music therapy may be beneficial in treating or managing dementia 
symptoms (Table 4.8.1). Linda Gerdner was one of the first to apply systematically 
individualised music as therapy for agitation in dementia 
488 489
. A statistically significant 
reduction in agitation was found during the presentation of music. Staff and family interviews 
provided convergent validity of these findings. Music also promoted meaningful interaction 
between the resident and others. Gerdner 
489
 suggested that music may help residents to shift 
focus from meaningless and confusing stimuli to the sort of stimuli a person with dementia is 
able to interpret 
490
. Hicks-Moore 
491
 found that relaxing music during mealtimes reduced 
agitated behaviour. At the end of the 4-week study, overall reductions in the cumulative 
incidence of total agitated behaviour were observed. Reductions in absolute numbers of 
agitated behaviour were achieved during the weeks with music. Clark et al. 
492
 investigated 
the response of aggressive behaviour to individualised music during bath time. While the 
music was playing, 12 out of 15 identified aggressive behaviour types decreased. Decreases 
were significant for the total number of observed types of behaviour and especially for the 
hitting type of behaviour. While the music was playing, carers frequently reported an 
improved state of mood and a general increase in cooperation with the bathing task. 
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  Garland et al. 
493
 compared simulated family presence with preferred music as 
treatment of agitated behaviour in NH residents with dementia. Simulated presence and 
preferred music both proved to be effective in reducing incidents of physically agitated 
behaviour. Simulated presence, but not music, resulted in significantly reduced incidents of 
verbally agitated behaviour. The placebo tape proved more effective than expected. 
Participants' responses to simulated presence and music varied widely. Incidents of agitated 
behaviour fell by one-half or more in many cases. However, other residents became more 
agitated.  
 Physical activity programmes have been evaluated and published in a Cochrane 
Review by Forbes et al. 
494
. Four trials met the inclusion criteria, but only two were included 
in the analyses. The result of this review suggests that there is insufficient evidence of the 
effectiveness of physical activity programmes in managing or improving cognition, function, 
behaviour, depression, and mortality in people with dementia. Few trials have examined these 
important outcomes. In addition, family carer outcomes and use of health care services were 
not reported in any of the trials included (Table 4.8.1). 
 Validation therapy – A Cochrane Review 495, found no statistically significant 
differences between validation and social contact or between validation and  standard therapy. 
There was no assessment of carers.  There is insufficient evidence from randomised trials 
(Table 4.8.1). 
 Hand massage and therapeutic touch were effective in producing a relaxation response 
in persons with dementia who had a history of agitated behaviour; they did not, however, 
decrease agitation behaviour. Hand massage was more effective in producing relaxation than 
was therapeutic touch 
496
.  
 Li-Chan Lin et al. 
497
 explored the effectiveness of acupressure and Montessori-based 
activities in institutionalized residents with dementia in a cross-over trial. They compared the 
treatment with the potentially calming presence of a visitor who acted as a control. All 
participants underwent all three treatments in three different sequences. Acupressure daily (6 
days weekly) for 4 weeks significantly decreased overall agitated behaviour, especially in the 
CMAI subcategories of physically non-aggressive and physically aggressive behaviour. 
Montessori-based activities significantly reduced aggressive behaviour and physically non-
aggressive behaviour. Neither approach decreased verbally agitated behaviour. Nursing 
assistants noted that it was easier to assist residents with eating, toileting, bathing, grooming, 
sleeping, walking, and various other activities after the acupressure or Montessori-based 
activities. 
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 A Cochrane review 
498
 (reviewed April 2008), described the effect of a method called 
Snoezelen, which is a multi-sensory stimulation programme. Four trials were included 
499-502
. 
They examined the short-term, and/or longer-term values of Snoezelen on the behaviour of 
people with dementia. Meta-analyses could not be performed because of the limited number 
of trials and different study methods used. Overall, there is no evidence showing the efficacy 
of Snoezelen for dementia (Table 4.8.1). 
Livingston et al. reviewed the literature 
503
 of psychological approaches in the management of 
neuropsychiatric symptoms of dementia (Table 4.8.1). They concluded:   
―Only behaviour management therapies, specific types of carer and residential care 
staff education, and possibly cognitive stimulation appear to have lasting effectiveness 
for the management of dementia-associated neuropsychiatric symptoms. Lack of 
evidence regarding other therapies is not evidence of lack of efficacy. Conclusions are 
limited because of the paucity of high-quality research (only nine level-1 studies were 
identified). More high-quality investigation is needed.‖  
  
Table 4.8.1.  Evidence for Psychological Therapies (Livingston 2005, Am J Psychiatry) 
Treatment RCT 
Cochrane 
Review 
Number of 
participants 
Evidence 
  Reality 
Orientation 
6 Spector 2002 ? withdrawn 
Validation 3 
Neal & Barton 
Wright 2003 
116 
Insufficient 
evidence 
Reminiscence 4 Woods 2005 144 
Promising 
indications 
Multi sensory - 
Snoezelen 
2 
Chung & Lai 
2002 
260 No evidence 
Light therapy 5 Forbes 2009 ? 
Insufficient 
evidence 
Physical activity 
programs 
2 Forbes 2008 145 
Insufficient 
evidence 
Music therapy 5 Vink 2004 125 (?) 
Promissing, but 
no conclusion 
 
References: 
487 494 495 498 504 505
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Kverno et al. 
506
 performed another systematic literature review focusing on treatment of 
neuropsychiatric symptoms in persons with advanced dementia. Out of 215 only 21 
specifically focused on treatments for individuals with moderately severe to very severe 
dementia. These 21 studies provided moderate to high quality evidence for the use of sensory- 
focused strategies, including aroma therapy, music preferred by the patient or live music, and 
multi-sensory stimulation. Interventions appear to work best when they are tailored to balance 
individual arousal patterns.  
 O‘Connor et al. 507 performed a further systematic review of 12 selected experimental 
studies to evaluate the effectiveness of psychosocial treatments in reducing psychological 
symptoms in dementia (e.g. anxiety, depression, irritability and social withdrawal). They 
concluded:  
―Some psychosocial interventions appear to have specific therapeutic properties, over 
and above those due to the benefits of participating in a clinical trial. Their effects 
were generally modest with an unknown duration of action. This limited efficacy 
suggests that treatments will work best in specific, time-limited situations, tailored to 
individuals' requirements. There is no preferred method to rate psychological 
symptoms.‖ 
4.8.2. Environmental changes 
Evidence that carer and environmental precipitating factors are of importance for BPSD is 
scattered 
508 509
. Testad et al. conducted 
510
 a comparative survey comparing environmental 
influences on agitation and the use of psychotropics in NH residents in three European 
countries: Norway, Austria and England. They found differences in agitation and 
antipsychotic drug use which are likely to be related to structural and cultural differences in 
nursing homes between these three countries. The findings suggest that structural changes can 
improve the quality of care and the quality of life for nursing-home residents. 
  Zuidema et al. 
511
 reported that the prevalence of neuropsychiatric symptoms differed 
between SCUs, also after correcting for patient factors. Patient-related factors explained 7 to 
21% of the total variance of neuropsychiatric symptoms. When the staff spent more time on 
care activities, patients‘ level of apathy decreased. He further described a substantial variation 
of prevalence rates between SCUs. This finding in combination with the clustering of 
symptoms within SCUs is strong evidence that environmental factors contribute to 
neuropsychiatric symptoms in dementia. 
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4.8.3. Educational approaches 
Boustani et al. 
347
 studied the characteristics associated with behavioural symptoms related to 
dementia in long-term care residents. The prevalence of BPSD was associated with staff 
training and residents‘ cognition, mood, mobility, and psychotropic use. They concluded that 
attention to staff training and depression management might improve BPSD. 
  Graff et al. 
512
 provided a 10-session occupational therapy programme over five 
weeks. The patients were trained to use aids to compensate for cognitive decline. The family 
carers learned how to cope better with challenging behaviour in patients. The intervention 
improved patients' daily functioning and reduced the burden on the carers, despite the 
patients' limited learning ability. Effects were still present at 12 weeks, which justifies 
implementation of this intervention. Graff et al. 
513
 concluded in another article that 
community occupational therapy should be advocated both for dementia patients and their 
carers, because it improves their mood, the quality of life, and health status and the carers' 
sense of control over life. Effects were still present at the follow-up interview. In addition, 
Graff et al. showed 
514
 that community occupational therapy intervention for patients with 
dementia and their carers is cost effective. 
 Spijker et al. 
515
 have developed the Systematic Care Program for Dementia (SCPD). 
They found an urgent need for cost-effective support programmes, including education, that 
may prevent informal carers of people with dementia from becoming overburdened, which 
might result in a delay or decrease in patient institutionalisation. Spijker et al. reported the 
aim and design of an ongoing multi-centre, cluster randomised, controlled trial. 
  The Tailored Activity Program (TAP) 
516
 is a home-based occupational therapy 
intervention. In a randomised trial, this intervention showed that it could reduce behavioural 
symptoms and the burden on carers. TAP involves 8 sessions over a period of 4 months. 
Preserved capabilities, the previous roles, habits, and interests of individuals with dementia 
are identified. Thereafter, activities customized to individual profiles are developed; and the 
families are trained in the use of the relevant activities. Carers reported great confidence in 
using these activities, being less upset with behavioural symptoms (86%), enhanced skills 
(93%) and personal control (95%). Therapists observed enhanced engagement (100%) and 
pleasure (98%) in individuals with dementia during the sessions. 
  Shah and De 
517
 studied the effect of an educational intervention programme with the 
aim of reducing aggressive behaviour directed towards nursing staff. The efficacy was 
prospectively evaluated over an 18-week period. The programme was administered during the 
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middle 6-week period. Aggressive behaviour was measured using the RAGE and SOAS 
scales. Aggressive behaviour measured with both scales was reduced after the educational 
intervention.  
  Testad et al. 
364
 investigated the effect of staff training on the use of constraints in a 
single-blind controlled trial. The content of the educational programme focused on the 
decision-making process in the use of restraint and alternatives to restraint. The intervention 
consisted of a full day seminar, followed by a one-hour session of guidance per month over 
six months. The primary outcome measures were number of restraints per patient in the 
nursing-homes in one week and agitation was measured with the Brief Agitation Rating Scale 
(BARS). After the intervention period, the number of restraints had declined by 54% in the 
treatment group, and increased by 18% in the control group. 
  Fossey et al. 
518
 delivered training and support intervention to nursing-home staff over 
10 months, focusing on alternatives to drugs for the management of agitated behaviour in 
dementia (FITS trial). At 12 months the proportion of residents taking antipsychotics in the 
intervention homes (23.0%) was significantly lower than that in the control homes (42.1%). 
No significant differences were found in the levels of agitated or disruptive behaviour 
between intervention and control homes. The overall QoL was not improved, but individual 
QoL may have been improved. These results showed that educational intervention and 
support are an effective alternative to antipsychotics.  
  Cohen-Mansfield et al. 
519
 explored the effect of staff education on how to enable 
engagement in persons with dementia. Significant, positive correlations were found between 
higher cognitive functioning and longer engagement duration, more attention, a more positive 
attitude and a lower refusal rate. There was a positive and significant correlation between the 
co-morbidity index and engagement duration, and between the number of medications and 
attention. All functional status variables yielded significance in a positive direction. 
Participants with poor hearing had a higher refusal rate. Cognitive status was the most 
consistent and potent predictor of engagement in this population. 
  Ballard et al. 
520
 conducted a study to examine the effect of a psychiatric liaison 
service in care homes. The main outcomes were changes in NPI, reduction of use of 
antipsychotics and GP visits. There was a significant reduction in the use of antipsychotics in 
the facilities receiving the liaison service, but not amongst those receiving standard clinical 
support. There were also significantly less GP contacts for residents in the facilities receiving 
the liaison service, and a three-fold reduction in psychiatric in-patient bed usage (bed days per 
person 0.6 vs. 1.5). Residents in care facilities receiving the liaison service experienced 
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significantly less deterioration in expressive language skills, but there were no significant 
differences in BPSD or wellbeing. 
  Kuske et al. published a review on NH staff training 
521
. A total of 21 studies were 
identified, mostly published in the United States. Most were of poor methodological quality. 
Although nearly all reported positive effects, their results must be interpreted cautiously due 
to methodological weaknesses. Vasse et al. 522 performed a systematic review for the use of 
communication strategies in residential and nursing-homes. The aim of this review was to 
study the effects of non-pharmacological interventions in residential and nursing-homes on 
(1) communication between residents with dementia and care staff, and (2) the 
neuropsychiatric symptoms of residents with dementia. Interventions around daily care 
activities had positive effects on communication outcomes. Effects of both types of 
interventions on neuropsychiatric symptoms were divergent. 
  Levy-Storms 
523
 reviewed critically the contemporary experimental research and found 
that the following therapeutic communication techniques can be taught and can benefit staff 
and older adults' quality of life: verbal and non-verbal communication behaviour including 
open-ended questions, positive statements, eye contact, affective touch, and smiling. Nursing 
aides need not only more training in therapeutic communication, but also ongoing, dedicated 
supervision in psychosocial aspects of care. 
 
Non-pharmacological interventions offer the potential for safer alternatives to 
pharmacotherapy and, therefore, should always be the first approach. Ballard et al. 
486
 
reviewed the increasing evidence in support of psychological interventions or alternative 
therapies (such as aromatherapy) as a first-line management strategy for agitation, as well as 
the potential pharmacological alternatives to atypical antipsychotics - preliminary evidence 
for memantine, carbamazepine, and citalopram is encouraging. That leads on to the next 
chapter. 
 4.9. Studies on psychopharmacological treatment of agitation 
4.9.1. Antipsychotic agents 
Antipsychotics are widely used as the first-line pharmacological approach to treat the 
neuropsychiatric symptoms of dementia. Efficacy has been examined in eight randomised, 
double-blind, placebo-controlled trials with typical antipsychotics and 18 double-blind, 
placebo-controlled trials with atypical antipsychotics. The atypical antipsychotic risperidone 
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was recommended in view of its modest efficacy and relative safety until FDA warnings were 
issued in 2005 and 2008 and meta-analytic studies showed no significant difference to 
placebo. The U.S. Food and Drug Administration‘s (FDA) warnings on the cardiac, 
metabolic, cerebrovascular, and mortality risks have caused serious concerns for the use of 
typical and atypical antipsychotic agents for elderly patients with dementia. The following 
overview will provide the results of studies investigating the effectiveness and side effects of 
antipsychotics prescribed for agitation in dementia, proceeding historically. 
4.9.1.1. First generation antipsychotics (vs second generation) 
Schneider et al. 
524
 performed a meta-analytic review of the existing literature as early as 
1990. Results indicated that antipsychotics were significantly more effective than a placebo, 
but that the effect was small (r = .18). This indicates that 18 out of 100 dementia patients 
benefited from antipsychotic treatment (beyond that of a placebo) and is consistent with the 
modest efficacy described in previous qualitative reviews. In six studies comparing 
thioridazine with another antipsychotic, and in five studies comparing haloperidol with 
another antipsychotic, meta-analysis results did not show that these two medications differed 
significantly from the comparison medications, which is not inconsistent with the opinion that 
no single antipsychotic is better than another. This was the evidence base in 1990.  
  A Cochrane Review performed by Lonergan et al. 
34
 studied the effectiveness of 
haloperidol. Five trials were included and led to the following results: there was no significant 
improvement in agitation among haloperidol treated patients, compared with controls treated 
with a placebo. Aggression decreased among patients with agitated dementia treated with 
haloperidol; other aspects of agitation were not affected significantly. Although two studies 
showed increased drop-out rates due to adverse effects among haloperidol patients, there was 
no significant difference in drop-out rates when haloperidol-treated patients were compared 
with controls. The data were insufficient to examine response to treatment in relation to 
length of treatment and degree of dementia. Authors‘ conclusion: No evidence has been found 
of any significant general improvement in manifestations of agitation, other than aggression, 
among demented patients treated with haloperidol, compared with placebo-treated controls.  
4.9.1.2. Comparison of first generation with second generation antipsychotics 
De Deyn et al. 
525
 studied the effectiveness of risperidone and haloperidol compared with a 
placebo in patients with dementia. A 13-week double-blind study involving 344 patients with 
dementia randomly assigned patients to receive a placebo or flexible doses (0.5 to 4 mg/d) of 
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risperidone or haloperidol. Behavioural symptoms were assessed by the BEHAVE-AD, the 
CMAI, and the Clinical Global Impression (CGI) scale. The mean dose at the endpoint was 
1.1 mg/d of risperidone and 1.2 mg/d of haloperidol. Although not significant, a higher 
percentage of patients receiving risperidone than those receiving a placebo showed clinical 
improvement (30% or more reduction from baseline to endpoint in BEHAVE-AD total score). 
Reductions in the BEHAVE-AD total score were significantly greater with risperidone than 
with a placebo at week 12. In a further analysis of aggression, the most dominant symptom in 
these patients, BEHAVE-AD and CMAI aggression cluster scores were significantly reduced 
compared with a placebo at the endpoint and at week 12. Severity of extrapyramidal 
symptoms with risperidone did not differ significantly from that of a placebo and was less 
than that of haloperidol. A post hoc analysis showed significantly greater reductions in the 
BEHAVE-AD aggressiveness score with risperidone than haloperidol at week 12. The authors 
concluded that low-dose risperidone (mean 1.1 mg/d) was well tolerated and associated with 
reductions in the severity and frequency of behavioural symptoms, particularly aggression, in 
elderly patients with dementia.  
  Chan et al. 
526
 conducted a RCT comparing risperidone with haloperidol in 58 patients 
with DSM-IV diagnosis of dementia of Alzheimer's type or vascular dementia. They were 
randomly assigned to receive flexible doses (0.5 to 2 mg/day) of haloperidol or risperidone. 
Clinical response was evaluated using the CMAI, the BEHAVE-AD, Simpson-Angus Scale 
(evaluates drug-related extrapyramidal syndromes), Functional Assessment Staging and 
Cantonese version of the Mini-Mental State Examination. The study obtained the following 
results: the mean doses during the last week were 0.90 mg/day of haloperidol and 0.85 
mg/day of risperidone. Both haloperidol and risperidone significantly reduced the severity of 
BPSD (scores on CMAI and BEHAVE-AD), with no significant between-group differences. 
Haloperidol-treated patients showed a worsening on the Simpson-Angus scale, while there 
was no significant change in this measure in risperidone-treated patients.  
  Suh et al. 
527
 performed a similar study comparing haloperidol with risperidone. This 
was an 18-week double-blind, crossover study involving 120 patients who were randomly 
assigned to receive flexible doses (0.5-1.5 mg/day) of risperidone or haloperidol. BPSD were 
assessed using the BEHAVE-AD, the CMAI, and the Clinical Global Impression of Change 
scale (CGI-C). Both risperidone and haloperidol were efficacious in alleviating BPSD. 
However, when receiving risperidone, patients showed significantly greater improvement 
than when receiving haloperidol in the total and sub-scale scores of the BEHAVE-AD, the 
total and sub-scale scores of the CMAI, and the scores on the CGI-C scale. Also, risperidone 
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had an additional benefit on aggressiveness and anxiety/phobia. The risk of antipsychotic-
induced parkinsonism throughout this study was significantly lower with risperidone than 
with haloperidol.  
  Gareri 
528
 evaluated the efficacy and safety of risperidone or olanzapine vs. promazine 
in the treatment of BPSD. In this study 60 patients were randomised to the intervention. The 
NPI was administered at baseline, after 4 and 8 weeks. Patients had at least a total score of 24 
or more on NPI at baseline. The scale was administered by an clinical research assistant who 
was not aware of the kind of treatment of the patients. 20 patients were randomly assigned to 
1 mg daily of risperidone in divided doses; 20 patients were randomly assigned to 5mg of 
olanzapine at bedtime, and 20 patients were randomly assigned to 50 mg of promazine daily. 
If there was a lack of clinical response after 4 weeks, the dose could be increased to 2 mg/day 
of risperidone, 10 mg/day of olanzapine, and to 100 mg/day of promazine in the respective 
groups. At the end of the 8th week, a global improvement was obtained in 80% of the patients 
treated with risperidone and olanzapine, vs. 65 % of patients treated with promazine (p < 
0.01). The authors concluded that  
―risperidone in doses of 1-2 mg/day and olanzapine in doses of 5-10 mg/day are 
effective and safe in the treatment of BPSD. Risperidone presents a major and dose-
dependent antidopaminergic action and seems to be preferable when hallucinations 
and delusions are the prevailing symptoms, though it also gives good results on 
aggression and wandering. Olanzapine seems to be faster in its sedative effect, 
probably because of its H1 receptor blockade. Moreover, 5-HT6 antagonism may 
favour acetylcholine release and this explains why these patients did not present with 
cognitive worsening. However, both drugs are comparable or even superior to 
promazine, with significantly fewer side effects of both anticholinergic and 
extrapyramidal character.‖ 
 Tariot et al. 
529
 conducted a multicentre, double-blind, placebo-controlled, randomised trial of 
flexibly dosed quetiapine and haloperidol. Primary outcomes were change in the total Brief 
Psychiatric Rating Scale (BPRS) and Clinical Global Impressions-Severity of Illness (CGI-S) 
scores at week 10. Secondary outcomes included BPRS factors, NPI, and the Physical Self-
Maintenance Scale (PSMS). Of the 284 randomised participants, 63.4% completed the study. 
The median of the mean daily dose was 96.9 mg for quetiapine and 1.9 mg for haloperidol. 
BPRS agitation factor scores improved with quetiapine versus a placebo, but no difference 
was found between quetiapine and haloperidol. BPRS anergy scores worsened with 
haloperidol versus quetiapine, but not quetiapine versus a placebo. No NPI factors showed 
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change, including the agitation factor. PSMS total scores worsened with haloperidol 
treatment, but not in patients treated with quetiapine. Somnolence occurred in 25.3%, 36.2%, 
and 4.1% of the quetiapine, haloperidol, and placebo groups, respectively. Parkinsonism was 
most prevalent in the haloperidol group. Other safety and tolerability measures differed little 
between the groups. All treatment groups showed improvement in measures of psychosis 
without significant differences between them when planned comparisons were performed. 
Participants treated with quetiapine or haloperidol showed inconsistent evidence of 
improvement in agitation. Tolerability was better with quetiapine compared with haloperidol. 
  Gill et al. 
530
 performed a population-based, retrospective cohort study to investigate 
the risk of death at 30, 60, 120, and 180 days after the initial dispensing of antipsychotic 
medication. Two pairwise comparisons were made: atypical versus no antipsychotic use and 
conventional versus atypical antipsychotic use. A total of 27,259 matched pairs were 
identified. New use of atypical antipsychotics was associated with a statistically significant 
increase in the risk of death at 30 days compared with non-use in both the community-
dwelling cohort and the long-term care cohort. Excess risk seemed to persist to 180 days, but 
unequal rates of censoring over time may have affected these results. The study concluded 
that atypical antipsychotic use is associated with an increased risk of death compared with 
non-use among older adults with dementia. The risk of death may be greater with 
conventional antipsychotics than with atypical antipsychotics. 
  Schneeweiss et al. 
531
 performed a retrospective cohort study in British Columbia, 
Canada, of 37,241 adults, 65 years of age or older, who were prescribed conventional 
(12,882) or atypical (24,359) antipsychotic medications for any reason between January 1996 
and December 2004. The investigators compared the 180-day mortality from any cause with 
use of a conventional antipsychotic versus treatment with an atypical antipsychotic. They 
found that the risk of death in the group of patients treated with conventional antipsychotic 
medications was comparable to, or possibly greater than, the risk of death in the group of 
patients treated with atypical antipsychotic medications. The causes of death with the highest 
relative risk were cancer and cardiac disease. As a consequence of this study and the study 
performed by Gill et al., the FDA considered that the methodological limitations in these two 
studies preclude any conclusion that conventional antipsychotics carry a greater risk of death 
than atypical antipsychotics. FDA (FDA Allert 2008) has determined, however, that the 
overall weight of evidence, including these studies, indicates that the conventional 
antipsychotics share the increased risk of death in elderly patients with dementia-related 
psychosis that has been observed for the atypical antipsychotics 
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(http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProv
iders/ucm124830.htm). 
  Tyrer et al. 
532
 investigated the use of antipsychotics compared with a placebo in the 
treatment of aggressive challenging behaviour for people with intellectual disabilities (the 
NACHBID trial). Mean daily dosages were 1.07 mg rising to 1.78 mg for risperidone and 
2.54 mg rising to 2.94 mg for haloperidol. Aggression declined dramatically with all three 
treatments by 4 weeks, with the placebo showing the greatest reduction (79%, versus 57% for 
combined drugs) (p = 0.06). Placebo-treated patients showed no evidence of inferior response 
in comparison to patients receiving antipsychotic drugs. An additional study found that 
clinicians who had not participated in clinical trials before were less likely to recruit. The 
mean total cost of accommodation, services, informal care and treatment over the 6 months of 
the trial was £16,336 for the placebo, £17,626 for haloperidol and £18,954 for risperidone.  
4.9.1.3. Second generation antipsychotics 
Risperidone 
Risperidone was the first atypical antipsychotic shown to be effective in treating BPSD and is 
currently the only atypical antipsychotic that is approved for the treatment of BPSD in a 
number of countries, including Norway.  
  Katz et al. 
233
 reported the findings from the first large, double-blind, placebo-
controlled study conducted to evaluate the efficacy and safety of risperidone in the treatment 
of psychotic and behavioural symptoms in institutionalized elderly patients with dementia. 
Each patient was randomly assigned to receive a placebo or 0.5 mg/day, 1 mg/day, or 2 
mg/day of risperidone for 12 weeks. The primary outcome measure was the BEHAVE-AD. 
The study was completed by 70% of the patients. At the endpoint, significantly greater 
reductions in BEHAVE-AD total scores and psychosis and aggressiveness sub-scale scores 
were seen in patients receiving 1 and 2 mg/day of risperidone than in placebo patients. More 
adverse events were reported by patients receiving 2 mg/day of risperidone than 1 mg/day. 
The most common dose-related adverse events were extrapyramidal symptoms, somnolence, 
and mild peripheral edema. The frequency of extrapyramidal symptoms in patients receiving 
1 mg/day of risperidone was not significantly greater than in placebo patients.  
  Brodaty et al. 
533
 randomised elderly patients with dementia of the Alzheimer's type, 
vascular dementia, or a combination of the two in a RCT. The participants had significantly 
aggressive behaviour and received for a period of 12 weeks a flexible dose of either a placebo 
or risperidone solution up to a maximum of 2 mg/day. Outcome measures were the CMAI, 
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the BEHAVE-AD, and the Clinical Global Impression of Severity (CGI-S) and of Change 
(CGI-C) scales. The trial was completed by 67% of patients in the placebo group and 73% of 
patients in the risperidone group. The mean dose of risperidone was 0.95 mg/day. The 
primary endpoint of the study, the difference from baseline to endpoint in CMAI total 
aggression score, showed a significant reduction in aggressive behaviour for risperidone 
versus placebo. A similar improvement was also seen for the CMAI total non-aggression sub-
scale and for the BEHAVE-AD total and psychotic symptoms sub-scale. Overall, 94% and 
92% of the risperidone and placebo groups, respectively, reported at least 1 adverse event. 
Somnolence and urinary tract infection were more common with risperidone treatment, 
whereas agitation was more common with a placebo. There was no significant difference in 
the number of patients who reported extrapyramidal symptoms between the risperidone (23%) 
and placebo (16%) groups. The authors concluded: treatment with low-dose (mean = 0.95 
mg/day) risperidone resulted in significant reduction in aggression, agitation, and psychosis 
associated with dementia. 
  From the year 2005 on, pooled analyses, systematic reviews and meta-analyses 
showed that there is a greater risk for serious adverse events connected to the use of atypical 
antipsychotics in patients with dementia. At the beginning, the conclusions were more 
favourable for the use of antipsychotics than later on. One example of this is the pooled 
analysis performed by De Deyn et al. 
534
, which included three randomised, placebo-
controlled double-blind trials in NH residents treated with risperidone in the management of 
agitation, aggression, and psychosis associated with dementia. The aim of this analysis was to 
assess the risk and benefit of the use of risperidone in this population. The efficacy data 
(risperidone n=722, placebo n=428) were obtained from the CMAI and the BEHAVE-AD 
total and sub-scales. Additionally, clinical global impression (CGI) assessments were 
performed. The mean dose of risperidone at the end point was 1.0 mg/day. The observed 
mean change at the end point was significantly higher for risperidone than for placebo on 
CMAI total score, and total aggression score, BEHAVE-AD total score, and psychotic 
symptoms score. The main treatment effects of risperidone were similar in all subgroup 
analyses. Additionally, risperidone-treated patients scored significantly better than placebo-
treated patients on the CGI scales at the end point. The incidence of treatment-emergent 
adverse events was comparable between risperidone (84.3%) and the placebo (83.9%). More 
patients discontinued due to adverse events in the risperidone-treated group (17.2%) than in 
the placebo group (11.2%). Differences in adverse event incidences between the placebo and 
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risperidone were observed for extrapyramidal symptoms (EPS), mild somnolence and the less 
common cerebrovascular adverse events (CAE).  
  Of all atypical antipsychotics, risperidone has the largest database of double-blind 
controlled trials to support its efficacy and safety in the treatment of agitation, aggression, and 
psychosis associated with dementia. At the recommended doses, risperidone displayed a 
favourable risk-benefit profile. In view of the risk for CAEs, risperidone should be targeted 
towards the treatment of those patients in whom psychotic and behavioural symptoms of 
dementia are prominent and associated with significant distress, functional impairment or 
danger to the patient. 
Olanzapine 
Street et al. 
535
 conducted a multicentre, double-blind, placebo-controlled, 6-week study in 
NH residents with AD who exhibited psychotic and/or behavioural symptoms. Patients were 
randomly assigned to placebo or a fixed dose of 5, 10, or 15 mg/d of olanzapine. The primary 
efficacy measure was the sum of the ‗agitation/aggression‘, ‗hallucination‘, and ‗delusion‘ 
items (Core Total) of the NPI-NH. The conclusion of this study was that low-dose olanzapine 
(5 and 10 mg/d) was significantly superior to placebo and well tolerated in treating 
agitation/aggression and psychosis in this population of patients with AD. 
  Following a double-blind, 6-week exposure to fixed-dose olanzapine (5, 10, or 15 
mg/d), patients entered an additional 18-week, open-label, flexible-dose treatment 
536
. 
Baseline was defined from the start of the extension phase. Patients improved significantly on 
the primary efficacy measure, defined a priori, which consisted of the sum of the 
‗agitation/aggression‘, ‗delusion‘, and ‗hallucination‘ items ('Core') of the NPI-NH. 
Olanzapine also significantly improved scores for the NPI-NH total and the Core item. 
  De Deyn et al. 
537
 randomly assigned patients with AD and delusions or hallucinations 
to a 10-week double-blind treatment with a placebo or fixed-dose olanzapine (1.0, 2.5, 5.0, 
7.5 mg/day). Repeated-measures analysis showed significant improvement from baseline in 
NPI-NH Psychosis Total scores (sum of Delusions, Hallucinations items - primary efficacy 
measure) in all five treatment groups, but no pairwise treatment differences were seen at the 
10-week endpoint. However, under LOCF analysis, improvement in the 7.5 mg olanzapine 
group was significantly greater than with a placebo, while endpoint CGI-C scores showed the 
greatest improvement in the 2.5 mg olanzapine group compared to the placebo. Neither the 
incidence of any other individual events, including extrapyramidal symptoms, nor of total 
adverse events occurred with significantly higher frequency in any olanzapine group relative 
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to the placebo. No clinically relevant significant changes were seen across groups in cognition 
or any other vital sign or laboratory measure, including glucose, triglyceride, and cholesterol. 
While 1.0 mg olanzapine did not show significant differences from placebo, the 2.5 mg dose 
was a reasonable starting dose. Olanzapine at 7.5 mg/day significantly decreased psychosis 
and overall behavioural disturbances and was well tolerated. 
  Clark et al. 
538
 studied the effects of olanzapine in reducing the emergence of 
psychosis among NH patients with AD. Of the patients without hallucinations or delusions at 
baseline, the placebo-treated patients showed significantly greater development of these 
symptoms (NPI-NH hallucinations + delusions mean change score) compared with 
olanzapine-treated patients. Similarly, of the patients without baseline hallucinations, the 
placebo-treated patients showed greater hallucinations score increases than did olanzapine-
treated patients. Patients without baseline delusions showed no significant treatment effect. 
The conclusion at this time was that olanzapine had a favourable safety profile in each patient 
subset. 
  Bigos et al 
539
 investigated, as part of the Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE), the impact of sex, race, and smoking on the olanzapine exposure. 
Smokers cleared olanzapine 55% faster than those who had never smoked. Men cleared 
olanzapine 38% faster than women. Patients who identified themselves as black or African 
American cleared olanzapine 26% faster than other races. Differences in olanzapine exposure 
due to sex, race, and smoking may account for some of the variability in response to 
olanzapine. 
Quetiapine 
Ballard et al. 
540
 randomised 93 patients with AD and clinically significant agitation, 
measured by the CMAI, into three intervention groups: atypical antipsychotic (quetiapine), 
cholinesterase inhibitor (rivastigmine), or a placebo (double dummy). 80 (86%) patients 
started treatment (25 rivastigmine, 26 quetiapine, 29 placebo), of whom 71 (89%) tolerated 
the maximum protocol dose (22 rivastigmine, 23 quetiapine, 26 placebo). Compared with the 
placebo, neither group showed significant differences in improvement on the CMAI either at 
six weeks or 26 weeks. In this study, the Severe Impairment Battery (SIB) was used to 
measure cognition at baseline, at six weeks and 26 weeks. Compared with the placebo, 
quetiapine was associated with significantly greater cognitive decline as measured by SIB. 
  Kurlan et al. 
541
 assessed the efficacy and tolerability of quetiapine for agitation or 
psychosis in patients with dementia and parkinsonism by performing a multicentre 
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randomised, double-blind, placebo-controlled parallel group clinical trial. They involved 
patients with dementia with Lewy bodies (n=23), Parkinson disease (PD) with dementia 
(n=9), and Alzheimer disease with parkinsonian features (n=8). The main outcome measure 
for efficacy was change in the Brief Psychiatric Rating Scale (BPRS) from baseline to 10 
weeks of treatment. For tolerability, the Unified PD Rating Scale (UPDRS) motor section was 
used. No significant differences in the primary or secondary outcome measures of efficacy 
were observed. An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), 
and inadequate power may have contributed to lack of demonstrable benefit. Quetiapine was 
generally well-tolerated and did not worsen parkinsonism, but was associated with a trend 
toward a decline in functioning in daily activities.  
Aripirazol 
De Deyn et al. 
542
 compared the efficacy, safety, and tolerability of aripiprazole with placebo 
in patients with AD associated with psychosis. This 10-week, double-blind, multicentre study 
randomised outpatients with AD-associated psychosis to aripiprazole (n=106) or placebo 
(n=102). The initial aripiprazole dose of 2 mg/d was titrated upwards (5, 10, or 15 mg/d) 
according to efficacy and tolerability. Evaluations included NPI (Psychosis sub-scale) and 
Brief Psychiatric Rating Scale (BPRS), adverse event (AE) reports, extrapyramidal symptoms 
(EPS) rating scales, and body weight. Overall, 83% completed the study. Mean aripiprazole 
dose at the end point was 10.0 mg/d. The NPI Psychosis sub-scale score showed 
improvements in both groups (aripiprazole, -6.55; placebo, -5.52; P = 0.17 at the end point). 
Aripiprazole-treated patients showed significantly greater improvements from baseline in 
BPRS Psychosis and BPRS Core sub-scale scores at the end point compared with the placebo. 
Adverse events were generally mild to moderate in severity and included (aripiprazole vs. 
placebo): urinary tract infection (8% vs. 12%), accidental injury (8% vs. 5%), somnolence 
(8% vs. 1%), and bronchitis (6% vs. 3%). Somnolence was mild and not associated with falls 
or accidental injury. There were no significant differences from the placebo in EPS scores, or 
clinically significant ECG abnormalities, vital signs, or weight.  
  Mintzer et al. 
543
 assessed the efficacy and safety of aripiprazole in AD patients with 
psychosis in a double-blind, placebo-controlled multicentre study. 487 institutionalized 
patients were randomised to placebo or aripiprazole, 2, 5 or 10 mg/day. Primary efficacy 
assessment was the mean change from baseline to week 10 on the NPI-NH (Psychosis Sub-
scale score). Secondary measures included NPI-NH Total, Clinical Global Impression-
Severity of Illness (CGI-S), BPRS Core and Total, and the CMAI scores. Aripiprazole 10 
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mg/day showed significantly greater improvements than placebo on the NPI-NH Psychosis 
Sub-scale. Aripiprazole 5 mg/day showed significant improvements versus placebo on BPRS 
and CMAI scores. Aripiprazole 2 mg/day was not efficacious compared to placebo. 
Cerebrovascular adverse events were reported: aripiprazole 2 mg/day, N=1; 5 mg/day, N=2; 
10 mg/day, N=4; placebo, N=0. No deaths in any group (aripiprazole 2 mg/day, 3%; 5 
mg/day, 2%; 10 mg/day, 7%; placebo, 3%) were considered to be treatment-related.  
  In a review of three trials 
542-544
,  Madhusoodanan and Shah 
545
 concluded that these 
studies showed that aripiprazole improved psychotic symptoms in AD patients compared to 
placebo. The safety and tolerability profile of aripiprazole suggests a low potential for 
negative impact on dementia and overall patient health, but there was increased incidence of 
CVAEs (e.g., stroke, transient ischemic attack), including death, in aripiprazole-treated 
patients. In the fixed-dose study of Mintzer et al. 
543
 there was a statistically significant dose-
response relationship for CVAEs in patients treated with aripiprazole. 
4.9.1.4. Comparison between second generation antipsychotics 
In a double-blind parallel study allowing dose titration over 14 days, 39 agitated persons with 
dementia residing in long-term care facilities were administered olanzapine (N=20) or risperidone 
(N=19) as acute treatment 
546
. The primary outcome measures were the CGI and the NPI. Both drugs 
produced significant reductions in CGI and NPI scores, but there was no significant difference 
between the two drugs. The mean olanzapine dose was 6.65 mg/day; for risperidone, the mean dose 
was 1.47 mg/day. The positive drug effect was not accompanied by decreased mobility, and there was 
improvement on a quality-of-life measure. The main adverse events were drowsiness and falls. At 
baseline, 42% of subjects in both groups had extrapyramidal symptoms that increased slightly, but not 
significantly, by the end of the study. Low-dose, once-a-day olanzapine and risperidone appear to be 
equally safe and equally effective in the treatment of dementia-related behavioural disturbances in 
residents of care facilities. 
  Schneider et al. 
547
 assessed the effectiveness of three atypical antipsychotic drugs in 
outpatients with AD, as part of the Clinical Antipsychotic Trials of Intervention Effectiveness 
(CATIE). In this 42-site, double-blind, placebo-controlled trial, 421 AD outpatients with 
psychosis, aggression, or agitation were randomly assigned to receive olanzapine (mean dose 
5.5 mg per day), quetiapine (mean dose, 56.5 mg per day), risperidone (mean dose 1.0 mg per 
day), or a placebo. Doses were adjusted as needed, and patients were followed for up to 36 
weeks. The main outcomes were the time from initial treatment to the discontinuation of 
treatment for any reason, and the number of patients with at least minimal improvement on 
the Clinical Global Impression of Change (CGIC) scale at 12 weeks. There were no 
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significant differences between treatments with regard to the time to the discontinuation of 
treatment for any reason: olanzapine (median 8.1 weeks), quetiapine (median 5.3 weeks), 
risperidone (median 7.4 weeks), and the placebo (median 8.0 weeks) (P=0.52). The median 
time to the discontinuation of treatment due to a lack of efficacy favoured olanzapine (22.1 
weeks) and risperidone (26.7 weeks) as compared with quetiapine (9.1 weeks) and the 
placebo (9.0 weeks) (P=0.002). The time to the discontinuation of treatment due to adverse 
events or intolerance favoured the placebo. Overall, 24% of patients who received olanzapine, 
16% of patients who received quetiapine, 18% of patients who received risperidone, and 5% 
of patients who received the placebo discontinued their assigned treatment owing to 
intolerance (P=0.009). No significant differences were noted among the groups with regard to 
improvement on the CGIC scale. Improvement was observed in 32% of patients assigned to 
olanzapine, 26% of patients assigned to quetiapine, 29% of patients assigned to risperidone, 
and 21% of patients assigned to the placebo (P=0.22). The authors concluded that adverse 
effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of 
psychosis, aggression, or agitation in patients with AD.  
4.9.1.6. Long-term follow up of antipsychotic use in NHs 
Alanen et al. 
548
 designed a retrospective study in Finland with three identical cross-sectional 
samples originating from the same long-term care facilities, and collected data from 1 July to 
31 December in 2001, 2002 and 2003. The prevalence of the use of one or more antipsychotic 
drugs decreased from 42% in 2001 to 39% in 2003. The overall confounder-adjusted decrease 
in antipsychotic use was not statistically significant. However, the use of antipsychotics 
decreased among residents for whom wandering was a behavioural problem and increased 
among residents with concomitant use of anxiolytic medications.  
  Kleijer er al. 
549
 observed the course of behavioural problems in elderly NH patients 
with dementia when treated with antipsychotics (N=556). During treatment of NH residents 
with dementia with antipsychotics the severity of most behavioural problems continues to 
increase in most patients, with only one out of six patients showing improvement. After 
withdrawal of antipsychotics, behavioural problems remained stable or improved in 68% of 
patients after 3 months and 58% after 6 months. 
  Selbaek et al. 
261
 reported the natural 12-month course of psychiatric and behavioural 
symptoms and the concomitant use of psychotropic medication in NH patients with dementia. 
At baseline a representative sample of 1,163 NH patients participated, of whom 933 had 
dementia. At the follow-up interview after 1 year, 633 of the patients who had dementia at 
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baseline were assessed. Individual symptoms, such as depression (58%), delusions (56%), and 
agitation/aggression (47%) had resolved at a high rate. Persistent use of antidepressants 
(79%), antipsychotics (75%), or any psychotropic drug (88%) was common. There were no 
differences between users and non-users of antipsychotics or antidepressants regarding the 
course of psychosis, agitation, or depression over the 1-year observation period.   
4.9.1.5. Use of antipsychotic medication in NHs and some studies about physical restraints 
Nijk et al. 
550
 registered psychotropic drug use in 1,322 patients on 59 dementia special care 
units (SCUs) in 25 nursing-homes. Psychotropic drugs in general and antipsychotics in 
particular were most frequently prescribed in GDS stage 6, and in patients aged between 65 
and 75 years. Psychotropic drugs in general were positively associated with depression, night-
time behaviour disturbances and agitation. Antipsychotic drug use was positively associated 
with psychosis, agitation and night-time behaviour and was negatively associated with apathy. 
In particular, the association with neuropsychiatric symptoms raises questions of the efficacy 
of these drugs and the risk of chronic use. 
  Feng et al.‘s 551 study compared inter- and intra-country differences in the prevalence 
of the use of physical restraints and antipsychotic medication in NHs, and examines 
aggregated resident conditions and organizational characteristics correlated with these 
treatments. Population-based, cross-sectional data were collected using a standardized 
Resident Assessment Instrument (RAI) from 14,504 long-term care facilities providing NH 
level services in five countries participating in the inter-RAI consortium, including Canada, 
Finland, Hong Kong (Special Administrative Region, China), Switzerland, and the United 
States. Facility-level prevalence rates of physical restraints and antipsychotic use were 
examined both between and within the study countries. The prevalence of the use of physical 
restraint varied more than five-fold across the study countries, from an average 6% in 
Switzerland, 9% in the US, 20% in Hong Kong, 28% in Finland, and over 31% in Canada. 
The prevalence of antipsychotic use ranged from 11% in Hong Kong, 26 to 27% in Canada 
and the US, 34% in Switzerland, and nearly 38% in Finland. Within each country, substantial 
variations existed across facilities in both them use of physical restraint and antipsychotic use 
rates. In all countries, neither facility case mix nor organizational characteristics were 
particularly predictive of the prevalence of either treatment or the use of restraints. There 
exists large, unexplained variability in the prevalence of physical restraint and antipsychotic 
use in nursing-home facilities both between and within countries.  
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4.9.1.6. Reviews and meta-analyses of antipsychotic trials against agitation 
Up to the year 2001, at least 35 trials have investigated the efficacy and safety of the use of 
conventional antipsychotics for this condition 
552
.  
  Lee et al. 
553
 reviewed 77 abstracts. Five randomised trials (1570
 
patients) evaluating 
risperidone and olanzapine were identified.
 
Most participants lived in institutions (> 96%) and 
had AD (76.3%). Trials lasted 6 to 12
 
weeks. Treatment with atypical antipsychotic drugs was 
superior
 
to placebo for the primary endpoint in three of the five trials.
 
Two trials comparing 
risperidone with haloperidol did not find
 
any differences in the primary measures of efficacy. 
Adverse
 
events were common and included extrapyramidal symptoms, somnolence,
 
and 
abnormal gait. 
 Sink et al. 
35
 evaluated the evidence of the efficacy of pharmacological agents used in 
the treatment of BPSD by performing a systematic review of articles published from 1966 to 
July 2004. For typical antipsychotics, 2 meta-analyses and 2 RCTs were included. Generally, 
no difference between specific agents was found, efficacy was small at best, and adverse 
effects were common. Six RCTs with atypical antipsychotics were included. The results 
showed modest, statistically significant efficacy of olanzapine and risperidone, with minimal 
adverse effects at lower doses. Atypical antipsychotics were associated with an increased risk 
of stroke. 
  Ballard and Howard 
32
 presented a meta-analysis to assess the efficacy of the 
antipsychotic drugs for the treatment of psychiatric symptoms in AD, and discussed the more 
limited evidence for their potential benefits in other dementias. They recommended that these 
treatments should be limited to the short-term treatment of psychiatric symptoms associated 
with serious distress or risk. Table 4.9.1 shows the number needed to treat (NNT) and the 
number needed to harm (NNH) for haloperidol and risperidone. 
  Schneider at al. 
30
 performed a meta-analysis of randomised, placebo-controlled trials 
to study the efficacy and adverse effects of atypical antipsychotics prescribed for people with 
dementia. Sixteen trials comparing atypical antipsychotics with a placebo, met the selection 
criteria: aripiprazole (n=3), olanzapine (n=5), quetiapine (n=3), and risperidone (n=5). A total 
of 3,353 patients were randomised to a drug and 1,757 to a placebo. 
 Efficacy on rating scales was observed by meta-analysis for aripiprazole and 
risperidone, but not for olanzapine. Response rates were frequently not reported. There were 
smaller effects for less severe dementia, outpatients, and patients with psychosis. 
Approximately one-third dropped out. Adverse events were mainly somnolence and urinary 
tract infection or incontinence across drugs, and extrapyramidal symptoms or abnormal gait 
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Table 4.9.1.   Number Needed to Treat (NNT) and Number Needed to Harm (NNH) for  
                      different  antipsychotics (Ballard and Howard 2006). 
 
 Haloperidol Risperidon 
Efficacy (NNT)   3-6 6-8 
EPS (NNH) 4-9 7-13 
Somnolence (NNH) 8 10-13 
 Typical antipsychotics Atypical antipsychotics 
Death risk ++ + 
 
with risperidone or olanzapine. Cognitive test scores worsened with drugs. There was no 
evidence for increased injury, falls, or syncope. There was a significant risk of 
cerebrovascular events, especially with use of risperidone. Small statistical effect sizes on 
symptom rating scales support the evidence for the efficacy of aripiprazole and risperidone.  
  Aupperle 
554
 made a review searching medical databases for clinical trials with a focus 
on atypical antipsychotics. Because of the safety concerns associated with the use of atypical 
antipsychotics in this population, he recommended that these drugs should be used 
judiciously. For patients with severe BPSD such as psychosis, agitation, or aggression, for 
whom there are few options, atypical antipsychotics, particularly risperidone and olanzapine, 
should be considered. 
  A Cochrane systematic review 
555
 included studies published up to December 2004. 
The evidence suggested that risperidone and olanzapine are useful in reducing aggression and 
risperidone in reducing psychosis, but both are associated with serious adverse 
cerebrovascular events and extrapyramidal symptoms. Despite the modest efficacy, the 
significant increase in adverse events confirms that neither risperidone nor olanzapine should 
be used routinely to treat dementia patients with aggression or psychosis, unless there is 
severe distress or risk of physical harm to those living and working with the patients. 
Although insufficient data were available from the considered trials, a meta-analysis of 17 
placebo-controlled trials of atypical antipsychotics for the treatment of behavioural symptoms 
in people with dementia conducted by the FDA suggested a significant increase in mortality 
(OR 1.7). A peer-reviewed meta-analysis 
556
 of 15 placebo-controlled studies (nine 
unpublished) found similarly increased risk in mortality (OR=1.54) for the atypical 
antipsychotics. 
  Herrmann and Lanctot 
557
 published another systematic review. Studies of reasonably 
high quality indicate that risperidone and olanzapine are more effective than a placebo in 
institutionalized patients with severe agitation, aggression, and psychosis. The efficacy of 
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antipsychotics is counterbalanced by safety concerns that include the risk of cerebrovascular 
adverse events and mortality. They concluded that although there have been numerous well-
designed studies of the pharmacotherapy of neuropsychiatric symptoms in AD, safer and 
more effective treatments are urgently needed. 
  Jeste et al. 
558
 produced an update, the ACNP White Paper: Update on Use of 
Antipsychotic Drugs in Elderly Persons with Dementia. They concluded that there is 
insufficient evidence to suggest that psychotropics other than antipsychotics represent an 
overall effective and safe, let alone better, treatment choice for psychosis or agitation in 
dementia. 
  Ballard et al. 
31
 authored a review to describe the current state of knowledge regarding 
the management of agitation and aggression associated with AD and discussed the 
controversies and possible solutions. There is increasing evidence to support the value of 
simple psychological interventions and staff-training programmes as a first-line management 
strategy for agitation prior to pharmacotherapy. The most widely prescribed pharmacological 
treatments - atypical antipsychotics - have a modest but significant beneficial effect in the 
short-term treatment of aggression (over 6 to 12 weeks), but limited benefits in longer-term 
therapy. In addition, there have been increasing concerns regarding the potential for serious 
adverse outcomes, including stroke and death. The potential pharmacological alternatives to 
atypical antipsychotics with the most encouraging preliminary evidence include memantine, 
carbamazepine and citalopram. 
    Rochon et al. 
559
 compared the rate of developing any serious event, a composite 
outcome defined as an event serious enough to lead to an acute care hospital admission or 
death within 30 days of initiating antipsychotic therapy, so as to give a better estimate of the 
overall burden of short-term harm associated with these agents. In this population-based, 
retrospective cohort study, they identified 20,682 matched older adults with dementia living 
in the community and 20,559 matched individuals living in NHs. Relative to those who 
received no antipsychotic therapy, community-dwelling older adults newly dispensed an 
atypical antipsychotic therapy were 3.2 times more likely, and those who received 
conventional antipsychotic therapy were 3.8 times more likely to develop any serious event 
during the 30 days follow-up period. The pattern of serious events was similar but less 
pronounced among older adults living in a NH. Therefore, antipsychotic drugs should be used 
with caution even when short-term therapy is being prescribed. 
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4.9.1.7. Cerebrovascular adverse events (CVAE)  
Herrmann et al. 
560
 examined the association between atypical antipsychotic use and stroke in 
the elderly. The authors conducted a retrospective population-based cohort study of patients 
over the age of 66 by linking administrative health care databases. Three cohorts - users of 
typical antipsychotics, risperidone, and olanzapine - were identified and compared. Model-
based estimates adjusted for covariates hypothesized to be associated with stroke risk revealed 
relative risk estimates of 1.1 (95% CI=0.5-2.3) for olanzapine and 1.4 (95% CI=0.7-2.8) for 
risperidone. They concluded that the use of olanzapine and risperidone was not associated 
with a statistically significant increased risk of stroke compared with the use of a typical 
antipsychotic. 
  Wooltorton et al. 
561
 studied the incidence of CVAE related to risperidone. In 4 
placebo-controlled trials lasting 1–3 months and involving more than 1,200 patients with AD 
or VaD, CVAE were twice as common in the risperidone-treated group (4%) as in the placebo 
group (2%). A further search of international databases of postmarketing adverse events 
revealed 37 cases of such events in elderly dementia patients taking risperidone, of which 16 
(43%) were fatal. Similar to warnings issued about risperidone and associations with 
hyperglycemia and cerebrovascular events, two years later a warning was issued for another 
second-generation drug, olanzapine. The same research group 
562
 studied the incidence of 
CVAE in patients using olanzapine. According to information supplied by the manufacturer, 
only 2 of the 5 studies have been published in full. The duration of the published trials was 
between 6 and 10 weeks, with doses of the drug ranging from 1 to 15 mg. Overall, the relative 
risk of a cerebrovascular event among patients taking olanzapine in the 5 trials was 3.1 and 
the absolute increased risk was 0.9%. The rates of cerebrovascular events were similar to 
those reported for risperidone. 
  Herrmann and Lanctot 
563
 investigated the question of whether atypical antipsychotics 
cause stroke. Post hoc analyses of pooled results from 11 randomised controlled trials of 
risperidone and olanzapine in elderly dementia subjects revealed an increased incidence of 
CVAE compared with a placebo. Re-analysis of the risperidone trials suggests that some of 
the increased incidence may be accounted for by nonspecific events that were not strokes. A 
larger number of subjects with vascular and mixed dementias were included in the risperidone 
studies compared with the olanzapine studies, which is likely to account for the increased 
incidence of cerebrovascular adverse events in the risperidone trials compared with the 
olanzapine studies. Potential mechanisms proposed to explain an association between atypical 
104 
 
antipsychotics and cerebrovascular adverse events include thromboembolic effects, 
cardiovascular effects (e.g. orthostatic hypotension, arrhythmias), excessive sedation resulting 
in dehydration and haemoconcentration, and hyperprolactinaemia. However, there is little 
evidence to support these hypothesised mechanisms at present. Therefore, the authors 
concluded that association between atypical antipsychotics and cerebrovascular adverse 
events requires further clarification. 
  Zheng et al. 
564
 analysed data from the CATIE-AD study to discover metabolic 
changes associated with second-generation antipsychotic use in AD patients. Women showed 
significant weight gain while change was not significant in men. Clinically significant weight 
gain was seen among patients with antipsychotic use of up to 12 weeks (OR=1.56), between 
12 and 24 weeks (OR=2.89), and more than 24 weeks (OR=3.38) relative to patients who did 
not use antipsychotics during the trial. Olanzapine and quetiapine treatments were 
significantly associated with weight gain. In addition, olanzapine was significantly associated 
with decreases in HDL cholesterol and increased girth relative to the placebo group. No 
treatment effects were noted for changes in blood pressure, glucose, and triglycerides. 
4.9.1.8. Mortality risk 
Wang et al. 
565
 conducted a retrospective cohort study involving 22,890 patients 65 years of 
age or older who had drug insurance benefits in Pennsylvania and who began receiving a 
conventional or atypical antipsychotic medication between 1994 and 2003. Analyses of 
mortality rates and Cox proportional-hazards models were used to compare the risk of death 
within 180 days, less than 40 days, 40 to 79 days, and 80 to 180 days after the initiation of 
therapy with an antipsychotic medication. They controlled for potentially confounding 
variables. Conventional antipsychotic medications were associated with a significantly higher 
adjusted risk of death than were atypical antipsychotic medications at all the intervals studied 
(up to 180 days: relative risk, 1.37; less than 40 days: relative risk, 1.56; 40 to 79 days: 
relative risk, 1.37; and 80 to 180 days: relative risk, 1.27) and in all subgroups defined 
according to the presence or absence of dementia or NH residency. The greatest increases in 
risk occurred soon after therapy was initiated and with higher dosages of conventional 
antipsychotic medications. Increased risks associated with conventional as compared with 
atypical antipsychotic medications persisted in confirmatory analyses. These results suggest 
that conventional antipsychotic medications are at least as likely as atypical agents to increase 
the risk of death among elderly persons and that conventional drugs should not be used to 
replace atypical agents discontinued in response to the FDA warning. 
105 
 
  Bronskill et al. 
566
 reported the difference in rate of antipsychotic prescription and the 
consequences of that.  Average antipsychotic dispensing ranged from 11.6% in the lowest 
quintile to 30.0% in the highest. Among residents with no recent hospitalization, all-cause 
mortality at 30 days was 2.5% in the lowest compared with 3.3% in the highest quintile and at 
120 days was 9.3% compared with 11.7%. Residents were at increased risk of death simply 
by being admitted to a facility with a higher intensity of antipsychotic drug use, despite 
similar clinical characteristics at admission. 
  Kales et al. 
567
 compared in a retrospective cohort study the mortality rates in the year 
following new antipsychotic medication starts for neuropsychiatric symptoms of dementia 
with rates after starts of other psychiatric medications. All groups taking antipsychotics had 
significantly higher mortality rates (22.6% to 29.1%) than patients taking non-antipsychotic 
medications (14.6%). Adjusted mortality risks for atypicals and for combined atypical and 
conventional antipsychotics were similar to those for conventional antipsychotics. The 
mortality risk was significantly lower for non-antipsychotic medications than conventional 
antipsychotics. Except for anticonvulsants, the adjusted risks for all individual classes of non-
antipsychotics were significantly lower than the risk for antipsychotics. Mortality risks did not 
change over 12 months. The proportions of patients taking antipsychotics who died from 
cerebrovascular, cardiovascular, or infectious causes were not higher than the rates for those 
taking non-antipsychotic psychiatric medications. The authors concluded that the association 
between mortality and antipsychotics is not well understood and may be due to a direct 
medication effect or the pathophysiology underlying neuropsychiatric symptoms that prompt 
antipsychotic use. 
4.9.1.9. Antipsychotics and cognition 
There are some concerns that antipsychotic use may worsen cognition in patients with 
dementia. McShane et al. 
568
 investigated this issue by performing a two year prospective, 
longitudinal study with interviews and autopsy follow up. The mean decline in cognitive 
score (score from expanded MMSE) in the 16 patients who took first-generation 
antipsychotics was twice that of the patients who did not receive antipsychotics. An increased 
rate of decline was also associated with aggression, disturbed diurnal rhythm, and persecutory 
ideas. However, only the use of antipsychotics and the severity of persecutory ideas were 
independently associated with more rapid cognitive decline when all other variables were 
adjusted for. The start of antipsychotic treatment coincided with more rapid cognitive decline: 
the median rate of decline was 5 points per year before treatment and 11 points per year after 
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treatment. Cortical Lewy body pathology did not account for an association between 
antipsychotic use and the more rapid decline of cognition. In conclusion, antipsychotics used 
to treat behavioural complications of dementia may worsen already poor cognitive function. 
  Scharre and Chang 
569
 performed a pilot study to examine cognition in patients treated 
with quetiapine. This study provided initial evidence that quetiapine does not significantly 
worsen cognition in AD outpatients, but Ballard et al. 
540
 showed that treatment with 
quetiapine resulted in cognitive decline measured by SIB. 
4.9.1.10. Antipsychotics in delirium 
Elie et al. 
570
 performed a retrospective, exploratory, secondary analysis of the association 
between antipsychotic use and mortality in elderly patients with delirium. The goal of this 
study was to compare mortality in delirious elderly medical inpatients treated with 
antipsychotics with those who did not receive antipsychotics. 326 elderly hospitalized patients 
were identified with delirium at an acute care community hospital. A nested case-control 
analysis was conducted on this cohort. Cases consisted of all patients who died in hospital 
within eight weeks of admission. Each case was matched for age and severity of illness to 
patients (controls) alive on the same day post-admission. Conditional logistic regression was 
used to assess the impact of exposure to antipsychotics on mortality. Covariates used for 
adjustment were the Charlson comorbidity score and the acute physiology score. 111 patients 
received an antipsychotic. A total of 62 patients died, 16 of whom were exposed to an 
antipsychotic. The OR of association between antipsychotic use and death was 1.53 in 
univariate and 1.61 in multivariate analysis. In elderly medical inpatients with delirium, the 
administration of antipsychotics was not associated with a statistically significant increased 
risk of mortality. Larger studies are needed to clarify the safety of antipsychotic medication in 
elderly patients with delirium. 
4.9.1.11. Antipsychotics and anticholinergic activity 
Older individuals with dementia are highly sensitive to the effects of muscarinic receptor 
blockade. Mulsant et al. 
571
 randomly assigned patients with probable AD, VaD, or mixed-
etiology dementia to treatment with olanzapine or risperidone. Anticholinergic activity was 
measured with a radioreceptor assay, and plasma levels of antipsychotic medications were 
determined. Primary outcomes were assessed with the Udvalg for Kliniske Undersøgelser 
(UKU) scale and for somnolence adverse events; secondary outcome measures included 
scores on the NPI and other scales. There were no between-treatment differences in the UKU 
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scale or in somnolence adverse events. Statistically significant improvements from baseline 
were found for the NPI measures, with no between-treatment group differences. Olanzapine 
was associated with significant increases from baseline in anticholinergic activity, while 
risperidone was not; the between-treatment group differences were not statistically 
significant. Increase in anticholinergic activity was associated with an increase in 
anticholinergic side effects and slower performance on the Trail Making Test Part A. Higher 
endpoint anticholinergic activity was associated with higher endpoint scores on several items 
from the NPI, including delusions, anxiety, and aberrant motor behaviour. Efficacious doses 
of olanzapine increased anticholinergic activity in older patients with dementia, while 
similarly efficacious doses of risperidone did not. Patients whose anticholinergic activity 
increased were more likely to experience anticholinergic side effects and to have worsening in 
certain cognitive domains. These data suggest that certain patients may be vulnerable to the 
anticholinergic activity associated with antipsychotic treatment. 
4.9.1.12. Antipsychotic drug withdrawal studies  
Longitudinal cohort studies 
572
 and placebo-controlled antispychotic withdrawal studies 
573-575
 
did not indicate benefit from antipsychotic therapy. However, all of the withdrawal studies 
continued for 3 months or less, leaving some uncertainty regarding long-term symptom 
outcome. In addition, the largest study did suggest a benefit for treatment with atypical 
antipsychotics in people with scores greater than 14 on the NPI.  
  Ballard et al. 
576
 performed a study with the aim of determining the impact of long-
term treatment with antipsychotic agents upon global cognitive decline and neuropsychiatric 
symptoms in patients with AD. They randomised patients currently prescribed the 
antipsychotics thioridazine, chlorpromazine, haloperidol, trifluoperazine or risperidone for 
behavioural or psychiatric disturbance in dementia for at least 3 months. The study was 
designed as a blinded, placebo-controlled parallel two-group treatment discontinuation trial 
for 12 months; patients continued with their antipsychotic drug or switched to an identical 
placebo. The primary outcome was the total Severe Impairment Battery (SIB) score. 
Neuropsychiatric symptoms were evaluated with the NPI. 165 patients were randomised (83 
to continue treatment and 82 to placebo, i.e., discontinue treatment), of whom 128 (78%) 
commenced treatment (64 continue/64 placebo). Of those, 26 were lost to follow-up (13 per 
group), resulting in 51 patients per arm analysed for the primary outcome. There was no 
significant difference between the continued treatment and placebo groups in the estimated 
mean change in SIB scores between baseline and 6 months. For neuropsychiatric symptoms, 
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there was no significant difference between the continue treatment and placebo groups in the 
estimated mean change in NPI scores between baseline and 6 months. Both results became 
more pronounced at 12 months. There was some evidence to suggest that those patients with 
initial NPI of at least 15 benefited with respect to neuropsychiatric symptoms from continuing 
treatment. For most patients with AD, withdrawal of antipsychotics had no overall detrimental 
effect on functional and cognitive status. Antipsychotics may be considered as maintenance 
treatment of more severe neuropsychiatric symptoms, but this benefit must be weighed 
against the side effects of therapy. 
  Ballard et al. 
577
 followed up the afore mentioned study because of mounting concerns 
about increased mortality in patients with AD who are prescribed antipsychotics; however, 
until now, there have been no mortality data from long-term placebo-controlled trials. They 
aimed to assess whether continued treatment with antipsychotics in people with AD is 
associated with an increased risk of mortality. This additional follow-up was done by 
telephone assessment to establish whether each participant was still alive 24 months after the 
enrollment of the last participant (range 24 to 54 months). Causes of death were obtained 
from death certificates. Kaplan-Meier estimates of mortality for the whole study period 
showed a significantly increased risk of mortality for patients who were allocated to continue 
antipsychotic treatment compared with those allocated to placebo. The hazard ratio for the 
ITT group was 0.58 for the ITT population after 12 months. The more pronounced differences 
between groups during periods of follow up longer than 12 months were evident at specific 
timepoints (24-month survival 46% vs 71%; 36-month survival 30%vs 59%). There is an 
increased long-term risk of mortality in patients with AD who are prescribed antipsychotic 
medication; these results further highlight the need to seek less harmful alternatives for the 
long-term treatment of neuropsychiatric symptoms in these patients. 
4.9.1.13. Antipsychotics and Public Advisory Warnings 
The discussion, if antipsychotics are as dangerous as the FDA and other drug regulatory 
agencies are presenting in their warnings, was launched anew by Suh 
578
 who wrote the 
following:  
  ―In 2003, Brodaty et al. (2003) reported higher rates of cerebrovascular adverse events     
  (CVAEs) and mortality in patients with dementia-associated agitation and psychosis  
  who were treated with risperidone compared with those receiving placebo in a  
  randomised trial. In 2004, the U.K. Committee on Safety of Medicines (CSM)   
  informed clinicians that risperidone and olanzapine should not be used to treat BPSD   
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  because of increased risk of strokes with both drugs and an increased mortality with   
  olanzapine.  
  In 2005, the US Food and Drug Administration (FDA) issued a public advisory 
warning alerting health care providers and the public about new safety information 
regarding all atypical antipsychotic medications. When 17 placebo-controlled trials 
relating to the use of olanzapine, arpiprazole, risperidone and quetiapine in dementia 
patients with BPSD (N=5106) were pooled, the mortality of the drug-treated group 
was 1.6 or 1.7 times that of the placebo group (4.5% vs 2.6%), predominantly due to 
heart-related or infectious causes (FDA, 2005; revised 2009).‖  
 Suh, then, discussed Simpson’s paradox, a statistical paradox, wherein the successes of 
groups seem reversed when the groups are combined 
579
:  
―Simpson‘s paradox occurs when we combine data. If a very large trial is poorly 
conducted and is part of a meta-analysis, the results of the meta-analysis can be 
adversely impacted by that trial (―garbage in, garbage out‖) 580….Data were combined 
by agent (i.e. risperidone only, olanzapine only) 
581
 or even by the supposed same 
category (i.e. atypical antipsychotics) 
30
 . There is no rationale for considering all 
atypical antipsychotics to be the same. Profiles of adverse events vary widely across 
different atypical antipsychotics. Even sociodemographic and clinical characteristics 
(i.e. age, gender, levels of cognition and behavioural disturbances) of the active 
treatment group and the comparator group vary widely across RCTs. In addition, none 
of the RCTs were initially designed to look for CVEs or mortality… There have been 
reports from non-experimental studies which contradict those of the U.K.‘s CSM and 
the U.S.A.‘s FDA.‖  
Furtheron, Suh referred to the following studies in his arguments against the warnings 
launched by the FDA. In 2005, Suh and Shah 
582
 reported results of a one-year prospective 
study comparing antipsychotic users and antipsychotic non-users in a NH (N=273). They 
reported that the mortality rate in those who had not received antipsychotics (26.8%) was 
higher than that in those who had received antipsychotics (20.8%). The mortyality rates of the 
two groups were statistically significantly different, even after controlling for possible 
confounding factors.  
In 2006, Schneider et al. 
547
 reported results of a prospective study entitled Clinical 
Antipsychotic Trials of Intervention Effectiveness in Alzheimer‘s Disease (CATIE-AD). In 
this study doses were adjusted as needed. Neither the incidence of CVE (two cases in the 
olanzapine group, one in the quetiapine group, one in the risperidone group, one in the 
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placebo group; p=0.92) nor mortality rates were statistically different in the overall 
comparison (one case in the olanzapine group, three in the quetiapine group, one in the 
risperidone group, three in the placebo group; p=0.68). The CATIE-AD study reported that 
the sum total of the risk/benefit equation of atypical antipsychotic therapy was no greater than 
that achieved by placebo.  
  In 2006, Nonino et al. 
583
 reported that the long-term survival of 294 dementia patients 
with BPSD treated with atypical antipsychotics may not significantly differ from that of 
dementia patients not treated with these drugs, using data from a population-based cohort 
study conducted in Modena, Italy. In 2006 and 2007, Barnett et al. 
584 585
 reported a 
retrospective review of the clinical outcomes of a large cohort of elderly patients admitted to 
hospital for pneumonia or for dementia. They found no increased risk of mortality in 
pneumonia patients treated with atypical antipsychotics, and no increased risk for CVE-
related hospital admission in dementia patients treated with atypical antipsychotics.  
  In 2007, Raivio et al. 
586
 reported results of a two-year prospective study with 254 very 
frail dementia patients from seven NHs and two hospitals in Finland, which concluded that 
neither atypical nor conventional antipsychotics increased mortality or hospital admissions 
among dementia patients.  
  A population-based retrospective cohort study (1997 to 2002) in Canada that included 
11,400 patients found no difference in the rate of strokes requiring hospitalization among 
users of the conventional antipsychotics, risperidone and olanzapine 
560
. The same research 
group reported an increased risk of death in the use of atypical antipsychotics compared to 
non-use among dementia patients, using data including the additional year of 2003 
530
. 
 
 Simoni-Wastila 
587
 examined retrospectively the prevalence of antipsychotics use and the 
association of antipsychotics and other drug use variables with hospital events and mortality. 
A total of 2,363 long-term care (LTC) Medicare beneficiaries, 1999 to 2002, were included in 
the analysis. Antipsychotic use rose markedly from 1999 to 2002 (26.4% to 35.9%), 
predominantly due to increased use of atypical agents. After controlling for sociodemographic 
and clinical factors, antipsychotic  use is not related to hospital events (hazard ratio [HR] = 
0.98). Antipsychotic use is associated with a slightly reduced mortality (HR = 0.83). The 
authors suggested that disease and drug burden factors may confound the antipsychotics-
mortality relationship. This study provided no evidence of increased hospital events or 
mortality in LTC residents who use antipsychotic medications.  
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  Suh concluded that none of the reports except one 
530
 support the findings from 
previous experimental clinical trials. Almost all non-experimental clinical studies have shown 
no increase in the risk of CVAE and mortality associated with the use of atypical 
antipsychotics. The results also suggest that they may be associated with a lower mortality 
rate than conventional antipsychotics 
531 588 589
. The final word in this case is not said yet, but 
we think that antipsychotics should be used with precaution as Ballard et al. 
577
mentioned in 
their latest antipsychotic withdrawal trial. 
4.9.2. Anticonvulsants 
4.9.2.1. Theoretical background for the use of anticonvulsive drugs 
Alzheimer's disease is characterized by disruptions in multiple major neurotransmitters like 
the noradrenergic 
590
, the cholinergic 
591
 and serotonergic 
592
 transmissions in both cortical 
and subcortical areas of the brain. The damage of serotonergic (5-HT) neurons seemed to be 
more generalised and more severe than that of noradrenergic neurons. GABA‘s association 
with such neuropsychiatric symptoms as anxiety 
593
, aggression 
594
 and psychosis 
593
, as well 
as its ability to regulate acetylcholine, dopamine, and serotonin, make it a therapeutic target 
for controlling BPSD. 
Rissman et al. 
595
 described the research that has focused on the role of calcium 
permeable glutamate receptors in promoting glutamate mediated excitotoxicity in AD cell 
death. Specifically, an ‗over-stimulation‘ of post-synaptic N-methyl-D-aspartate (NMDA) and 
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors by glutamate 
has been demonstrated to induce cell death by calcium-dependent pathways 
596
. 
Approximately 90% of hippocampal neurotransmitter neurons are glutamatergic. The 
remaining 10% of hippocampal neurons are inhibitory in nature, of which the majority is 
GABAergic. While the hippocampal glutamatergic cell populations are lost very early in the 
progression of AD, the hippocampal GABAergic system has been found to be relatively 
resistant to AD neuropathology. It is reasonable to consider that altered drug responses in 
elderly individuals may be related to a compensatory modulation of the molecular 
composition of the GABA-A receptor subunits. 
  Lanctot et al. 
597
 reviewed the evidence for change in GABA‘s function among 
patients with AD and suggest that the variable findings reflect subtypes of the disease that are 
possibly manifested clinically by differing behavioural symptoms. GABA, the major 
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inhibitory neurotransmitter, has long been a target for anxiolytics, hypnotic sedatives, and 
anticonvulsants. 
Carbamazepine (CBZ) 
The mechanism of action of CBZ and its derivatives is relatively well understood. Voltage-
gated sodium channels are the molecular pores that allow brain neurons to generate action 
potentials, the electrical events that allow neurons to communicate over long distances. After 
the sodium channels open to start the action potential, they inactivate, essentially closing the 
channel. CBZ stabilizes the inactivated state of sodium channels, meaning that fewer of these 
channels are available to open up, making brain cells less excitable. CBZ has also been shown 
to potentiate GABA receptors made up of alpha1, beta2, gamma2 subunits. CBZ reduces L-
type calcium channel activation by depolarisation, and may block the excitatory transmitter 
glutamate at NMDA-type receptors. 
 CBZ has been reported effective in the management of agitation/aggression 
associated with primary psychiatric disease (schizophrenia, affective disorder) and episodic 
dyscontrol and interictal and ictal aggression related to temporal lobe epilepsy in children and 
adolescents. The theoretical reasons and clinical experiences caused the researchers to think 
whether CBZ could be effective in treating aggression and agitation in dementia too.  
 
Table 4.9.2.  Placebo-controlled trials of carbamazepine (CBZ) in the treatment of BPSD 
  (Konovalov 2008), revised. 
 
 Name Subjects Design Results (-/+) Author’s conclusion 
Chambers et al., 
1982 
19 female 
Inpatients 
Nonrandom., 
crossover 
Overactivity: - 
Cogn.funct.: - 
Poorly tolerated 
CBZ is not effective in tx 
of agitation in dementia 
Tariot et al., 
1994 
25 NH- 
patients 
Nonrandom., 
crossover 
(6 weeks) 
Low dose;  
16 pts improved 
globally 
CBZ can reduce  
agitation in some 
patients 
Cooney et al., 
1996 
6 inpatients 
Nonblinded, 
crossover 
Aggression 
significantly 
reduced 
CBZ can be an effective 
antiaggressive agent in  
dementia 
Tariot et al., 
1998 
51 NH- 
patients 
Physician monitor 
and pharmacist 
were not blinded; 
randomised 
(6 weeks) 
Significant effect 
significantly more 
adverse events 
Short-term use of CBZ 
for agitation can be  
efficient 
Olin et al., 
2001 
21 
outpatients 
Physician adjusting 
dosage was not 
blinded, randomised 
 (6 weeks) 
Not significant  
difference between 
groups 
CBZ is not effective in 
the treatment of   
behavioural symptoms 
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  Placebo-controlled 
36 37 598-600
 and non-controlled studies 
601-604
 and case reports 
605 606
 
have investigated the effect of CBZ in the management of agitation and aggression in patients 
with dementia (Table 4.9.2). 
  Sink et al. 
35
 performed a systematic review, excluded three of the placebo-controlled 
studies because of methodological problems,  and concluded that two small RCTs 
36 37
 of 
CBZ had conflicting results.  
  There are some more concerns related to the use of CBZ in this population: central 
nervous system (dizziness, drowsiness, ataxia), hematologic (aplastic anemia, 
agranulocytosis), and hepatotoxic adverse effects may occur. In addition, the drug interaction 
potential with this potent hepatic enzyme-stimulating agent (stimulation of metabolism of 
phenytoin, warfarin, theophylline, haloperidol, oral contraceptive steroids, and valproate and 
inhibition of carbamazepine metabolism by macrolides, cimetidine, propoxyphene, isoniazid, 
fluoxetine, calcium-channel blockers) may make this a difficult agent to use in patients 
receiving multiple drug therapies. In addition, autoinduction of metabolism can result in 
decreased effectiveness after the first or second month of therapy.  
Oxcarbazepine 
Oxcarbazepine (OXC) as an alternative to CBZ with less interaction potential and less side-
effects will be revisited in chapter 5. 
Valproic acid  
On the basis of valproate‘s anti-aggressivity properties in animal studies and its ability to 
augment brain GABA and serotonin concentrations, valproate was theoretically a promising 
agent in the management of agitation/aggression in patients with dementia.  
  Reports on the use of valproate for treating BPSD in dementia patients have long been 
dominated by retrospective chart reviews 
607 608
 and reports or case series 
38 609 610
.   
  In a Cochrane Review Lonerghan et al. 
611
 examined three randomised, placebo-
controlled trials that investigated the effect of valproic acid on older people with dementia 
who were agitated. Meta-analysis of the pooled results of the included trials could not be 
performed because of the following problems. According to Porsteinsson 
40
, the physician 
who controlled the therapy knew which patients were receiving divalproex. Therefore, the 
trial did not satisfy the criterion of concealed allocation. In Tariot 
612
, 54% of the treated 
patients dropped out compared with 29% of the control patients. Of all treated patients, 22% 
dropped out because of adverse effects, and the study had to be discontinued prematurely. The 
third trial 
41
 had a cross-over design. No results from the first phase of the study were 
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available, and although the statistical section stated, "the t-test for independent samples is 
used to analyze the two-period cross-over trial", because the samples were not independent - 
they are the same patients in the treatment and placebo groups - a question must be raised 
about the correctness of the analyses. A limited meta-analysis, pooling the results concerning 
adverse effects 
349 613
 revealed the following: sedation occurred more frequently in patients 
treated with valproic acid than in controls. Urinary tract infection was more common among 
patients treated with valproic acid than controls. Because of differences in identifying adverse 
effects, it was not possible to pool other observations concerning adverse effects between the 
two studies that were examined. They concluded that on the basis of current evidence, 
valproate preparations cannot be recommended for the treatment of agitation in dementia.  
  An updated systematic review (October 2008) 
614
 of two new studies 
39 42
 applied 
meta-analysis to the effect of valproate on agitation in demented patients. This new meta-
analysis of pooled results showed no improvement of agitation among valproate-treated 
patients, compared with controls, and showed an increase in adverse events (falls, infection, 
gastrointestinal disorders) among valproate-treated patients. 
Gabapentin 
Gabapentin is structurally related to GABA. It probably acts by interfering with calcium 
channels to alter transmitter release 
615
.  
  One of the first reports of the successful use of gabapentin in the elderly with AD was 
by Regan and Gordon 
616
. Sheldon et al. 
617-619
 authored promising case reports. Herrmann et 
al. 
620
 performed a prospective open-label case-series study with gabapentin including twelve 
patients with moderate to severe dementia and severe behavioural disorders who were non-
responders to previous trials of antipsychotics. Average patient scores for the CMAI and the 
NPI remained unchanged after treatment with gabapentin. The authors concluded that 
gabapentin may have a role in treating a subgroup of dementia patients with severe 
behavioural disorders who have not responded to antipsychotics. Hawkins et al. 
621
 did a 
retrospective chart review of 24 NH residents. Gabapentin was used in cases where other anti-
aggressive medication (including haloperidol, risperidone, olanzapine, quetiapine, 
carbamazepine, valproic acid, buspirone and trazodone) failed to control aggressive 
behaviour. They found that 17 of 22 patients were much or greatly improved; 4 were 
minimally improved; and only 1 remained unchanged. Two of the 24 patients discontinued 
use of the medication because of excessive sedation. No other significant side effects were 
noted in treatment lasting up to 2 years. 
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4.9.2.2. Reviews and meta-analyses of mood stabilisers  
Sink et al. 
35
 included five RCTs with anticonvulsants in their systematic review 
36 37 41 349 612
 
and concluded: valproate does not appear to be effective for the treatment of neuropsychiatric 
symptoms of dementia whether in short- or long-acting preparations. In addition, valproate 
caused significantly more adverse events than a placebo, sedation being the most common. 
Based on 2 small trials (1 positive and 1 negative), there is currently not enough evidence of 
benefit to recommend the use of carbamazepine for treatment of neuropsychiatric symptoms, 
especially in light of the black box warning for hematologic toxicity and the potential drug-
drug interactions between carbamazepine and other drugs commonly prescribed to elderly 
individuals.  
  Konvalov et al. 
622
 reviewed the data on the use of anticonvulsant mood stabilisers 
(carbamazepine, valproic acid, gabapentin, lamotrigine, topiramate) in the treatment of BPSD 
to determine whether these medications can be recommended for routine clinical use. They 
analysed a total of seven RCTs (two for carbamazepine and five for valproate). One study 
showed statistically significant improvement of BPSD in the medication group compared to 
the placebo group; five studies showed no significant differences; one study showed 
statistically significant worsening of the symptoms in the medication group vs. placebo. The 
majority of the studies reported significantly more frequent adverse effects in the medication 
group. The report concluded that, although clearly beneficial in some patients, anticonvulsant 
mood stabilisers cannot be recommended for routine use in the treatment of BPSD. 
  The newest update over the use of anticonvulsants in agitation and aggression in 
dementia was authored by Amann et al. 
623
. They concluded, as other authors already had 
done, that the data on anticonvulsants used by patients with dementia and behavioural 
disturbances are not convincing.  
4.9.3. Serotonergic agents 
In this part, we will present the use of serotonergic agents as treatment for agitation. 
Trazodone 
Trazodone has specific but complex effects on the serotonergic system (mixed serotonin 
agonist and antagonist effects) and has a lesser effect on dopamine, histamine and cholinergic 
systems. It has a sedative and hypotensive effect due to α-adrenergic antagonism. The use of 
trazodone for the treatment of behavioural disturbances in dementia was examined in two 
uncontrolled studies with a total of 38 patients. 84% experienced at least mild improvement 
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and 32% were described as markedly improved 
624 625
. In a structured approach for selecting 
pharmacotherapy 
626
, 11 patients in a NH got trazodone in doses ranging from 50 to 100 
mg/day (mean dosage 70 mg/day). Nine of the patients demonstrated satisfactory treatment 
responses as shown by a decreased BEHAVE-AD score of 30% or more (average BEHAVE-
AD scores at baseline and 1 month after treatment were 13 +/- 4 and 4 +/- 3, respectively), 
and no clinical side effects were observed.   
  In the Cochrane Database of Systematic Reviews, the evidence of the use of trazodone 
for agitation in dementia is described 
627
. Only two randomised studies comprising 104 
participants with dementia met the inclusion criteria: Teri et al. 
628
 and Lebert et al. 
629
. The 
authors‘ conclusion was: there is insufficient evidence to recommend the use of trazodone as 
a treatment for behavioural and psychological manifestations of dementia. In order to assess 
effectiveness and safety of trazodone, longer-term randomised controlled trials are needed, 
involving larger samples of participants with a wider variety of types and severities of 
dementia. 
Fluvoxamine 
In a double-blind, controlled trial comparing fluvoxamine with a placebo given to 46 patients 
with dementia, there were no significant benefits in the fluvoxamine group compared to the 
placebo group 
630
. 
Citalopram 
Nyth and Gottfries 
631
 performed a Nordic multicentre study investigating the clinical efficacy 
of citalopram in the treatment of emotional disturbances in dementia disorders. In this 
multicentre study, the clinical efficacy of citalopram was
 
investigated in 98 patients with 
moderate AD or VaD using a combined
 
double-blind and open technique with placebo and 
citalopram. Analyses were
 
made for each diagnosis after four weeks of double-blind 
treatment.
 
Patients with AD treated with citalopram showed a significant
 
reduction in 
emotional bluntness, confusion, irritability, anxiety,
 
fear/panic, depressed mood and 
restlessness. Those improvements were not
 
found after treatment with a placebo. There were 
no significant improvements
 
in patients with VaD. No improvements were recorded in motor 
or cognitive
 
impairment. Citalopram provoked few and comparatively mild side-effects.
 
None 
of the changes observed during the double-blind withdrawal period were
 
identified as 
withdrawal symptoms or rebound phenomena. 
  Pollock et al. 
632
 conducted a double-blind, placebo-controlled study to compare the 
acute efficacy of the selective serotonin reuptake inhibitor (SSRI) citalopram and the 
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antipsychotic perphenazine with placebo for the treatment of psychosis and behavioural 
disturbances in non-depressed patients with dementia. Eighty-five hospitalized patients with 
at least one moderate to severe target symptom (aggression, agitation, hostility, 
suspiciousness, hallucinations, or delusions) were randomly assigned to receive either 
citalopram, perphenazine, or a placebo under double-blind conditions for up to 17 days. 
Patients treated with citalopram or perphenazine showed statistically significant improvement 
on several Neurobehavioural Rating Scale factor scores. Compared to those receiving a 
placebo only patients treated with citalopram showed significantly greater improvement in 
their total Neurobehavioural Rating Scale score, as well as in the scores for the 
agitation/aggression and lability/tension factors. Side-effect scores were similar among the 
three treatment groups. In another study, Pollock et al. 
633
 compared citalopram with 
risperidone in a 12-week randomised, controlled trial in non-depressed patients with dementia 
hospitalised because of behavioural symptoms (N=103). Participants were consecutively 
recruited on an inpatient unit if they had at least one moderate to severe target symptom 
(aggression, agitation, hostility, suspiciousness, hallucinations, or delusions). Once they 
improved sufficiently, they were discharged to NHs, personal care homes, or residential 
homes for continued treatment. Completion rates did not differ for citalopram and risperidone 
(overall completion rate: 44%). Agitation symptoms (aggression, agitation, or hostility) and 
psychotic symptoms (suspiciousness, hallucinations, or delusions) decreased in both treatment 
groups but the improvement did not differ significantly between the two groups. There was a 
significant increase in side-effect burden with risperidone but not with citalopram, such that 
the two groups differed significantly. The authors concluded that these findings need to be 
replicated before citalopram or other serotonergic antidepressants can be recommended as 
alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated 
with dementia. 
  Previous trials have shown reductions with SSRI treatment in impulsive aggression in 
subjects with personality disorders, decreases in irritability in non-depressed AD patients, and 
significantly greater improvements in behavioural symptoms in non-depressed dementia 
patients treated with citalopram compared with placebo. Siddique et al. 
634
 analysed data of 
patients who were enrolled in CATIE-AD. Of the 421 patients enrolled, 44 were started on a 
placebo and were, after phase 1 (36 days), randomly assigned to citalopram treatment. There 
were data available for 34 subjects who took a placebo for at least 14 days. In this citalopram 
group, there was a 60% reduction in irritability and apathy scores without sedation, no effect 
on scores for delusions, and a clinically insignificant drop in scores for hallucinations.  
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The National Institute on Aging intends to start a multi-centre randomised placebo-
controlled clinical trial study of citalopram for the treatment of agitation in AD. It will also 
investigate pharmacogenomic, genetic, and clinical predictors of response to citalopram 
therapy. The arguments for this study are that selective serotonin reuptake inhibitors (SSRIs) 
show promise as a treatment for agitation in AD, based on evidence of a link between 
agitation and brain serotonin system abnormalities in AD patients, and on preliminary clinical 
data from RCTs in which citalopram was superior to perphenazine, risperidone and a placebo.  
Sertraline 
Finkel et al.‘s 635 study was a randomised, placebo-controlled study. Patients with probable or 
possible AD, and a NPI total score greater than 5 (with a severity score of at least 2 in at least 
one domain), were treated with donepezil (5 to 10 mg) for 8 weeks, then randomly assigned to 
12 weeks of double-blind augmentation therapy with either sertraline (50 to 200 mg) or 
placebo. Primary efficacy measures were the 12-item NPI and the Clinical Global Impression 
Improvement (CGI-I) and Severity (CGI-S) scales. Twenty-four patients were treated with 
donepezil and sertraline and 120 patients treated with donepezil and placebo. There were no 
statistically significant differences at the endpoint of three primary efficacy measures. 
Sertraline augmentation was well tolerated in this sample of AD outpatients. In addition, post 
hoc analyses demonstrated a modest but statistically significant advantage of sertraline over 
placebo augmentation, and a clinically and statistically significant advantage in a sub-group 
of patients with moderate-to-severe behavioural and psychological symptoms of dementia. 
4.9.3.1. Reviews 
A Cochrane review 
636
 elucidated the evidence of the use of  antidepressants for depression  
in dementia.  They concluded that  
―available evidence offers weak support to the contention that antidepressants are an 
effective treatment for patients with depression and dementia. However, only three 
studies are included in the meta-analysis relating to efficacy, and sample sizes are 
small. Moreover, only one of the studies included in the analysis of efficacy data 
investigated the properties of the more commonly used selective serotonin reuptake 
inhibitors and no studies investigated the properties of newer classes of 
antidepressants (e.g. selective noradrenergic reuptake inhibitors). This review draws 
attention to the paucity of research and evidence in this area. It is not that 
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antidepressants are necessarily ineffective but there is not much evidence to support 
their efficacy either.‖  
 A new systematic review ―Antidepressants for agitation and psychosis in dementia‖ is under 
elaboration by Seitz et al. from the Dementia and Cognitive Improvement Group, Canada.  
Sink et al. 
35
, see Table 4.9.3, described five RCTs; we added the trial performed  
by Pollock et al. in 2007 
633. Sink et al.‘s conclusion was that although serotonergic agents are  
 
Figure 4.9.3.  Studies of antidepressants : Outcomes (Sink 2005), edited. 
 
Source Drug 
Number 
of 
partici- 
pants 
Outcomes 
Significance of 
primary outcome 
Statistic.  -  Clinical 
Adverse 
events and 
comments 
Auchus 
& 
Bissey-
Black 
1997 
Haloperidol, 
Fluoxetine, 
Placebo 
15 
outpatients 
No positive 
effect for 
CMAI, CSI 
BEHAVE-
AD 
No  
Haloperidol 
+ Fluoxetine 
groups more 
AE 
Teri et al. 
2000 
Trazodone, 
Haloperidol, 
BMT 
149 
Outpatients 
(16 weeks) 
No 
difference 
No  
No significant 
differences in 
AE 
Pollock 
et al. 
2002 
Citalopram, 
Perphenazine, 
Placebo 
84 
hospitalised 
patients 
(17 days) 
Significant 
effect for 
NRS total, 
agitation  
Yes Possibly 
52% 
Citalopram and 
57% Placebo 
patients 
dropped out 
Lyketsos 
et al. 
2003 
Sertraline, 
44 
outpatients 
(12 weeks) 
No 
difference 
in NPI total 
Depression:  
yes 
Agitation: 
no 
 
No significant 
differences in 
AE 
Finkel et 
al. 
2004 
Sertraline + 
Donepezil     
24 
outpatients 
No 
difference 
NPI, CGIC, 
CMAI, 
BEHAVE-
AD 
No Probably 
12% dropped 
out in both 
groups due to 
AE Donepezil + 
Placebo 
120 
outpatients 
(8 weeks) 
Pollock 
et al. 
2007 
Citalopram, 
Risperidone, 
Placebo 
103 
Hospitalised 
patients 
(12 weeks) 
NRS, No Possibly 
Significant 
increase of AE 
with 
risperidone 
 
References: 628 632 633 635 637 638  AE: Adverse events; BEHAVE-AD: Behavioural Pathology in Alzheimer's Disease rating 
scale; BMT: Behaviour Management Techniques; CGIC: Clinical Global Impression of Change; CMAI: Cohen-Mansfield 
Agitation Inventory; CSI: Community Screeing Instrument; NRS: Neurobehavioural Rating Scale;  
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well tolerated, they do not appear to be very effective in the treatment of neuropsychiatric 
symptoms. In the light of the results from Pullock et al.‘s study from 2007, the use of cipramil 
as treatment against agitation may be judged more favourably. 
4.9.4. Acetylcholinesterasis inhibitors 
Acetylcholinesterasis inhibitors (AChEI) are used to slow down cognitive and functional 
decline in AD. Furthermore, trials showed that they may have some effect in reducing BPSD. 
This will be elucidated in the following. 
Donepezil 
Tariot et al. 
211
 performed a 24-week, randomised, multicentre, double-blind, placebo-
controlled trial. Two hundred and eight nursing-home patients with a diagnosis of probable or 
possible AD, or AD with cerebrovascular disease were randomised to the trial; the mean age 
was 85.7 years. The primary outcome measure was the NPI-NH-12 total score. Eighty-two 
per cent of donepezil - and 74% of placebo-treated patients completed the trial. Eleven perm 
cent of donepezil - and 18% of placebo-treated patients withdrew because of AEs. Mean NPI-
NH 12-item total scores improved relative to baseline for both groups, with no significant 
differences observed between the groups at any assessment. No significant differences were 
observed between the groups on the Physical Self-Maintenance Scale (PSMS). Overall rates 
of occurrence and severity of AEs were similar between the two groups (97% placebo, 96% 
donepezil). Patients treated with donepezil maintained or improved in cognition and overall 
dementia severity in contrast to placebo-treated patients who declined during the 6-month 
treatment period. The authors concluded that given the apparent improvement in behaviour in 
the placebo group, and the high use of concomitant medications in both groups, the impact of 
donepezil on behaviour in the nursing-home setting is unresolved and merits further 
investigation.  
  Feldman et al. 
219
 randomised 290 patients to treatment in a 24-week, double-blind, 
placebo-controlled trial. Patients received either 5 mg/day donepezil for the first 28 days and 
10 mg/day thereafter as per the clinician's judgement (n=144) or a placebo (n=146). Patients 
receiving donepezil showed benefits on the CIBIC+, compared with a placebo, at all visits up 
to week 24. All other secondary measures, including the MMSE, Severe Impairment Battery 
(SIB), Disability Assessment for Dementia (DAD), Functional Rating Scale, and the NPI, 
showed significant differences between the groups in favour of donepezil at week 24. Eighty-
four per cent of donepezil- and 86% of placebo-treated patients completed the trial. 8% of 
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donepezil- and 6% of placebo-treated patients discontinued because of AE. These data 
suggest that donepezil has a significant effect on BPSD in more advanced stages of AD. 
  Gauthier et al. 
221
 performed a sub-analysis of a double-blind, placebo-controlled trial 
to examine the prevalence of behavioural symptoms in moderate to severe AD, and the effect 
of treatment with donepezil. Two hundred and ninety patients with moderate to severe AD 
(MMSE scores 5-17) were randomised to receive 24 weeks of 5 mg/day daily doses of 
donepezil for 28 days, and 10 mg/day thereafter per the clinician's judgment. The outcome 
measure of interest was the 12-item NPI. At baseline, the most common symptoms were 
apathy/indifference (67%), aberrant motor behaviour (53%), depression/dysphoria (52%), 
anxiety (49%), and agitation/aggression (45%). NPI individual item change from baseline 
scores at Week 24 using a LOCF analysis showed benefits with donepezil treatment 
compared with placebo for all items, with significant treatment differences for 
depression/dysphoria, anxiety, and apathy/indifference. When patients who were not 
receiving psychoactive medications at baseline were analysed separately, significant 
improvements in NPI 12-item total score were observed with donepezil compared with 
placebo at most visits and at Week 24 LOCF.  The agitation/aggression sub-score showed, 
however, no significant response to treatment with donepezil. 
  Holmes et al. 639 conducted a study to determine the efficacy of donepezil in the 
treatment of neuropsychiatric symptoms in patients with Alzheimer disease (AD) in a 
randomised withdrawal study. Patients with mild to moderate AD with marked 
neuropsychiatric symptoms at baseline (NPI > 11 points) were treated openly with donepezil 
5 mg daily for 6 weeks followed by 10 mg daily for a further 6 weeks. Patients were then 
randomised (60:40) to either placebo or 10 mg donepezil daily. All patients were assessed at 6 
weeks and provided there was no marked cognitive deterioration their blinded treatment was 
continued for a further 6 weeks. NPI and carer distress were assessed at 6 weekly intervals 
throughout the study. A total of 134 patients participated. Following randomisation patients 
who continued on donepezil 10 mg for 12 weeks had improvements in NPI compared with the 
placebo group and in NPI-Distress scores. During the open-label phase the total NPI and NPI-
Distress scores were lower after 12 weeks treatment with open label donepezil compared with 
baseline (total NPI 22 points vs13 points; NPI-Distress 13.5 vs 7.9 points). In the open-label 
phase all domains of the NPI (with the exception of elation) were improved (all p < 0.05 after 
Bonferroni correction). The conclusion was that donepezil has a significant effect in the 
treatment of neuropsychiatric symptoms in patients with mild to moderate AD. 
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  Cummings et al. 
460
 conducted an exploratory analysis of data pertaining to the 
efficacy of donepezil treatment of patients with severe behavioural disturbances. Most 
patients included in clinical trials have had low levels of psychopathology at baseline, and the 
effect of cholinesterase inhibitors on patients with more severe behavioural disturbances is 
unknown. The authors report the effects of donepezil on behavioural disturbances in patients 
with relatively severe psychopathology at baseline. This is a hypothesis-driven secondary 
analysis of a three-phase study involving donepezil and sertraline. In phase 1, psychotropic 
agents were withdrawn; in phase 2, patients were treated in an open-label fashion with 
donepezil for 8 weeks; and in phase 3, patients on donepezil were randomised to receive 
placebo or sertraline for an additional 12 weeks. The data set that was analysed comprised 
patients treated with donepezil (without sertraline) for 20 weeks. One hundred twenty patients 
were included in the analyses. Mean age was 76 years, average Mini-Mental State 
Examination Score was 18, and mean Neuropsychiatric Inventory (NPI) total score was 30. 
Primary efficacy assessments were the NPI, the Clinical Global Impression-Improvement, and 
the Clinical Global Impression-Severity scales. Secondary measures included the BEHAVE-
AD, the Hamilton Depression Rating Scale, and the Alzheimer's Disease Functional 
Assessment and Change Scale. The total score of the NPI was significantly reduced over the 
20 weeks of therapy with donepezil. Sixty-two per cent of patients had at least a 30% 
reduction in the total NPI score (significantly greater than the number with no meaningful 
response). Likewise, more patients had total or partial resolution of depression and delusions 
than those who had no meaningful change. The results of these analyses suggest that 
donepezil reduces behavioural symptoms, particularly mood disturbances and delusions, in 
patients with AD with relatively severe psychopathology. 
  Howard et al. 
640
  randomly assigned 272 patients with AD who had clinically 
significant agitation and no response to a brief psychosocial treatment programme to receive 
10 mg of donepezil per day (128 patients) or a placebo (131 patients) for 12 weeks. The 
primary outcome was a change in the score on the CMAI at 12 weeks. There was no 
significant difference between the effects of donepezil and those of the placebo on the basis of 
the change in CMAI scores from baseline to 12 weeks. Twenty-two of 108 patients (20.4%) 
in the placebo group and 22 of 113 (19.5%) in the donepezil group had a reduction of 30% or 
greater in the CMAI score. There were also no significant differences between the placebo 
and donepezil groups in scores for the NPI, or the Clinician's Global Impression of Change.  
  Birks et al. 
641
 authored a Cochrane review including 24 trials, involving 5,796 
participants, of which 15 reported results in sufficient detail for the meta-analyses. Most trials 
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lasted 6 months or less. Patients in 20 trials had mild to moderate disease, in two trials 
moderate to severe, and in two severe disease. People with mild, moderate or severe dementia 
due to AD, treated for periods of 12, 24 or 52 weeks with donepezil, experienced benefits in 
cognitive function, performing the activities of daily living and behaviour but not on the 
quality of life score. 
Rivastigmine 
Some studies showed that rivastigmine is better tolerated and has a better effect than 
donepezil 
642 643
. Donepezil is a selective acetylcholine esterase (AChE) inhibitor, while 
rivastigmine inhibits both AChE and butyrylcholine esterase (BuChE). Analysis of response 
by BuChE genotype suggested that this differential effect may be due to the inhibition of 
BuChE, in addition to AChE, by rivastigmine 
644
. 
  Cummings et al. 
645
  enrolled a total of 173 patients in a study. After 26 weeks of 
rivastigmine treatment, patients showed statistically significant improvements of NPI sub-
scores from baseline (delusions, hallucinations, agitation, apathy/indifference, 
irritability/lability, aberrant motor behaviour, nighttime disturbances, and appetite/eating 
changes). The study was open label and not restricted to patients with behavioural 
disturbances at baseline, which limit the results.  
  Burn et al. 646 included a total of 541 PDD patients in a study, 188 with visual 
hallucinations (118 on rivastigmine, 70 on a placebo) and 348 with non-visual hallucinations 
(239 on rivastigmine, 109 on a placebo). Greater behavioural benefits in the hallucinating 
sub-group were evident on NPI-10 individual items, as well as overall NPI-10 change from 
baseline. The baseline mean NPI-10 score was, however, twice as high in the visual 
hallucinating sub-group compared with the non-hallucinating sub-group, raising the 
possibility of a ceiling effect to account for the intergroup difference in efficacy. Although the 
study was not powered to detect significant differences on the individual NPI items, a 
significant treatment effect was noted on one item: agitation/aggression. Low patient numbers 
reporting symptoms captured by other individual items on the scale might have contributed to 
non-significant effects on other items such as apathy. Visual hallucinations may appear to 
predict more rapid decline and possibly greater therapeutic benefit from rivastigmine 
treatment in PDD.  
  Emre et al. 
647
 reviewed data from large, placebo-controlled clinical trials conducted 
with rivastigmine in patients with PDD and AD to evaluate similarities and differences in 
response to treatment. In placebo groups, AD patients appeared to show more rapid cognitive 
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decline than those with PDD. Treatment effects (rivastigmine versus placebo) on cognitive 
performance over 6 months were quantitatively similar in both populations, but qualitatively 
different: in AD, cognitive abilities were stabilized by rivastigmine compared to declines in 
placebo groups, whereas in PDD symptomatic improvements above baseline drove treatment 
effects while placebo patients had limited change. In the activities of daily living, stabilization 
(rather than improvement) was observed in both dementia types. A more aggressive course of 
placebo decline, and greater treatment differences (rivastigmine versus placebo), were seen in 
sub-populations of both PDD and AD patients with hallucinations at baseline. The safety and 
adverse event profiles were comparable in the two populations. In conclusion, the magnitude 
of effect with rivastigmine versus placebo is quantitatively comparable in patients with AD 
and PD, but the treatment effect tended to be one of stabilization in AD, while in PDD 
improvements over baseline were seen. In both populations, hallucinations may identify 
patients who are likely to be more treatment-responsive. 
  Birks et al. 
648
 included in a Cochrane review analysis nine trials, involving 4,775 
participants. They concluded that rivastigmine appears to be beneficial for people with mild to 
moderate Alzheimer's disease. In comparisons with placebo, improvements were seen in the 
rate of decline of cognitive function, performance of the activities of daily living, and the 
severity of the dementia with daily doses of 6 to 12 mg. Adverse events were consistent with 
the cholinergic actions of the drug. Two studies assessed behavioural disturbance using the 
NPI-10 and NPI-12; there was no difference between rivastigmine and placebo. 
Galantamine 
Tariot et al. 
649
 reported the results from a 5-month multicentre, placebo-controlled, double-
blind trial. Following a 4-week placebo run-in, patients were randomised to one of four 
treatments: a placebo or galantamine escalated to final maintenance doses of 8, 16, or 24 
mg/day. Compared with placebo, the galantamine 16- and 24-mg/day groups also had a 
significantly better outcome on CIBIC-plus, performing the activities of daily living, and 
behavioural symptoms. 
 Wilkinson et al. 
650
 performed a post hoc analysis on pooled data from four pivotal 
studies in patients with 'advanced moderate' AD: baseline MMSE mean score 11 or 
Alzheimer's Disease Assessment Scale-cognitive sub-scale (ADAS-cog) mean score 39. Over 
5 to 6 months, cognitive abilities were improved with galantamine versus placebo. Cognitive 
and functional abilities were maintained around baseline; behavioural symptoms were 
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delayed. Over 6 months, galantamine provided a broad spectrum of benefits to patients with 
'advanced moderate' AD. 
  Cummings et al. 
651
 assigned 978 patients with mild to moderate Alzheimer's disease 
to placebo or galantamine (8, 16, or 24 mg/day). Behavioural changes were the primary 
outcome and were assessed with the NPI, and alterations in carer distress were measured by 
the NPI distress scale. Data collected at baseline and 12 and 21 weeks postbaseline were 
analysed. NPI scores worsened with the placebo, whereas patients treated with 16 or 24 
mg/day of galantamine had no change in total NPI scores. Treated patients, asymptomatic or 
symptomatic at baseline, had better NPI sub-scale scores than did patients receiving the 
placebo. Behavioural improvement in patients symptomatic at baseline ranged from 29% to 
48%. Changes were evident in patients receiving 16 or 24 mg/day of galantamine. High-dose 
galantamine was associated with a significant reduction in carer distress. Galantamine therapy 
was associated with reduced emergence of behavioural disturbances and improvement in 
existing behavioural problems in patients with mild to moderate Alzheimer's disease. 
  Suh et al. 
652
 enrolled a total of 300 patients (76, 78, 80, and 66 patients in the 8-, 16-, 
24-mg/d and community control groups, respectively). Significant improvements in all 3 
treatment groups were observed in mean BEHAVE-AD, and CIBIC-plus scores. Galantamine 
was relatively well tolerated. This study found that galantamine effected significant benefits 
on the cognitive, functional, and behavioural symptoms of mild to moderate AD. The 
tolerability results suggest that galantamine is well tolerated in these patients.  
4.9.4.1. Combination therapy 
Tariot et al. 
653
 performed the first study combining a cholinesterase inhibitor with 
memantine. They hypothesised that administration of memantine to patients with moderate to 
severe AD receiving stable donepezil therapy would result in clinical benefit and would be 
safe and well tolerated. Of the 404 patients who entered the study, 201 were randomised to 
placebo and 203 were randomised to memantine, added on to donepezil. Specifically, 
measures of cognitive function, performance of the activities of daily living, behaviour, and 
clinical global status were significantly improved with memantine compared with the placebo. 
Treatment with memantine during the 6-month trial in patients with MMSE scores of 5 to 14 
resulted in the maintenance of cognitive function (0.9 increase in SIB score compared with 
baseline), whereas treatment with the placebo was associated with cognitive decline (2.5 
decrease in SIB score compared with baseline). McShane 
654
 commented on this article in 
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Evidence Based Mental Health and concluded: Memantine significantly improves physical 
and mental health in people with severe to moderate Alzheimer‘s taking donepezil. 
  Atri et al. 
655
 compared the clinical effectiveness in patients with AD treated with 
combination (COMBO) therapy consisting of cholinesterase-inhibitor (CI) plus memantine 
(MEM) versus CI alone versus no treatment with either. Three hundred eighty-two subjects 
with probable AD underwent serial clinical evaluations at a memory disorders unit. One 
hundred forty-four subjects received standard care without CI or MEM (NO-RX), 122 
received CI monotherapy, and 116 received COMBO therapy with CI plus MEM. The mean 
follow-up period was 30 months (4.1 visits) and the mean cumulative medication treatment 
time was 22.5 months. The COMBO group had significantly lower mean annualised rates of 
deterioration compared with the CI and NO-RX groups. Similar comparisons significantly 
favoured the CI over the NO-RX group. COMBO therapy slowed cognitive and functional 
decline in AD compared with CI monotherapy and no treatment. These benefits had small-to-
medium effect sizes that increased with time on treatment and were sustained for years. 
  Lopez et al. 
656
 performed an observational study investigating the time to NH 
admission and death in 943 probable AD patients who had at least a 1-year follow-up 
evaluation. Of these patients, 140 (14.9%) used both ChEIs and memantine, 387 (41%) used 
only ChEIs, and 416 (44.1%) used neither. The mean follow-up time was 62.3 months. 
Compared with those who never used cognitive enhancers, patients who used ChEIs had a 
significant delay in NH admission (HR 0.37); this effect was significantly augmented with the 
addition of memantine (HR 0.29) (memantine+ChEI vs ChEI alone). ChEIs alone, or in 
combination with memantine had no significant association on time to death. This study 
revealed that the addition of the N-methyl-D-aspartate (NMDA) receptor antagonist 
memantine to the treatment of AD with ChEI significantly altered the treated history of AD 
by extending time to NH admission by factor 3.5. 
4.9.4.2. Reviews and consensus statements 
Trinh et al. 
657
  conducted a systematic review and meta-analysis to quantify the efficacy of 
cholesterinase inhibitors for neuropsychiatric and functional outcomes. Ten trials included the 
ADAS-noncog and six included the NPI. Compared with the placebo, patients randomised to 
cholinesterase inhibitors improved 1.72 points on the NPI, and 0.03 points on the ADAS-
noncog. For functional outcomes, 14 trials used ADL and 13 trials used IADL scales. There 
was no difference in efficacy among various cholinesterase inhibitors. The results indicated 
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that cholinesterase inhibitors have a modest beneficial impact on neuropsychiatric and 
functional outcomes for patients with AD.  
   Burns et al. 658 authored a consensus statement from the British Association for 
Psychopharmacology. They concluded that there is type 1b evidence for AChEIs for the 
treatment of people with Lewy body disease (particularly neuropsychiatric symptoms). 
  Birks et al. 
659
 performed a Cochrane review of 13 randomised, double- blind, placebo-
controlled trials and could demonstrate that treatment for periods of 6 months and one year, 
with donepezil, galantamine or rivastigmine at the recommended dosage for people with mild, 
moderate or severe dementia due to AD produced improvements in cognitive function. 
Benefits of treatment were also seen on measures of performance in the activities of daily 
living and behaviour. None of these treatment effects are large. It was not possible to identify 
those who will respond to treatment prior to treatment.  
  Raina et al. 
660
 performed a large review of 96 publications representing 59 unique 
studies. Both cholinesterase inhibitors and memantine had consistent effects in the domains of 
cognition and global assessment, but summary estimates showed small effect sizes. Outcomes 
in the domains of behaviour and quality of life were evaluated less frequently and showed less 
consistent effects. Most studies were of short duration (6 months), which limited their ability 
to detect delay in onset or progression of dementia. Three studies directly compared different 
cholinesterase inhibitors and found no differences in cognition and behaviour. Of the 9 studies 
that evaluated behaviour, all but 1 used the NPI. Summary estimates for this outcome were not 
significant in patients with AD. 
  Rodda et al. 
661
 did a systematic review of randomised, placebo-controlled trials of 
donepezil, rivastigmine and galantamine to answer whether cholinesterase inhibitors are 
effective in the management of the BPSD of dementia in AD. Fourteen studies were identified 
that matched the inclusion criteria. Nine were of donepezil, three of galantamine and two of 
rivastigmine. Median study treatment length was 24 weeks (range 12 to 170). Most studies 
used the NPI as a behavioural outcome measure although three used specific scales for either 
agitation or apathy. Four studies were specifically designed to assess behavioural outcomes 
whilst in the majority of studies behavioural outcomes were only secondary measures. Three 
studies found statistically significant, albeit modest, differences in the change of NPI total 
score between drug and placebo. The interpretation of the results of many studies is limited by 
methodological considerations, including generally low NPI scores at baseline and the 
investigation of BPSD as secondary outcomes. The evidence base regarding the efficacy of 
cholinesterase inhibitors in BPSD is limited, in part due to methodological considerations. In 
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the absence of alternative safe and effective management options, the use of cholinesterase 
inhibitors is an appropriate pharmacological strategy for the management of BPSD in 
Alzheimer's disease.  
4.9.5. Memantine 
Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) 
receptor antagonist and has a totally different pharmacological target than the cholinesterase 
inhibitors. It may prevent excitatory neurotoxicity in dementia. 
  The objective of Cummings et al. 
662
 was to investigate the behavioural effects of 
memantine in moderate to severe AD. The authors conducted an exploratory analysis of a 24-
week, double-blind, placebo-controlled trial comparing memantine (20 mg/day) with a 
placebo in subjects with moderate to severe AD on stable donepezil treatment. They 
employed the NPI-NH, administered at baseline, week 12, and week 24, to assess the effects 
of memantine on behaviour. Global, cognitive, and functional measures were collected and 
relationships between these assessments and changes in behaviour were determined. Patients 
treated with memantine had significantly lower NPI total scores than patients treated with 
placebo. Analyses of the 12 NPI domains revealed significant effects in favour of memantine 
on agitation/aggression, eating/appetite, and irritability/lability. Of patients who exhibited 
agitation/aggression at baseline, those treated with memantine showed significant reduction of 
symptoms compared with placebo-treated patients. Memantine-treated patients without 
agitation/aggression at baseline evidenced significantly less emergence of this symptom 
compared with similar patients receiving the placebo. Carers of patients receiving memantine 
registered significantly less agitation-related distress.  
   Aarsland et al. 
663
 aimed to test the safety and efficacy of memantine in patients with 
PDD and DLB in a parallel-group, 24-week, randomised controlled study of memantine (20 
mg per day) versus placebo at four psychiatric and neurological outpatient clinics in Norway, 
Sweden, and the UK. The primary outcome measure was the CGIC. Seventy-two patients 
with PDD or DLB were randomly assigned and started treatment: 34 with memantine and 38 
with placebo; 56 (78%) completed the study. All withdrawals were owing to adverse events, 
but the proportion of withdrawals was similar in both groups. At week 24 the patients in the 
memantine group had better CGIC scores than those taking placebo. With the exception of 
improved speed on attentional tasks (A Quick Test on cognitive speed - AQT) in the 
memantine group, there were no significant differences between the groups in secondary 
outcome measures (NPI, MMSE, DAD). Murat Emre 
664
 commented on this study and 
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elucidated some limitations but concluded that ―although not conclusive, these results are 
encouraging, but they await confirmation before memantine can be added to the list of 
treatments for these patients. A larger, randomised placebo-controlled, multicentre trial 
including 199 patients with either DLB or PDD has just been completed and the results are 
being analysed. Should these results of Aarsland and colleagues be confirmed, the choices of 
treatment for physicians managing such patients might be expanded.‖ 
4.9.5.1. Reviews 
McShane et al. 
665
 published the results of a systematic Cochrane review:  (1) Moderate to 
severe AD. Two out of three six-month studies show a small beneficial effect of memantine. 
Pooled data indicate a beneficial effect at six months on cognition, activities of daily living 
and behaviour (2.76 points on the 144 point NPI, 95% CI 0.88 to 4.63, P=0.004), supported 
by clinical impression of change. (2) Mild to moderate AD. Pooled data from three 
unpublished studies indicate a marginal benefical effect at six months on ITT cognition,  
which was barely detectable clinically but no effect on behaviour, activities of daily living or 
OC analysis of cognition. (3) Mild to moderate vascular dementia. Pooled data from two six- 
month studies indicated a small beneficial effect of memantine on cognition, and behaviour 
but this was not supported by clinical global measures. (4) Patients taking memantine were 
slightly less likely to develop agitation (134/1739 [7.7%] versus 175/1873 [9.3%]; OR=0.78, 
95% CI 0.61 to 0.99, P=0.04). This effect was slightly larger, but still small, in moderate to 
severe AD (58/506 [12%] vs 88/499 [18%]; OR=0.6, 95% CI 0.42 to 0.86, P=0.005). There is 
no evidence either way about whether it has an effect on agitation which is already present. 
  Wilkinson and Andersen 
666
 pooled data from 6 randomised, double-blind, placebo-
controlled, 6-month studies and a subgroup of patients (867 on placebo, 959 on memantine) 
with moderate to severe AD (MMSE <20) was analysed. More placebo-treated than 
memantine-treated patients showed some clinical worsening (28% vs. 18%), and 21% of the 
placebo-treated patients compared to 11% of the memantine-treated patients had marked 
clinical detoriation. In this population of moderate and severe AD patients, treatment with 
memantine was associated with reducing worsening of clinical symptoms in AD during the 6-
month study period. 
  Winblad et al. 
212
 summarised the efficacy data for memantine by a meta-analysis of 
1,826 patients in six trials. Efficacy was assessed using measures of global status, cognition, 
function, and behaviour (NPI). Results (without replacement of missing values) showed 
statistically significant effects for memantine (vs. placebo) in each domain. Memantine was 
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well tolerated, and the overall incidence rates of adverse events were comparable to placebo. 
This meta-analysis supports memantine's clinically relevant efficacy in patients with moderate 
to severe AD. 
  Wilcock et al. 
667
 reported the results of a pooled analysis of three studies. Sixty 
percent of the total patient group had baseline symptoms of agitation/aggression, delusions, or 
hallucinations on the NPI. At both 12 and 24/28 weeks, there was a significant treatment 
advantage for memantine over placebo for the proportion of patients showing improvement 
on the defined neuropsychiatric symptom cluster (55.6% vs. 44.4% at week 12; 58.0% vs. 
44.8% at week 24/28) and specifically for the treatment of agitation/aggression (55.3% vs. 
43.1% at week 12; 61.0% vs. 45.0% at week 24/28). Placebo-treated patients in this 
population demonstrated an accelerated disease progression for global, cognitive, and 
functional outcomes, but memantine conferred statistically significant benefit for all 
measures. Tolerability in this population remained good, and fewer memantine-treated 
patients than placebo-treated patients withdrew due to adverse events. This post hoc analysis 
provides important evidence from placebo-controlled trials that memantine may be a safe and 
effective treatment in AD patients with agitation/aggression or psychosis, who are otherwise 
prone to rapid progression.  
  Gauthier et al. 
668
 performed a pooled data analysis of six 24/28-week, randomised, 
placebo-controlled, double-blind studies. Of the 2,311 patients included in these studies, 
1,826 patients with moderate to severe AD (MMSE <20) were included in this analysis, 
corresponding to the extended indication for memantine in Europe. In this subgroup, 959 
patients received memantine 20 mg/day and 867 received a placebo. Behavioural symptoms 
were rated using the NPI total and single-item scores at weeks 12 and 24/28. At weeks 12 and 
24/28, ITT analysis demonstrated that memantine treatment produced statistically significant 
benefits over placebo treatment in the NPI total score, and in NPI single items: delusions, 
hallucinations, agitation/aggression, and irritability/lability, LOCF population. Analysis of the 
patients without symptoms at baseline indicated reduced emergence of agitation/aggression 
(p=0.002), delusions (p=0.047), and disinhibition (p=0.011), at week 12, and of 
agitation/aggression (p=0.002), irritability/lability (p=0.004), and night-time behaviour 
(p=0.050) at week 24/28 in those receiving memantine. The data suggest that memantine is 
effective in treating and preventing the behavioural symptoms of moderate to severe AD. 
Specific persistent benefits were observed on the symptoms of delusions and 
agitation/aggression, which are known to be associated with rapid disease progression, 
increased carer burden, early institutionalisation, and increased costs of care. 
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  Grossberg et al. 
669
 provided an overview of the prevalence, assessment, and treatment 
of behavioural disturbances in AD, and summarized current knowledge regarding the effects 
of memantine on the behaviour of community-dwelling patients. They searched EMBASE 
and PubMed (January 1992 to October 2008) for reports on memantine trials that involved 
outpatients with moderate to severe AD. All previously unpublished data were obtained from 
Forest Laboratories, Inc. Behavioural outcomes were assessed in three completed, double-
blind, placebo-controlled trials. Overall, patients who received memantine performed better 
on behavioural measures than those treated with placebo. Post-hoc analyses suggest that 
memantine treatment was associated with a reduced severity or emergence of specific 
symptoms, particularly agitation and aggression. Prospective, well-designed trials are 
warranted to evaluate the efficacy of memantine in patients with significant behavioural 
symptoms. 
4.9.6. Benzodiazepines and others 
The GABA receptor comprises various binding sites for GABA, benzodiazepines, 
barbiturates, and steroids. Each of these sites may be involved in the regulation of 
GABAergic neurons with respect to its inhibitory effects on other neuronal systems. 
Administration of exogenous agents that bind specifically to each site on the GABA receptor 
may be useful in producing or inhibiting typical GABA-related phenotypes, such as anxiety, 
aggression, and sleep. The benzodiazepine class of drugs has been used for many years to 
reduce anxiety and promote sleep. Unfortunately, these agents may produce tolerance after 
long-term use, as well as other side effects such as sedation, dizziness, and ataxia. Therefore, 
there is a concern with benzodiazepine use among the elderly. Stahl and colleagues 
670
 
showed that a large proportion of AD patients receiving donepezil also received hypnotics for 
the management of behavioural symptoms.  
Alprazolam (Xanor®), lorazepam (Temesta®, Ativan®), clonazepam (Rivotril®), diazepam 
(Valium®, Stesolid®), oxacepam (Sobril®, Alopam®) 
The different benzodiazepines have been tested, on average in small RCTs and chart reports 
671-684
. They compared benzodiazepines either to antipsychotics and/or a placebo. With 
respect to efficacy, the authors did not find significant differences between the medication 
groups and the placebo.  
 Meehan et al. 
685
 published the only RCT using benzodiazepines for acutely agitated 
patients with dementia. They reported the results using intramuscular lorazepam treatment, 
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compared with those treated with placebo in a double-blind, randomised study. Significant 
adverse events noted with lorazepam were drowsiness and dry mouth. 
  The Dementia and Cognitive Improvement Group from Cochrane is planning a review 
of benzopdiazepines in dementia, led by Huang from China. 
  In summary, though many of the benzodiazepines lack data from RCTs, they are 
widely used in NHs in Norway 
13
. To date, there seems to be limited evidence for the use of 
benzodiazepines in managing BPSD. The primary concern with these agents is the potential 
for serious adverse events such as confusion, falls, depression of respiration, and they may 
paradoxically increase agitation in patients with dementia 
686 687
. Consistent with this 
information, the report published by the Expert Consensus Panel for Agitation in Dementia 
generally recommended against the use of benzodiazepines except for short-term or 
occasional use for anxiety symptoms 
688
. 
4.9.7. Beta Blocker  
Peskind et al. 
208
 randomised 31 subjects (age 85, SD 8) with probable or possible AD and 
persistent disruptive behaviour that interfered with necessary care to propranolol (n=17) or a 
placebo (n=14) in a double-blind study. Stable doses of previously prescribed psychotropics 
were maintained at pre-study dose during the study. Following a propranolol or placebo dose 
titration period, subjects were maintained on the maximum achieved dose for 6 weeks. 
Primary outcome measures were the NPI and the CGIC. Propranolol augmentation (mean 
achieved dose 106, SD 38 mg/d) was significantly more effective than the placebo for 
improving overall behavioural status on the total NPI score and CGIC. Improvement in 
individual NPI items within propranolol subjects was significant only for 
‗agitation/aggression‘ and ‗anxiety‘, and reached borderline statistical significance favouring 
propranolol over the placebo only for ‗agitation/aggression‘.  
4.9.8. Aroma therapy 
Ballard et al. 
574
 randomly assigned 72 people residing in care facilities to aromatherapy with 
Melissa essential oil (N=36) or a placebo (sunflower oil) (N=36). These patients had clinically 
significant agitation in the context of severe dementia. The active treatment or placebo oil was 
combined with a base lotion and applied to patients' faces and arms twice a day by carers. 
Changes in clinically significant agitation (CMAI) and the QoL indices (percentage of time 
spent socially withdrawn and percentage of time engaged in constructive activities, measured 
with DCM) were compared between the 2 groups over a 4-week period of treatment. Seventy-
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one patients completed the trial. No significant side effects were observed. Sixty percent 
(21/35) of the active treatment group and 14% (5/36) of the placebo-treated group 
experienced a 30% reduction of CMAI score, with an overall improvement in agitation (mean 
reduction in CMAI score) of 35% in patients receiving Melissa balm essential oil and 11% in 
those treated with placebo. QoL indices also improved significantly more in people receiving 
essential balm oil. 
  Shortly, Burns et al. will publish the Essence study presenting a 24 week placebo-
controlled, double-blind trial comparing donepezil, melissa aromatherapy, with a placebo. 
The study with better blinding showed significant benefits in both therapy groups, but no 
statistically significant difference between the groups. This raises a question that is relevant in 
all trials: Is this a negative study or does it demonstrate non-specific benefits? 
4.9.9. Different subjects related to drug therapy in dementia 
4.9.9.1. Anticholinergic drugs  
Medications prescribed to elderly persons often have an anticholinergic effect, as do many 
commonly used over-the-counter drugs. Anticholinergic medications are known to produce 
psychomotor and cognitive slowing, especially in older persons. 
  Mulsant et al. 
689
 measured the serum anticholinergic activity (SAA), as measured by a 
radioreceptor assay, in 201 subjects who were randomly selected among the participants in an 
epidemiological community study, based on their age and sex. Cognitive performance was 
assessed with use of the MMSE. Serum anticholinergic activity was detectable in 180 (89.6%) 
participants (range 0.50 to 5.70 pmol/mL). Univariate testing showed a significant association 
between SAA and MMSE scores. Logistic regression analysis indicated that subjects with 
SAA at or above the sample's 90th percentile (i.e., SAA >/=2.80 pmol/mL) were 13 times 
(OR 12.81; 95%CI 1.08-152.39) more likely than subjects with undetectable SAA to have a 
MMSE score of 24 or below. This confirmed that even low SAA is associated with cognitive 
impairment. 
  Nebes et al. 
690
 found that an elevated SAA was associated with a significant slowing 
in both gait speed and simple response time. Cumulative anticholinergic burden may be one 
of the factors contributing to an increased risk of falls in the older population. 
  Landi et al.‘s 691 results confirmed that among old-old subjects the use of 
anticholinergic drugs is associated with impaired physical performance and functional status. 
   Chew et al. 
692
 measured the anticholinergic activity (AA) of 107 medications 
commonly used by older adults. Six clinically relevant concentrations were assessed for each 
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medication. The authors presented a list with medications in typical doses administered to 
older adults, categorising them into ‗no AA‘, ‗mild AA‘ (AA values less than 5 pmol/mL), 
‗moderate AA‘ (AA values of 5 to 15 pmol/mL), ‗severe AA‘ (AA values exceeding 15 
pmol/mL). 
  Carnahan et al. 
693
 described the Anticholinergic Drug Scale (ADS) as a measure of 
drug-related anticholinergic burden and investigated the scale‘s associations with serum 
anticholinergic activity. ADS scores were significantly associated with SAA. Therefore, the 
ADS may be a clinically useful tool for preventing anticholinergic adverse effects. 
4.9.9.2. Inappropriate prescribing 
Blix et al. 
694
 performed a prospective study with the aim of describing the frequency and 
types of drug-related problems (DRPs) in hospitalised patients, and to identify risk factors for 
DRPs and the drugs most frequently causing them. The patients used an average of 4.6 drugs 
on admission. Of the 827 patients, 81% had DRPs, and an average of 2.1 clinically relevant 
DRPs was recorded per patient. The DRPs most frequently recorded were dose-related 
problems (35.1% of the patients) followed by need for laboratory tests (21.6%), non-optimal 
drugs (21.4%), need for additional drugs (19.7%), unnecessary drugs (16.7%) and medical 
chart errors (16.3%). A multivariate analysis showed that the number of drugs on admission 
and the number of clinical/pharmacological risk factors were both independent risk factors for 
the occurrence of DRPs, whereas age and gender were not. 
4.9.9.3. Covert medication 
Kirkevold and Engedal 
695
 reported that nearly a quarter (23.5%) of patients in Norwegian 
nursing-homes who received medications had drugs mixed in food or beverages. Fourteen per 
cent of the patients in SCUs and nearly 10% of the patients in RUs received medicine blended 
in food or beverages without their knowledge (covert medication). Compared with patients 
who were treated openly, a significantly higher proportion of patients who were treated 
covertly received antipsychotics (20% vs 30%, respectively; p < 0.001). In most cases, the 
decision to administer covert medication was made by the staff together with the physician or 
by the physician alone (61.4% of occasions in SCUs and 52.8% in RUs). About two-thirds of 
cases of covert medication had been documented to some extent in the patients' records. Low 
mental capacity, low ADL function and the presence of agitation and learning disability were 
associated with covert medication. 
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4.9.9.4. Drug related problems 
Ruths et al. 
696
 performed a multidisciplinary review of drug use in nursing-home-residents 
with the aim of identifying the most frequent clinically relevant medication problems and to 
analyse them according to the drugs involved and types of problems; 2,445 potential 
medication problems were identified in 1,036 (76%) residents. Psychoactive drugs accounted 
for 38% of all problems; antipsychotics were the class most often involved. Multiple 
psychoactive drug use was considered particularly problematic. Potential medication 
problems were most frequently classified as risk of adverse drug reactions (26%), 
inappropriate drug choice for indication (20%), and underuse of beneficial treatment (13%). 
4.9.10. Summary of chapter 4.9. 
Ballard, C. G., Gauthier, S., Cummings, J. L., Brodaty, H., Grossberg, G. T., Robert, P., and 
Lyketsos, C. G. 
697
 have published a paper on ‗Management of agitation and aggression 
associated with Alzheimer disease‘ and concluded that the most widely prescribed 
pharmacological treatments for these symptoms - atypical antipsychotics - have a modest but 
significant beneficial effect in short-term treatment (over 6 to 12 weeks) of aggression but 
limited benefits in longer-term therapy. Benefits are less well established for other symptoms 
of agitation. In addition, concerns are growing over the potential for serious adverse outcomes 
with these treatments, including stroke and death. A detailed consideration of other 
pharmacological and non-pharmacological approaches to agitation and aggression in patients 
with AD is, therefore, imperative. This article reviewed the increasing evidence in support of 
psychological interventions or alternative therapies (such as aromatherapy) as a first-line 
management strategy for agitation, as well as the potential pharmacological alternatives to 
atypical antipsychotics - preliminary evidence for memantine, carbamazepine, and citalopram 
is encouraging. 
 4.10. Oxcarbazepine in the treatment of agitation and  
   aggression in dementia 
4.10.1. Pharmacology 
Oxcarbazepine (OXC) is a structural derivative of carbamazepine, with a ketone in place of 
the carbon-carbon double bond on the dibenzazepine ring. This difference helps to reduce the 
impact on the liver during the metabolising of the drug, and also prevents the serious forms of 
anemia or agranulocytosis occasionally associated with carbamazepine. In vitro 
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electrophysiological studies indicated that OXC blocks the voltage-sensitive sodium channels, 
resulting in stabilization of hyper excited neural membranes, inhibition of repetitive neuronal 
firing, and diminution of propagation of synaptic impulses. In addition, increased potassium 
conductance and modulation of high-voltage activated calcium channels may contribute to the 
anticonvulsant effects of the drug. No significant interactions of OXC with brain 
neurotransmitter or modulator receptor sites have been demonstrated.  
  Following oral administration, OXC is completely absorbed and is rapidly reduced by 
cytosolic enzymes in the liver to its 10-monohydroxy metabolite, MHD, which is primarily 
responsible for the pharmacological effect. The half-life of the parent is about two hours, 
while the half-life of MHD is about nine hours, so that MHD is responsible for most 
antiepileptic activity. Approximately 40% of MHD is bound to serum proteins, predominantly 
to albumin. MHD is metabolized further by conjugation with glucuronic acid and cleared 
from the body mostly by the kidneys. More than 95% of the dose appears in the urine, with 
less than 1% as unchanged OXC.  There is a linear correlation between creatinine clearance 
and the renal clearance of MHD. When OXC (Trileptal®) is administered as a single 300-mg 
dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life 
of MHD is prolonged to 19 hours. Following administration of single (300 mg) and multiple 
(600 mg/day) doses of Trileptal to elderly volunteers (60 to 82 years of age), the maximum 
plasma concentrations of MHD were 30% to 60% higher than in younger volunteers (18 to 32 
years of age). Comparisons of creatinine clearance in young and elderly volunteers indicate 
that the difference was due to age-related reductions in creatinine clearance. No gender-
related pharmacokinetic differences have been observed in children, adults, or the elderly. 
  Clinically significant hyponatremia (sodium <125 mmol/L) can develop during OXC 
use. In the 14 controlled epilepsy studies, 2.5% of Trileptal-treated patients (38/1,524) had a 
sodium level of less than 125 mmol/L at some point during treatment, compared to no patients 
assigned to a placebo or active control. When OXC was discontinued due to hyponatremia 
patients experienced normalization of serum sodium within a few days without additional 
treatment. 
4.10.2. Oxcarbazepine’s (OXC) use in psychiatry 
Previous clinical studies in psychiatric disorders, clinical experience, and published individual 
cases of BPSD 
698 699
 indicated that OXC may be an effective alternative to existing 
treatments in BPSD. This has not been investigated in prospective RCTs. OXC is effective in 
affective disorders, especially in mania 
700 701
. In Benedetti et al.‘s study, OXC was as 
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effective as haloperidol. OXC was used as add-on therapy to lithium in bipolar disorders, 
especially mania and mixed states. It has been shown to be significantly more effective than 
lithium alone in 60 % of the patients 
702
. In some recommendations, OXC is preferred to 
carbamazepine (CBZ) in mania (Texas Guidelines, 2002). OXC has shown a CBZ-like effect 
703 704
. CBZ was effective in BPSD 
36
 and its efficacy and tolerability was not limited to any 
particular type of dementia 
705
.   
5. Characteristics of the studies included in the thesis  
5.1. Background 
Dementia is a serious health problem that becomes more prevalent in a population as its 
average age increases. It is the main reason for institutionalizing elderly people. Disruptive 
and agitated behaviour affects 30 to 50% of all individuals with dementia at some point in the 
course of the illness. Such behaviour decreases the quality of life of patients and carers, puts 
heavy strains on relatives as well as professional carers and poses a diagnostic, therapeutic 
and economic challenge.  
  There is a need for new pharmacological and non-pharmacological treatments, 
because the existing drugs have shown only limited benefits and are associated with poor 
tolerance and serious side effects. Furthermore, there is a need for validated assessment tools 
to evaluate patients before therapy and during a follow-up period. Given the daily routine in 
nursing-homes with many competing demands on staff time brief instruments are preferable.  
5.2. Objectives 
The thesis had three aims: 
1) To evaluate the effect of oxcarbazepine (OXC) in the treatment of severe agitation 
and aggression in patients residing in nursing-homes with Alzheimer‘s disease or 
vascular dementia or a mixture of both.  
2) To study the psychometric properties of the Norwegian version of the Brief 
Agitation Rating Scale (BARS) by performing a factor analysis on a large sample of 
Norwegian nursing-home patients and testing the reliability and validity on another 
sample. 
3) To test the reliability and validity of the Norwegian version of the Neuropsychiatric 
Inventory, Nursing-home Version (NPI-NH). 
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5.3. Design  
5.3.1. Main study 
This was an eight-week, multicentre, double-blind, randomised, placebo-controlled trial 
performed independently of the pharmaceutical industry. The pharmaceutical company 
Novartis donated the supply of the drug, but was neither involved in the study design, 
analyses, interpretation of the results, nor in the writing of reports or scientific papers. The 
authors and a protocol committee designed the trial and wrote the protocol (see appendix). 
For safety reasons and to track adverse events, patients were followed up for an additional 4 
weeks after the trial medication had been discontinued. The study was approved by the 
Norwegian state authorities in charge of regulating research and the Regional Ethics 
Committee. 
  Patients were randomly assigned in blocks of four to treatment with 300–900 mg OXC 
(Trileptal®, Novartis) per day or a placebo in a 1:1 ratio (for study assignment, see Fig. 1). 
Personalised dosing, similar to Pierre N. Tariot‘s study, was chosen in view of the limited 
amount of published
 
data on the safety, tolerance, and efficacy of this
 
agent for this kind of 
population. Treatment started with 75 mg in the morning and 225 mg in the evening. Doses 
were increased stepwise, reaching a total daily dose of 900 mg OXC after 3 weeks. For this 
quite old and frail population, we followed the principles of geriatric medicine and reduced 
the dose to half of the highest possible dose. Our clinical experience using OXC in elderly 
patients also led us to use 900 mg as a maximum dose. The highest well-tolerated dose for 
each patient was maintained for the rest of the study. Dose adjustments were permitted if 
there were adverse events or other problems. All personnel involved in conducting the study 
remained unaware of the treatment groups until all the data had been retrieved, double data 
entry had been checked, a blind review had been performed, and the report of the analysis had 
been written. 
  Efficacy assessments were made at baseline and at weeks 2, 4, 8, and 12. The primary 
efficacy variable was change in the agitation and aggression sub-score of NPI-NH. This sub-
score is the product of intensity scores (0–3 points) and frequency scores (0–4 points) and 
ranges from 0 to 12, with higher scores indicating more severe symptoms. Secondary clinical 
outcome variables were change in agitation, as measured by the Norwegian version of the 
Brief Agitation Rating Scale (BARS) and change in the burden of care as measured by NPI-
NH. The Norwegian version of BARS is a 10-item scale, for which each score ranges from 1 
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(never) to 7 (more than once an hour); the total score ranges from 10 to 70, higher scores 
indicating more frequent symptoms of agitation. 
5.3.2. Study of the factor analysis of BARS 
We used a set of previously published data from a cross-sectional study that analysed the 
effect of patient and ward characteristics on the use of restraints in Norwegian nursing-homes, 
Kirkevold et al. 
363
, and performed a factor analysis of the BARS. 
5.3.3. Study of the reliability and validity of the Norwegian version of the Brief 
Agitation Rating Scale (BARS) in dementia 
We used the existing Norwegian translation of the BARS because it had already been 
introduced and widely used, especially in clinical trials. It consists of ten items, which are 
scored from 1 (never) to 7 (several times an hour), retrospectively reporting the frequency of 
the agitated behaviour during the preceding two weeks. Thus, the sum score may range from 
10 to 70. Normally, the total score of BARS is used. Another way is to sum up the scores of 
the types of agitation related to factors of the BARS. After conducting a factor analysis we 
identified three factors, ‗physically aggressive behaviour‘, ‗physically non-aggressive 
behaviour‘ and ‗verbal agitation‘, in a large sample (n=1,870) of Norwegian nursing-home 
patients. In the present study we used the scores of these three sub-scales in our analysis.  
5.3.4. Study of the reliability and validity of the Norwegian version of the 
Neuropsychiatric Inventory, Nursing-home Version (NPI-NH) 
The NPI rates the occurrence, frequency and severity of psychiatric symptoms and 
behavioural disturbances commonly seen in dementia. The structure and the scoring-rules of 
the scale have been comprehensively described by Cummings et al., and the validity and the 
reliability are reported to be satisfactory 
706
. 
The NPI-NH was translated into Norwegian, translated back into the original 
language, and then harmonized into Norwegian by Aarsland and Dramsdahl according to 
procedures recommended for the translation of psychometric scales (Aarsland, personal 
communication). 
5.4. Materials 
5.4.1. Main study 
The patients included both males (29.1%) and females (70.9%) resident in nursing-homes for 
at least 4 weeks prior to inclusion. They had a median age of 84 years (range: 63–98) and had 
140 
 
received a diagnosis of Alzheimer‘s disease or vascular dementia according to ICD-10, 
Diagnostic Criteria for Research 
134
. We did not differentiate between Alzheimer‘s disease 
and vascular dementia, because it is difficult to discriminate between Alzheimer‘s disease and 
vascular dementia in this age-group and in the late stages of dementia 
707 708
. We followed 
Pierre N. Tariot‘s 36 study design to make our study comparable to the only trial using 
antiepileptics that showed a significant effect. The dementia was of moderate to severe degree 
as defined by a Mini Mental State Examination score of 0 to 20 
709
, and the patients had a 
history of agitation or aggression for at least 1 week and a score of ≥ 6 on the NPI-NH sub-
scale for agitation and aggression 
26 200
. Our definition of agitation and aggression was 
pragmatic: the sub-scale agitation/aggression of the NPI-NH was used to identify eligible 
patients. Patients with the following clinical abnormalities were excluded: low sodium serum 
levels (< 135 mmol/L); severely impaired renal function (creatinine clearance < 30 ml/min, 
calculated with Cockroft and Gault‘s formula); or hepatic failure (transaminases -GT and 
ALAT three times or more above the upper normal limit). Furthermore, patients with the 
following diseases were excluded: AV-block II and III and all kinds of arrhythmia 
necessitating treatment; severe somatic diseases that might demand a change of medication; 
severe or acute neurological disease (e.g., epilepsy, acute cerebrovascular events, severe 
Parkinson‘s disease, acute confusion) or a severe psychiatric disorder such as bipolar disorder 
or schizophrenia; dementia other than Alzheimer‘s disease or vascular dementia. Patients who 
had participated in another clinical trial during the previous 3 months or who earlier had been 
randomly assigned to the same study were excluded. Finally, patients were excluded if they 
had used cholinesterase-inhibitors or memantine for less than 3 months or if any change in the 
dosage had been introduced during the previous 2 weeks; the following concomitant 
medications were an exclusion criterion: cyclosporin or strong analgesics such as opioids, like 
codeines, and all morphines; carisoprodol; antiepileptics or antipsychotics; MAOI or lithium. 
  Participants were allowed to take 1 g of paracetamol three to four times a day. Those 
who used a psychotropic drug were not allowed to make any dose changes within 2 weeks 
before or during the study, nor was the commencement of treatment with new psychotropic 
medication (except rescue medication with haloperidol) permitted during this period. 
5.4.2. Study of the factor analysis of BARS 
Data were collected from two samples: The first comprised 1,501 patients in nursing-homes 
in 54 out of 430 municipalities in Norway. The patients were randomly selected from 222 
wards in large, medium and small municipalities in all the four health regions of the country. 
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The second sample consisted of 425 patients; it included all the patients from four teaching 
nursing-homes (TNH), and in addition all the patients from two wards of a fifth TNH. Thus 
the study comprised 1,926 patients in 251 wards, 1,362 patients in 160 regular units (RUs) 
and 564 patients in 91 special care units, specializing in the care of patients with dementia 
(SCUs). Further details can be found in Kirkevold et al. 
363
. 
5.4.3. Study of the reliability and validity of the Norwegian version of the Brief 
Agitation Rating Scale (BARS) in dementia 
The study of the internal consistency and the test-retest reliability was performed by enrolling 
56 patients in three nursing-homes in rural Norway. The mean age of the patients was 85.6 
years (SD 6.22); 67.9% were women. 
In the validation study, we included 138 patients from six nursing-homes, 56 who took 
part in the reliability study and an additional 82 who were only included in the validation 
study. Their mean age was 84.7 years (SD 7.4); 65.9% were women.  
5.4.4. Study of the reliability and validity of the Norwegian version of the 
Neuropsychiatric Inventory, Nursing-home Version (NPI-NH) 
5.4.4.1. Reliability study  
A sample of 41 patients from a nursing-home in a rural area of Norway was enrolled in the 
reliability study. The mean age of the sample was 84.3 years (SD 7.38, range 54-97). Seventy-
one per cent were female. Eighty-five per cent suffered from dementia (CDR ≥ 1). 
5.4.4.2. Validity study 
A sample of 50 patients from two other nursing-homes in the same area was included in the 
validation study. The mean age of the sample was 84.4 years (SD 5.50, range 70-94). Sixty-
four per cent were female.  
5.5. Data Collection 
5.5.1. Main study 
Patients were recruited from 35 nursing-homes across Norway under the guidance of 15 
investigators who had specialised either in geriatric psychiatry or geriatric medicine. Prior to 
inclusion, the diagnosis of each patient‘s dementia, mental and physical capacity, and mental 
health status were assessed. Except for one patient who had the capacity to consent to the 
142 
 
study himself, the legally authorized representatives of the patients gave written informed 
consent. 
  Specialized registered nurses from departments of geriatric psychiatry or geriatrics 
carried out the assessments by interviewing the patients‘ primary professional carers. In 
addition, the study nurses always interviewed the same carer. Prior to the study they attended 
a 1-day training course in the use of the NPI-NH and the BARS. We organised this in order to 
increase the test-retest reliability. The Norwegian version of NPI-NH was tested for reliability 
and validity and found excellent 
227
. 
  Safety evaluations included recording adverse events, laboratory tests conducted at 
screening and in weeks 2 and 6, electrocardiography obtained at screening and in week 2, and 
measurements of blood pressure and pulse rates. Adverse events were coded with the use of a 
standard glossary related to body systems. A central laboratory conducted all of the laboratory 
tests; if some results were out of the normal range, a safety manager warned the investigators 
at the relevant study site by telephone. Concomitant medication and dose changes were 
recorded. 
5.5.2. Study of the factor analysis of BARS 
The data were collected during the period March-November 2000. Twelve research nurses 
were trained to use the interview questionnaires. They carried out a structured interview with 
the nursing-home member of staff who knew the patient best and the nurses in charge of the 
wards. The age and gender of each patient were recorded. In addition, the number of beds in 
the ward, the staff ratio (i.e. the number of patients per staff member on an ordinary morning 
shift), education level of the staff and whether the ward was organized as a RU or SCU, were 
recorded. To measure aggression and agitation the BARS was applied. It scores agitation on a 
7 point scale: 1=never; 2=once in two weeks; 3=two or more times in two weeks; 4=once a 
week; 5=two or more times a week; 6=once a day; 7=several times an hour. Carers, who 
knew the patients well, were interviewed and the symptoms were rated as they occurred over 
the preceding two weeks. The original American version consists of ten symptoms (hitting, 
grabbing, pushing, pacing/aimless wandering, repetitious mannerisms, restlessness, 
screaming, repetitive sentences or questions, making strange noises, complaining) and the 
total score ranges from 10 to 70. In the Norwegian version of BARS, the item ―screaming‖ 
differed from the English version, and was rejected in the analysis. Therefore, we performed 
the analysis of BARS with the remaining nine items. In addition, the patients‘ level of 
functioning in the activities of daily living (ADL) were classified with the Physical Self-
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Maintenance Scale (PSMS) 
710
. The PSMS sum score ranges from 6 to 30; a higher score 
indicates poorer ADL functioning. The severity of dementia symptoms was categorised by 
means of the Clinical Dementia Rating Scale (CDR) 
711
. The overall score ranges from zero to 
three; a higher score indicates poorer mental functioning. 
 
5.5.3. Study of the reliability and validity of the Norwegian version of the Brief 
Agitation Rating Scale (BARS) in dementia 
5.5.3.1. Reliability study 
The respondents were the nursing-home staff (registered nurses and nursing assistants) who 
knew the patients well. Staff members were interviewed twice by a psychiatrist (OS) about 
each patient, using the BARS, with an interval of seven days and preferably with the same 
respondent for each patient on both occasions. In the second interview, he did not have access 
to the results of the first interview. Demographic characteristics and ward characteristics were 
collected.  
  In addition, patients were tested with the Mini Mental State Examination (MMSE) 
709
, 
examining cognitive abilities of patients in different areas (range 0-30), and the Clinical 
Dementia Rating Scale (CDR) 
711
, an observational scale that measures the degrees of 
dementia (categories: no dementia – 0 and 0.5; dementia – 1, 2 and 3, where 3 indicates 
severe dementia).  
5.5.3.2. Validation study 
For the validity study, we used the BARS results from the first interview for those who 
participated in both studies. In addition, we collected the biographical data and applied the 
following measures: the CDR, the MMSE, the Cornell Scale for Depression in Dementia 
(CSDD) 
238
, an observational scale measuring depression in dementia (range 0-38) and the 
NPI-NH, an observational scale evaluating 12 psychological and behavioural symptoms in 
dementia (the total score ranging from 0 to 144; and the product score of frequency and 
intensity ranging from 0 to 12 per item). It has an item called agitation/aggression (NPI-
NH/AA) that was used for our analyses. 
5.5.4. Study of the reliability and validity of the Norwegian version of the 
Neuropsychiatric Inventory, Nursing-home Version (NPI-NH)  
All of the patients were assessed by a geriatric psychiatrist (GS) or a medical doctor 
specializing in geriatric psychiatry (OS). Patients went through a physical examination and 
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data from their medical records were collected. The Mini Mental State Examination (MMSE) 
was completed. On the basis of these findings and an interview with a carer, the BEHAVE-
AD was completed. A diagnosis of dementia and the type of dementia, as well as a diagnosis 
of major depression, were established according to DSM-IV criteria. Seventy-eight per cent 
suffered from dementia. Of the patients with dementia, 61.5 per cent had Alzheimer‘s disease, 
28.2 per cent had vascular dementia and 10.3 per cent had other types of dementia. The 
MMSE scores ranged from 0 to 28, the mean was 14.3 (SD 9.1). 
A research nurse, who was blind to the results of the physical examination, interviewed 
the patient‘s professional carer, the registered nurse who was most knowledgeable about the 
patient, using the NPI-NH scale and the Cornell scale 
238
. The research nurse and the 
psychiatrist did not use the same nurse as an informant. The research nurse attended, prior to 
the interviews, a two-day course on the use of the NPI. 
5.6. Ethical and legal considerations 
5.6.1. Main study 
We distributed three different information letters, one for patients with full mental capacity, 
one for patients with reduced capacity, and one for the next of kin. Only one patient had the 
capacity to give consent. Therefore, the next of kin of all the other patients were informed 
about the study and all the possible risks and disadvantages, like side effects of the drug and 
that there were restrictions for using other drugs against agitation, and how we planned to 
make the study as safe as possible. The next of kin had the authority to reject the inclusion of 
the patient in the trial and also to decide to interrupt his/her participation in the study after it 
had begun.  
  Safety evaluations included recording adverse events, laboratory tests conducted at 
screening and in weeks 2 and 6, electrocardiography obtained at screening and in week 2, and 
measurements of blood pressure and pulse rates. Adverse events were coded with the use of a 
standard glossary related to body systems. A central laboratory conducted all of the laboratory 
tests; if some results were out of the normal range, a safety manager warned the investigators 
at the relevant study site by telephone. For security reasons and to track adverse events, 
patients were followed up for an additional 4 weeks after the trial medication had been 
discontinued. 
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  The study was approved by the Norwegian state authorities in charge of regulating 
research and the Regional Ethics Committee. The capacity of the patients was evaluated and 
consents signed. 
5.6.2. Study of the factor analysis of BARS 
Information on the patients was identified by the year of birth, gender, type of ward and type 
of nursing-home. No patients or family members were asked any questions or otherwise 
involved in the study. Identification of the carers, who were interviewed, was not recorded. 
The Regional Ethics Committee for Medical Research accepted the study design; the Data 
Inspectorate and the Directorate for Health and Social Affairs approved the procedure. 
5.6.3. Study of the reliability and validity of the Norwegian version of the Brief 
Agitation Rating Scale (BARS) in dementia 
The Regional Ethics Committee for Medical Research in Eastern Norway accepted the study 
design and approved the study. The Data Inspectorate and the Directorate for Health and 
Social Affairs approved the procedure. All participants, or their next-of-kin, got verbal and 
written information about the study and signed a consent form.  
5.6.4. Study of the reliability and validity of the Norwegian version of the 
Neuropsychiatric Inventory, Nursing-home Version (NPI-NH)  
Information about the reliability study was given in advance to the patients and their family 
members. Explicit consent was not required for enrolment but the patients or their next of kin 
were informed that they could refuse to participate at any stage in the study. In the validity 
study written consent was obtained from those of the patients who were able to consent. In the 
other cases, family carers confirmed that they did not object to the patient participating in the 
study. This procedure was approved by the Regional Ethics Committee, the Data Inspectorate 
and the Directorate for Health and Social Affairs. 
5.7. Statistical methods 
5.7.1 Main study 
The sample size necessary to demonstrate a statistically significant difference between the 
two treatments was determined prior to beginning the study. The standard deviation of the 
sub-scale for aggression and agitation in NPI-NH was estimated to be 1.8. Based on a two-
sided t-test with an assumed difference between the two treatments of 1.2 on the aggression 
and agitation sub-scale in NPI-NH (for the active drug an estimated reduction of 30% and for 
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the placebo an estimated reduction of 15%), a total of 78 randomised patients would be 
needed to detect this difference with 80% power. Adjusting for possible dropouts, we decided 
to enrol 100 patients in the study. All the patients who received at least one dose of the study 
medication were included in the primary and safety population and they made up the 
intention-to-treat population. Patients who dropped out were regarded as lost to follow-up, but 
the information on them that had already been collected was used in the analysis. A last-
observation-carried-forward approach was used for the imputation of missing values. Data 
were described by the mean and standard deviation; for variables that were not normally 
distributed, we used the median and the range. 
  The differences between the treatment groups for primary and secondary variables 
were analysed by a repeated measures model with an autoregressive covariance structure, 
including the baseline value as a covariate in the model. The normal distribution assumption 
was assessed using QQ-plots and histograms of residuals. Statistical analyses were performed 
with SAS software, version 9.1.3 (SAS Institute, Cary, NC). An alternative analysis was 
performed, where the data were treated as categorical and non-parametric methods were used. 
However, the results were very similar to the results achieved when using the more ‗classical 
approach‘.  
 
Table 5.7.1.  Materials of the four studies 
Materials Study I 
OXC   -   Plac. 
Study II 
RU  -  SCU 
Study III 
Reliab  - Valid 
Study IV 
Reliab - Valid 
Number of 
participants 
103 1870 138 91 
52 51 1353 517 56 138 41 50 
Women (%) 67.3 74.5 67.9 74.6 67.9 65.9 71 64 
Age in years  83 84 84 83 86 85 84 84 
 
Table 5.7.2.  Scales and statistics of the four studies 
Study I 
OBAD 
Study II 
BARS Factor anal. 
Study III 
BARS Reliab - Valid 
Study IV 
NPI Reliab - Valid 
NPI-NH, MMSE, 
BARS 
BARS, CDR, 
CCSD, NPI-NH 
BARS, CDR,MMSE 
CCSD, NPI-NH 
NPI-NH, CDR, 
MMSE, CCSD, 
BEHAVE-AD 
Repeated measures 
model, 
Two-sided t-test 
Cronbach‘s α, 
Principal component 
analysis (Varimax), 
linear & multiple 
regression 
Cronbach‘s α, 
Spearman‘s ρ,  
partial correlation 
Cronbach‘s α, 
Spearman‘s ρ, 
κ -statistic, 
 
147 
 
5.7.2. Study of the factor analysis of the BARS 
All statistical analyses were performed using SPSS version 15.0. First, the distribution of the 
continuous variables was examined. Second, we conducted preliminary analyses to examine 
whether any explanatory variable correlated with other variables, causing multicollinearity. 
These examinations proved that there was no need to exclude any variables from the analyses 
and that the data set was a reliable basis for performing factor analyses (multicollinearity 
0.119; Kaiser-Meyer-Olkin 0.74 and Bartlett‘s Test of Sphericity < 0.001). Third, we 
performed an exploratory factor analysis by applying a principal component analysis (PCA) 
using an orthogonal rotation procedure (Varimax). The number of factors to extract was 
determined using the eigenvalue ≥1.0 criterion and by examining the ‗scree plot‘. Factor 
loadings > 0.40 were considered statistically significant, which left us with three factors.  
Cronbach‘s alpha was calculated to measure the internal consistency of the factors. To 
validate the factors, we constructed three sub-scales by adding the items in each factor. 
Because of skewness, we calculated the logarithms of the three scores before we used them as 
dependent variables in three linear regression analyses.  
5.7.3. Study of the reliability and validity of the Norwegian version of the Brief 
Agitation Rating Scale (BARS) in dementia 
All the statistical analyses were performed using SPSS version 15.0. To test the internal 
consistency of the BARS and the two sub-scales, we used Cronbach‘s alpha coefficient. The 
test-retest reliability was examined by measuring the Spearman‘s rank correlation coefficient 
rho because the data were not normally distributed. 
  In the validation study, we examined the correlations between both the BARS total 
sum and the single BARS items with the NPI-NH/AA and the CSDD sub-scale Agitation 
(CSDD/A). None of the variables were normally distributed. Therefore, we applied a non-
parametric statistic using Spearman‘s correlation coefficient as a test for the concurrent 
validity. In a further analysis, we performed a first-order partial correlation analysis and 
looked at the difference in the correlations between the two test variables, controlling for the 
stage of dementia as a third modifying variable, to get a more accurate picture of what is 
happening. In this analysis, we controlled for the different stages of CDR, collapsing together 
the patients scoring 0, 0.5 and 1 into one group (<2), since the size of the groups would 
otherwise have been too small to conduct a valid statistical test.   
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5.7.4. Study of the reliability and validity of the Norwegian version of the 
Neuropsychiatric Inventory, Nursing-home Version (NPI-NH)  
The data were analysed using a SPSS (Statistical Program for Social Science) package 
version 14.01. We used Cronbach‘s alpha coefficient as an indicator of the internal 
consistency of the scale. The inter-rater reliability was established with kappa (κ) statistics. In 
order to use ordinary κ-statistics we combined NPI frequency scores 1 and 2 into one 
category. Thus, we had symmetrical 4x4 tables for both frequency and severity. The 
concurrent validity was analysed by calculating the Spearman correlation coefficients of the 
NPI sub-scales and the corresponding BEHAVE-AD sub-scales.  
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6. Abstracts of the papers included in the thesis  
 
Paper I. Effect of Oxcarbazepine in the Treatment of Agitation and  
    Aggression in Severe Dementia 
 
 
Background/Aims:  
To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression 
in patients with Alzheimer‘s disease, vascular dementia or both. 
 
Methods:  
This is an eight-week, multicenter, randomised, double-blind, placebo-controlled trial carried 
out independently of the pharmaceutical industry. Changes in the agitation and aggression 
sub-score of the Neuropsychiatric Inventory (NPI) were the primary outcomes. The secondary 
outcomes were the changes in the caregivers‘ total burden scores (measured by the NPI) and 
change in the Brief Agitation Rating Scale (BARS). 
 
Results:  
In total, 103 institutionalized patients residing at 35 different sites were randomised to the 
trial. After eight weeks, no statistically significant differences were found between the two 
groups for all outcomes. A trend was observed in favour of the OXC group in the reduction of 
the scores on the BARS (p = 0.07). 
 
Conclusion:  
This study found no significant effect of OXC in treatment of agitation and aggression in 
patients with dementia.  
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Paper II.  Factor Analysis of the Brief Agitation Rating Scale (BARS) in    
      a Large Sample of Norwegian Nursing-Home Patients 
 
 
Background:  
Agitation and aggression are prevalent in dementia and put heavy strains on caregivers. 
Validated assessment tools measuring these symptoms are required to evaluate patients before 
therapy and during the follow-up period. Given the daily routine in nursing-homes, 
abbreviated instruments are preferable. The Brief Agitation Rating Scale (BARS) is a short 
form of the Cohen-Mansfield Agitation Inventory (CMAI). Our aim was to examine the 
Norwegian version of the BARS by performing a factor analysis. 
 
Methods: 
The data came from 1,870 nursing-home patients. The primary caregivers were interviewed 
by research nurses using the Clinical Dementia Rating Scale (CDR), Lawton‘s Physical Self- 
Maintenance Scale (PSMS) and the BARS. 
 
Results: 
The exploratory factor analysis of the BARS revealed three dimensions: physically aggressive 
behaviour, physically non-aggressive behaviour and verbal agitation. Linear regression 
analysis showed that reduced functioning in activities of daily living (ADL) was associated 
with physically aggressive behaviour and verbal agitation, whereas increased severity of 
dementia and better ADL functioning were related to physically non-aggressive behaviour. In 
addition, verbal agitation was positively related to a higher number of drugs being taken per 
day.  
 
Conclusions:       
The factor analyses confirmed that the Norwegian version of the BARS measures the 
clinically relevant dimensions of agitation in dementia.  
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Paper III. Reliability and Validity of the Norwegian Version of the  
      Brief Agitation Rating Scale in Dementia  
 
Objective:  
To examine the test-retest reliability and validity of the Norwegian Brief Agitation Rating 
Scale (BARS), a short form of the Cohen-Mansfield Agitation Inventory (CMAI), assessing 
the frequency of agitation in dementia. 
 
Methods:  
We investigated the internal consistency, the test-retest reliability and the validity of the 
BARS. In the validity study, we compared the BARS scores with the Neuropsychiatric 
Inventory – Nursing-Home Version sub-scale Agitation/Aggression (NPI-NH/AA) and the 
Cornell Scale for Depression in Dementia sub-scale Agitation (CSDD/A). 
 
Results:  
In the reliability study, Cronbach‘s alpha was 0.76; the test-retest reliability of the BARS 
showed a Spearman‘s rho of 0.64, but this increased to 0.86 when we deleted the item 
‗complaining‘. In the validation study the BARS score correlated with the NPI-NH/AA and 
the CSDD/A scores, Spearman‘s rho was 0.55 and 0.52 respectively. These correlations 
changed when controlling for the Clinical Dementia Rating Scale (CDR) stages. The highest 
correlations between the BARS and the NPI-NH/AA and the BARS and the CSDD/A were 
found among patients with CDR score 2. 
 
Conclusions:  
The study indicates that the Norwegian version of BARS is a reliable and valid instrument to 
test agitation in dementia, but a version without the item ‗complaining‘ would be better. 
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Paper IV. The Reliability and Validity of the Norwegian Version of the  
      Neuropsychiatric Inventory, Nursing-Home Version (NPI-NH)  
 
 
Background:  
Psychiatric symptoms and behavioural disturbances are highly prevalent in the residents of 
nursing homes. The Neuropsychiatric Inventory (NPI) is a commonly used scale for the 
assessment of such symptoms in diverse settings. We have conducted a study of the reliability 
and the validity of the Norwegian version of the NPI nursing-home version (NPI-NH). 
Methods:  
The reliability study comprised 41 patients. We established inter-rater reliability between 
raters with various levels of health education using kappa (κ) statistics. Fifty patients were 
included in the validity study. The patients were examined by a physician, who also rated the 
patient‘s behaviour using ―behavioural pathology in Alzheimer‘s disease‖ (BEHAVE-AD). 
Subsequently, a research nurse performed a standardized interview using the NPI and the 
Cornell scale. Concurrent validity of the NPI and the BEHAVE-AD were analyzed. 
Results:  
Internal consistency, as measured by Cronbach's α, was above 0.8. Inter-rater reliability was, 
except for one item, between 0.85 and 1.0 across assessors with different levels of health 
education. All correlations between the NPI and the BEHAVE-AD were significant, ranging 
from 0.38 to 0.72. The weakest correlations were between items assessing affective and 
anxiety symptoms. 
Conclusion:  
The Norwegian version of the NPI-NH is a reliable and valid instrument for assessing 
psychiatric symptoms and behavioural disturbances in the residents of nursing homes. The 
investigation of depressive symptoms merits particular attention. 
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7. Discussion of the main results 
7.1. Main study 
7.1.1. OBAD study 
This randomised, placebo-controlled trial examined the effect of OXC in the treatment of 
agitation and aggression in patients with dementia. This study was neither designed nor 
financed by the pharmaceutical industry. Mood stabilizers as valproate and carbamazepine 
have been investigated in four and two RCTs respectively. Only one study with 
carbamazepine showed a statistically significant effect. Our data failed to prove that OXC is 
efficacious in treating aggression and agitation in patients with dementia. We observed a 
trend, however, that patients randomly assigned to OXC performed better than those assigned 
to the placebo (p = 0.07), as measured by the BARS.  
  Poor statistical power may be one reason why we could not prove that OXC was 
efficacious. Our power calculation, done prior to the study, was based on a much larger 
estimated difference between the groups and a lower placebo effect. The placebo group 
showed a 36.3% reduction in agitation and aggression score on the NPI-NH compared to 
39.0% in the OXC group, but our estimates were 15% and 30% respectively for the two 
groups. In order to detect a significant effect with such a small difference, the study would 
have required the enrolment of 232 patients. Other short-term studies in similar populations 
have reported high placebo response rates, ranging from 21% to 58% 
36 37 40
. A high placebo 
effect may be caused by the disease‘s fluctuating course or by the Hawthorne effect 712, that 
is, people being observed in a research context tend to behave in a different way than they 
otherwise would 
713
. Indirectly, a high placebo effect may also indicate that approaches other 
than psychotropic drugs can improve behaviour in patients with dementia in nursing-homes. 
The choice of the patient population could also influence the placebo effect. In our study the 
patients had high scores for symptoms such as agitation and aggression at baseline, thus 
increasing the probability of a lower score later (i.e., the regression toward the mean 
phenomenon) 
714
. 
  Another aspect that ought to be considered is the sensitivity of the outcome measures. 
Items 1 to 4 of the agitation and aggression sub-scale of NPI-NH are directed to a passive 
form of aggression, whereas items 5 to 8 address active aggression, including an impulsive 
type of behaviour. The form of aggression that causes the most stress for nursing-home staff 
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and other patients is the striking out, impulsive, uncontrolled form of aggression. This type of 
aggression is often the reason why psychotropic drugs are prescribed. This may be why we 
found a nearly statistically significant improvement in favour of the OXC group compared 
with the placebo group using the BARS as a measure of efficacy. We speculate that the 
treatment with OXC could be effective in dementia patients with uncontrolled and impulsive 
aggression. Although BARS seems to capture uncontrolled aggression better than NPI-NH, 
there is still a need for a more specific instrument that can measure the kind of aggressive 
behaviour that we are most interested in: the impulsive, unexpected, physical form of 
aggression directed toward carers and the other patients in nursing-home wards. In post hoc 
sub-analyses we found that a high level of aggression (NPI-NH agitation/aggression score 9 
or 12) showed a tendency to a better response to the active drug after four weeks (p=0.095), 
but not after eight weeks (p=0.30).  
  Despite the potential variability that might have been caused by our use of many sites, 
we do not believe that there are large differences between the various nursing homes in 
Norway. Extensive care was taken to select study nurses and give them special training so that 
the inter-rater variability was kept to a minimum. The adverse event profile of OXC in older 
patients is similar to that in younger patients. No special age-related adverse events have been 
observed. Safety data from more than 6,600 patients with epilepsy in the files of the producer 
of OXC, including elderly patients, support the safe use of OXC. Friis et al. 
715
 published 
safety data on 947 patients taking OXC. However, clinical practice and a vast majority of 
clinical studies show that patients with dementia respond differently from the healthy elderly 
to psychotropic drugs, those with dementia being more sensitive to side-effects. In our trial 
the profile of adverse events shows that OXC led to sedation in 25% of the patients, a side-
effect that must be considered as a particular disadvantage for physically and mentally ill 
patients. Consequently, there was a stronger tendency toward ataxia and falls among this 
group. In sum, our study results, these side-effects and serious concerns lead to the conclusion 
that the prescription of OXC could not be recommended in this population. 
  There is a great need for further research to enhance our understanding of the 
neurobiological changes in agitation and aggression in dementia, which might lead to more 
adequate drug therapy, if that is the best treatment strategy. The present study and other drug 
studies have shown that the placebo response in patients with dementia is high, which 
highlights the importance of psychosocial, environmental, and educational strategies in 
treating behavioural and psychological symptoms of dementia. 
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7.1.2. Placebo effect in studies of dementia 
While neurotransmitter changes have been shown to affect behaviour and they provide 
support for a biological theory of agitation in dementia, pharmacological treatment for 
dementia and for agitation have had only limited effectiveness. This may be the result of the 
limited types of pharmacological agents available, and/or that other factors in addition to 
neuropathological changes are responsible for agitated behaviour in dementia. All the trials 
investigating the effect of drugs showed a quite clear placebo effect. Target symptoms 
improve in trials with psychotropics, to varying degrees, in approximately a third of patients 
given a placebo 
716
. Side effects also occur; the so-called nocebo effect. Although 
pharmacologically inert, a placebo can cause direct physiological effects, at least in the short 
term, that are consistent with the effects of active drugs; this has been demonstrated in 
neuroimaging studies 
717 718
. The activation of pain-suppressive, endogenous opioid 
neurotransmission after administration of a placebo with the expectation of analgesia has been 
directly demonstrated in recent work with humans using molecular imaging techniques 
719
. 
These initial data suggest that in the case of endogenous opioid mediated placebo analgesic 
responses, the individual experience of pain, in particular its affective elements, the internal 
affective state of the individuals during pain and a measure of sustained pain sensitivity are 
important factors contributing to the formation of a placebo effect.  
  Many of the placebo-effect papers have investigated the placebo effect in depression, 
which is quite high, but the same principles apply to the treatment of other disorders. 
  In the OBAD study, only one out of 103 participants had the mental capacity to give 
consent. The mean MMSE score was 5.4 (95% CI 5.4) and 6.2 (95% CI 5.7) in the placebo 
and OXC group, respectively, indicating that the participants were suffering from a severe 
stage of dementia. It is reasonable to conclude that the majority of the patients did not know 
that they were part of a study. Therefore, the explanation that the placebo effect is caused by 
the patient‘s belief in the positive outcome of the intervention could not be applied to our 
study. However, the conviction of the carers and relatives that the intervention could be 
effective, the excitement of the staff taking part in a trial, the more intense observation of and 
focus on the patient, all these may be pieces in the puzzle of the placebo effect. In addition, 
there are other well-known facts that may explain the placebo response, like the Hawthorne 
effect, the participants and staff getting more attention, that the use of an assessment scale is a 
kind of educational intervention, and that the staff got additional training by being 
interviewed and realised that the different kinds of behaviour were part of the disease. As 
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consequence, they may have developed more tolerance, which may have resulted in lower 
scores. The CRAs in our study also often discussed other patients with the staff, a fact that 
may have contributed to debriefing the staff and a form of supervision with a positive 
influence on the environment in the ward from which, consequently, patients may have 
profited. A further fact is the fluctuating nature of agitation. A certain percentage of the 
placebo effect may be explained by the spontaneous resolution of agitation. It is difficult to 
separate the placebo effect from spontaneous remission. The higher the spontaneous 
remission rate, the more difficult it is to calculate the study power to show treatment effects 
720
. 
  Patients in our study were bound to have high scores in agitation/aggression. 
Symptoms are likely to improve in the majority, irrespective of the intervention. This is the 
so-called ‗regression to the mean‘ phenomenon 721. 
More generally, twenty years ago, the placebo effect in studies with 
psychopharmacological drugs was not as high as it is now 
722
. We believe that the ethical 
regulations and the legal position have contributed to patients, carers and next of kin being 
better informed. This fact may contribute to a higher expectation of an effect. A further 
explanation may be the increasing recruitment of mildly ill patients into trials because of 
clinicians‘ reluctance to risk randomising severely ill patients into the placebo-receiving 
group. This reason may not apply to our study. 
  Not all placebos are the same. Patients perceive two brightly coloured tablets to be 
more effective than one small white one. Capsules, injections and branding also increase 
expectations of efficacy 
716
. This may partly explain different placebo response rates in 
studies with a similar design. In our study the tablets were not brightly coloured; they were a 
light brown colour. 
  Placebo responses may be short-lived. Studies are usually too short to pick up placebo 
relapsers 
723
. Our study could show that the placebo response rate was deteriorating during the 
four week follow-up period. 
  The placebo response increases according to expectancy. That can be demonstrated 
because the placebo effect is greater in studies randomising 2:1 active:placebo than in those 
randomising 1:1; the chance of receiving the active drug, and thereby the expectation, is 
greater in the 2:1 administration.   
  Also other effects may operate: a ‗wish bias‘ probably exaggerates the efficacy of new 
drugs compared with established agents 
724
. 
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  Rothwell and Robertson 
725
 studied 26 meta-analyses of 241 trials and found that when 
the trials within each meta-analysis were ordered according to year of publication; there was a 
significant variation in the proportion of trials in which the treatment was better than the 
control, with a significant excess of positive outcomes in the earlier trials and often a lower 
percentage of placebo effect. This variation is independent of trial size. Therefore, it is 
reasonable to assume that the trials conducted by Tariot in 1997 with carbamazepine showed 
a better effect than our study did years later. Early trials overestimated the treatment effect in 
comparison with subsequent trials in 20 out of 26 meta-analyses studied. One explanation for 
this phenomenon may be the publication bias: If an initial trial is positive, it is likely to be 
published – and sooner – than if it is negative. However, once a treatment is considered to be 
effective and established, a negative trial becomes interesting. Thus meta-analyses done early 
in the evolution of published trials overestimate a positive treatment effect. Another reason 
for this observation may be that earlier trials had fewer legal or ethical constraints – especially 
because the participants were given less information and the rules for Good Clinical Practice 
(GCP) and monitoring were not so well established. It is much more time-consuming to 
conduct a study nowadays than it was ten to twenty years ago. This means, in practice, that 
the staff involved have to spend more time filling in reports and are, therefore, more 
observant and are spending more time with the participants nowadays.   
  Brunoni 
726
 performed a meta-analysis of the placebo response of non-
pharmacological and pharmacological trials concerning major depression (MDD). Forty-one 
studies met the inclusion criteria - 29 in the repetitive transcranial magnetic stimulation 
(rTMS) group and 12 in the escitalopram group. They extracted the mean and standard 
deviations of the depression scores in the placebo group of each study. Then, they calculated 
the pooled effect size for the escitalopram and rTMS groups separately, using Cohen's d as the 
measure of effect size. They found that placebo responses are large for both escitalopram 
(Cohen's d: 1.48; 95%C.I. 1.26 to 1.6) and rTMS studies (0.82; 95%C.I. 0.63 to 1). Thereby, 
they confirmed that the placebo response in MDD is large regardless of the intervention and 
they speculated that the placebo response is associated with the resistance of depression to 
treatment and treatment combinations (add-on rTMS studies). They concluded that the 
magnitude of the placebo response seems to be related to the study population and study 
design rather than the intervention itself. 
  Schneider and Sano 
727
 studied the effect of drugs developed for AD compared to a 
placebo. They concluded that increasing variability and relatively little change overall in the 
ADAS-cog placebo groups, eg, about 25% of patients do not worsen by more than 1 point, 
158 
 
might make it more unlikely than previously assumed that a modestly effective drug can be 
reliably recognized, especially when the drug might work only to attenuate decline in function 
and not to improve function. These observations would be strengthened by pooling data from 
individual trials, and pharmaceutical sponsors should participate in such efforts. 
  Tyrer et al. 
532
 studied the effects and cost-effectiveness of haloperidol, risperidone 
and a placebo on aggressive challenging behaviour in adults with intellectual disabilities 
(NACHBID). There is no evidence from this trial that either risperidone or haloperidol, given 
in conventionally low doses, offer any advantages over a placebo, on the contrary, over 4 
weeks the placebo was found to be more effective in reducing aggression. Placebo treatment 
was also cheaper in terms of total cost than the other two treatments over a 6-month period.  
 In summary, the large placebo effect in our study may well be more a treatment effect 
of the unintended psychosocial activities and more thorough physical and psychological 
examination of patients using instruments like the NPI and the BARS; thereby, they got more 
quantitative and qualitative attention from the carers, and that is known to have a positive 
therapeutic influence on problem behaviour. 
7.1.3. What can be done to prevent high placebo effects? 
Shah et al. 
360
 recommended a "run in" period of at least 4 weeks in intervention studies using 
the SOAS to reduce contamination by spontaneous decline. The total number of aggressive 
incidents on the SOAS, the SOAS total score, spontaneously declined after week four and 
became established by week five. Thereby, a more normalised experience of being part of a 
trial may be reached and the Hawthorne effect of getting involved into a trial may be reduced 
and, consequently, the placebo effect will be less prominent. 
  The properties of the measurements should be considered more thoroughly. Treating 
the patients‘ ‗agitation‘ as the endpoint is too unspecific as an aim. The symptoms of agitation 
one wants to treat should be defined and the scale that is appropriate to inform about the 
change over time should be carefully chosen. As our studies show, it looks as though the 
BARS is more sensitive to change than the NPI. In addition, it may be of interest to use the 
factors of BARS as specific goals of interest.  
7.2. BARS factor analysis 
This study is, to our knowledge, the largest factor analytic study of a scale measuring 
agitation in an unselected nursing-home population. Our sample represents 4.4% of the 
Norwegian nursing-home population (N=42,236 in the year 2000) (Statistics Norway: 
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http://www.ssb.no/pleie/tab-2009-07-02-02.html) and had the same demographic 
characteristics as described in a large epidemiological survey including all Norwegian 
nursing-homes in 1999 
728
. These statistics demonstrate that our study sample is 
representative of the nursing-home population in Norway.  
  We could replicate the findings of Finkel et al. 
230
, who published a factor analysis of 
the BARS. Shah et al.‘s  362 study provided evidence of the concurrent validity of the BARS, 
the CMAI and the RAGE. Because it is the shortest one, the BARS was recommended by 
Shah et al. as the easiest to incorporate into nursing care plans both in psychogeriatric wards 
and in nursing-homes. Finkel et al. edited the BARS to represent the three factors that Cohen-
Mansfield et al. found, using the items that were most frequent. Therefore, Finkel et al.‘s 
factor analysis of the BARS conformed to the previous factor analyses of the CMAI 
24 320
, 
which produced the following components: physically aggressive behaviour, physically non-
aggressive behaviour and verbally agitated behaviour. The same factors were found in later 
studies 
19 334 339 340 342 343 345
. The Norwegian version of the nine items of the BARS represents 
the same factors and is therefore congruent with the original ten items of the BARS and the 
29 items of the CMAI. The third factor, verbal agitation, was not represented as clearly as in 
the analyses of the original English version of the BARS and the CMAI. It could be argued 
that it may be caused by the rejection of the item ‗screaming‘ in the Norwegian version. 
Nonetheless, three out of the nine items of the Norwegian version of the BARS represent 
verbal expressions (repetitive sentences and questions, making strange noises and 
complaining). Screaming did not contribute essentially to the factors of the CMAI found in 
various studies using a factor analysis of the CMAI 
19 24 334 339 343
. Additionally, Rabinowitz 
reports that in six studies performing a factor analysis on the CMAI only three showed a 
loading of ‗screaming‘ as ≥0.40. In Rabinowitz et al.‘s study comparing three study samples 
233 525 533, ‗screaming‘ loaded to different factors. Therefore, it may be legitimate to omit 
screaming from a further reduced version of the BARS. 
  The three multiple linear regression analyses showed a different pattern for the three 
factors of the BARS. The degree of cognitive impairment as measured by CDR was a 
significant explanatory variable only for physically non-aggressive behaviour. The total 
number of drugs per day was related to verbal agitation, but there was no association between 
psychotropic drugs and the factors we found, although we would have expected that side 
effects like akathisia or other extrapyramidal symptoms would contribute to some of the 
factors.  
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  We found an apparently contradictory association between level of functioning in the 
activities of daily living (ADL) and physically non-aggressive behaviour and between 
physically aggressive behaviour and ADL. It is reasonable to assume that patients who 
function better in the ADL have more symptoms related to physically non-aggressive 
behaviour than those who function less well in the ADL because Lawton and Brody‘s  ADL 
scale assesses walking abilities 
710
. Wandering, as an expression of physically non-aggressive 
behaviour, has often been observed in patients with dementia. Patients who function less well 
in the ADL are more aggressive than those who function better in the ADL. Perhaps 
physically aggressive behaviour is related to frustration resulting from being more dependent 
on others and the difficulty of communicating unmet needs 
729
.  
  The type of ward was significant both for physically aggressive behaviour and for 
physically non-aggressive behaviour, indicating that the selection of patients with dementia to 
SCU works. The regulations governing residence in a SCU for dementia in Norway require 
that patients can walk and take part in simple everyday activities, like setting a table. The staff 
ratio had no influence on any of the factors.  
 A weakness of our study is that our sample comprised the whole nursing-home 
population and not just patients with dementia. Some studies, performing a factor analysis of 
the CMAI, included only those patients with moderate to severe dementia 
19
 or patients with 
dementia exhibiting behavioural problems 
343
.  A further limitation of our study is that the 
results cannot be generalized, but are restricted to Norwegian nursing-home patients.  
  One strength is that we could replicate the same three factor solution which was found 
in the majority of previous factor analyses of the CMAI and the BARS in nursing-home 
samples. This may support the assumption that the factors ‗physically aggressive behaviour‘, 
‗physically non-aggressive behaviour‘ and ‗verbal agitation‘ are three separate phenomena.   
 
7.3. BARS reliability and validity study 
With a huge increase in the number of people with dementia and the challenge of how to deal 
with the related behavioural disturbances, caregivers require instruments that are reliable, 
easy and quick to apply, given the daily routine in nursing-homes with its many competing 
demands on staff time. The BARS has ten items, and is a short form of the CMAI with its 29 
items. It was designed to meet the requirements of a busy clinical setting. As the Norwegian 
version of the BARS was increasingly being applied in Norwegian nursing-homes, we saw 
that it was important to validate it. 
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We performed a literature search in PubMed (‗Brief AND Agitation AND Rating‘ in 
the Title field) to find studies investigating the reliability and validity of the BARS, resulting 
in the articles by Finkel et al. 
230
 conducting a factor analysis and by Shah et al. 
362
 comparing 
the CMAI, the RAGE and the BARS with each other. 
7.3.1. Reliability 
The test-retest reliability, expressed by Spearman‘s correlation coefficients, was good, taking 
into consideration that agitation is, along with depression and delusions, one of those 
behaviour symptoms in dementia that resolves over a one-year period in nearly 50 per cent of 
patients 
261
 and shows considerable short-term fluctuation.  
Cronbach‘s alpha showed good internal consistency for the BARS total sum, 
especially when ‗complaining‘ was omitted. The item ‗complaining‘ was a symptom that 
lowered the internal consistency of the scale, implying that the psychometric properties of the 
scale would have been better without this item. As ‗complaining‘ also results in lower test-
retest reliability, we suggest that this item should be omitted from the Norwegian version of 
the BARS. 
In their sample, Finkel et al. did not find that the item ‗complaining‘ created reliability 
problems. This may be a reflection of cultural differences between the American and 
Norwegian ways of reacting to discomfort. Complaining may be less prominent in a health 
system like Norway‘s, where the social welfare system is quite good and, i.e., the stay in a 
nursing home is affordable for everyone. Furthermore, Finkel et al. recruited their patients 
from a skilled nursing, long-term care facility for the Jewish elderly with possible differences 
in staff density and care settings. The residents‘ religion, forming behavioural patterns 
throughout their lifetime, might create other ways of expressing agitation in dementia. Some 
studies indicate that pre-morbid personality traits do cause differences in behaviour in persons 
with dementia 
730 731
, i.e. that pre-morbid agreeable behaviour was negatively correlated with 
agitation and irritability. Another possible explanation for the discrepancy between the results 
may be that Finkel‘s research was conducted 15 years ago. The agitation observed in a new 
generation of elderly patients may present itself by a different symptom spectrum, but that has 
yet to be proven by further research.   
7.3.2. Validity  
Agitation is a poorly defined fragment in the mosaic of neuropsychiatric symptoms and 
syndromes in dementia, although many have investigated and tried to define it. Therefore, we 
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find quite a number of different scales and are confronted with the fact that many studies are 
difficult to compare because the results are dependent on which scale has been used. As an 
example, in a study of treating patients with oxcarbazepine against agitation and aggression in 
dementia, Sommer et al. 
210
 found an almost statistically significant outcome measured with 
the BARS, but no significance at all with the agitation/aggression sub-scale of the NPI (NPI-
NH/AA). In the present study, we have found that the BARS correlates better with the Cornell 
Scale for Depression in Dementia/Agitation (CSDD/A) than with the NPI-NH/AA, 
reinforcing the belief that agitation as measured by the BARS contains some other 
information than the NPI-NH/AA.  
This difference increased further when we deleted the item ‗complaining‘ from the 
BARS. The agitation questions in the CSDD address aspects of agitated behaviour related to 
restlessness, playing with one‘s hands or hair, hand-wringing, hair-pulling, and/or lip-biting, 
as such behaviour can be seen in depressed patients. The NPI-NH/AA contains different 
aspects of agitation and aggression such as getting upset, resisting bathing or changing 
clothes, wanting things their own way, being uncooperative, resisting help from others, 
slamming doors, kicking furniture and throwing things. These aspects are not found in the 
BARS or in CSDD/A. Therefore it may be possible that the concepts of agitation in the BARS 
and the CSDD/A are more congruent than that of the BARS and the NPI-NH/AA. It might 
also be that depression and agitation have a closer connection. Others have also come to 
similar conclusions: Ellis 
324
 found in a sample of 64 persons with dementia, residing in 
assisted living accommodation, that depression is one of the main co-morbid disorders related 
to agitation. Bartels et al. 
732
 found that dementia is often complicated by a mix of agitation 
and depression, and Cohen-Mansfield and other researchers 
286 322 733
 found that depression 
may play a role in verbally aggressive behaviour. One may argue that, in many cases, 
agitation is an expression of depression or that the same patho-physiological processes are 
causing similar and overlapping symptoms. Decreased levels of serotonin are related to 
depressive disorders and impulsive/aggressive behaviours 
734-737
.  
A limitation of our study is that the population in Norwegian nursing-homes may 
differ from those in other countries and, therefore, the generalizability of our results to other 
countries may be biased. The validation part of our investigation has a weakness because no 
scale has been established as a ―gold standard‖. We used the NPI-NH/AA and CSDD/A for 
our validation because both are parts of instruments widely used in clinical practice in 
nursing-homes and in research. Finally, we used an already existing and much-used 
translation, rather than creating a new one, applying strict research criteria. A further 
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limitation may be that we did not diagnose the patients‘ dementia according to ICD-10 or 
DSM-IV criteria, but used the CDR and the MMSE. However, studies have shown that the 
CDR is a valid instrument for evaluating the stages of dementia 
738
.   
7.4. NPI reliability and validity study 
 
The reliability and validity of the Norwegian version of the NPI-NH was tested in two 
unselected nursing-home populations. This is to our knowledge the first study of the 
reliability and validity of a Scandinavian version of the NPI. In this study the internal 
consistency was high even though the sample studied was more heterogeneous than the 
majority of earlier studies. The high internal consistency is concurrent with most previous 
studies. As could be expected, the two last items, night-time behaviour and eating behaviour, 
correlated least well with the total.  
  The inter-rater reliability was excellent for all items, apart from the severity score of 
the item ‗eating behaviour‘. One explanation could be that a registered nurse might see 
changes in eating behaviour in another context, and rate it more positively, than psychiatric 
health-workers would do. The high inter-rater reliability in our study indicates that the NPI is 
robust and can be used by assessors from different professions and with different levels of 
medical education. 
  The concurrent validity of most NPI items, when compared with the BEHAVE-AD, 
was satisfactory, though somewhat lower than in the initial study by Cummings 
706
. This 
might be due to the greater heterogeneity of our sample and the fact that we used professional 
carers and not family carers as informants.  
  The low correlation of depressive symptoms of the NPI with the BEHAVE-AD is 
consistent with previous studies. The BEHAVE-AD presents a relatively narrow concept of 
depression, taking only crying and a depressed mood into account, whereas the NPI has a 
broader approach to depressive symptoms. Furthermore, the correlation between items 
concerning depression in the BEHAVE-AD and the Cornell scale is low. However, the 
diagnosis of depression correlated poorly with all three scales. This result is a bit odd, bearing 
in mind that the diagnosis of depression and the rating of the BEHAVE-AD, as well as the 
Cornell scale and the NPI had been done by the same assessors. It might reflect the fact that 
depression in dementia is an elusive disorder that is poorly described by diagnostic criteria 
and current psychiatric rating scales.  
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  The possibility of generalising our results to more specific dementia populations is 
limited. However, we have demonstrated that the NPI can also be useful in unselected 
nursing-home populations. Reliable and valid instruments for research and clinical purposes 
in nursing-homes are sorely needed.  
7.5. Methodological issues 
One of the unsolved issues in the field of dementia research is the clear definition of agitation 
and aggression. That leads to the use of different scales and, thereby, to difficulties in 
comparing and interpreting the results. There is no generally agreed definition of aggressive 
behaviour. Many studies 
362 739-741
 have failed to define aggressive behaviour clearly. Varying 
definitions of aggressive behaviour have included verbal abuse or threatening behaviour 
742 
743
, excessive vocal activity 
744
, damage to property 
745 746
, physical attacks on people 
including other patients, staff and informal caregivers 
743 747
, sexually aggressive behaviour 
328 
742
 and self-harm 
746 748
. Differing combinations of these facets have been used in different 
studies. One of the most comprehensive definitions of aggressive behaviour in the elderly is 
that by Patel and Hope 
331: ―Aggressive behaviour is an overt act, involving the delivery of 
noxious stimuli to (but not necessarily aimed at) another organism, object or self, which 
clearly is not accidental.‖ Cohen-Mansfield produced the widely used, but still not 
unanimously accepted, definition of agitation in dementia: ‗Inappropriate verbal, vocal or 
motor activity that is not explained by needs or confusion per se‘. But, one may ask: 
Inappropriate for whom? In addition, this definition excludes need driven behaviour and, 
therefore, all the studies investigating agitation as an expression of the unmet needs of the 
disabiled or agitation as result of lack of proper verbal communication and interaction 
between caregiver and patient. Cohen-Mansfield‘s definition seems to be influenced by the 
important emphasis in her research on agitation resulting from unmet needs, but it seems to be 
too exclusive and confines the definition of agitation to the unexplainable cases alone. The 
lack of a precise definition and the complexity of the problem may lead to research 
difficulties in terms of defining research questions and relevant outcome measures. 
 In the main study there were considerable difficulties in recruiting patients because of 
ethical and consent doubts, but also because there was no established research network and no 
tradition of conducting drug trials in nursing-homes. Therefore, we had to recruit new 
research centres and nursing-homes during the ongoing trial. Our original plan to conduct the 
study in two enrolment periods in autumn 2005 and spring 2006 with an ongoing evaluation 
process of the progress and the safety of the participants had to be supplemented by a third 
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enrolment period in summer 2006. We have been confronted with the ‗law‘ attributed to 
Lasagna 
749
, according to which clinical experience shows there are more patients who could 
be recruited to a trial than are found during an ongoing trial.  
 Designing the OBAD study we tried to make it as comparable as possible with 
Tariot‘s study 36, which investigated carbamazepine‘s effect on agitation in dementia. At the 
same time, we applied different scales because we wanted to use NPI as this instrument was 
used in many drug trials in dementia. It would have been an advantage to use the CGI scale 
too. Tariot et al.‘s results showed an improvement in the Clinical Global Impression Scale 
(CGI) in 77% of the patients taking carbamazepine and 21% of those taking a placebo. That 
misled us into underestimating the placebo effect. We learned that the comparison of studies, 
and consequently the designing of a new study, has to take into consideration similar 
precautions as reviews or meta-analyses. Verstraete 
580
 published a paper that focused on 
these issues: Differences in patients‘ characteristics (selection bias), the care provided 
(performance bias), assessment of outcomes (detection bias) and exclusion of randomised 
patients (attrition bias). Turner et al. 
750
, in a widely discussed article in the New England 
Journal of Medicine, asked the question: ―How accurately does the published literature 
convey data on drug efficacy to the medical community?‖ The investigators compared data 
from 74 FDA-registered randomised controlled trials submitted for regulatory approval, with 
the published literature. They found evidence for the ―file drawer effect,‖ that is, publication 
bias in favour of positive studies.  Selective reporting 
751
 of scientific research, the ―adverse 
effects‖ of industry influence 752, and also other reasons for underreporting of trials is 
haunting the validity of reviews and meta-analyses: It appears that only about half of the 
abstracts presented at conferences are later published in full 
753
 (publication bias). Based on 
research proposals approved by the ethics committees of four leading medical schools, only 
49 to 67% are fully published in medical journals 
754 755
. Of trials funded by the National 
Institutes of Health, 20% are still unpublished several years after completion 
754
 
756
. This 
hidden information is unfortunately not a random process but mainly affects trials with 
negative results. In future investigations, we would take even more time to search the 
literature before designing a study. Anyway, one aspect of the publishing bias that may also in 
the future lead to similar problems in planning intervention trials is that it is not easy to get a 
negative study published, as we ourselves have experienced, because the journal editors have 
to look to the economic consequences and tend to publish papers that are likely to ―sell‖ best. 
 Suh 
578
 discussed some critical points related to RCTs in patients with dementia, 
mainly focusing on trials with antipsychotics:   
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―RCTs are considered the most reliable form of scientific evidence in healthcare 
because they eliminate spurious causality and bias. As the name suggests, RCTs 
involve the random allocation of different treatments to patients. This ensures that 
known and unknown confounding factors are evenly distributed between the groups. 
However, patients who are allocated to the active treatment group may be at higher 
risk of SAE than those allocated to the placebo group. This might be due to following 
reasons: 
(i) Contrary to steadily declining cognition and function in dementia patients, BPSD is 
not constantly presenting, but sometimes spontaneously goes into remission. BPSD 
often fluctuates and can have an episodic course. Most BPSD are expected to respond 
to antipsychotics within one or two weeks, and most symptoms go into remission 
soon. Then, in usual clinical practice, ideally clinicians maintain antipsychotics for a 
time-limited period and then taper and discontinue the medication. Medication is often 
used on an ―as needed‖ basis.  However, in RCTs, patients in the active treatment 
group continue to take antipsychotics to the end of the trial, most for 8 to 36 weeks, 
even though they do not need antipsychotics any longer because their symptoms are 
now very mild or in remission. This means that patients in the active treatment group 
are unnecessarily exposed to a higher risk of harm.    
(ii) The experimental condition itself may put patients on the active treatment at higher 
risk for harm. Once recruited for RCTs, every patient takes the trial medication as 
scheduled. To guarantee the safety of patients, protocols of RCTs of antipsychotics for 
BPSD did not exclude patients using drugs which had been regularly used to control 
stable general medical conditions (e.g. hypertension, diabetes) throughout the trial 
period. Older people are dangerously overmedicated in the real world, yet many 
frequently omit to take medications. However, in the experimental condition, they 
have to take medications without omission throughout the trial period. The 
compulsory continuous use of these different drugs in RCTs may increase the chance 
of drug-disease interactions or drug-drug interaction with the trial medication. In 
RCTs of antipsychotics for BPSD, by fixing the doses and requiring that patients be 
kept on medication throughout the trial, many patients are placed at increased risk for 
adverse events and do not have the potential to benefit from individualised dosing 
adjustments. By comparison, in usual clinical practice, medication might have been 
discontinued, decreased, increased or switched. Thus, the clinical trial may reflect both 
more AE and less efficacy than are actually experienced by patients in ‗real life‘.‖ 
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Therefore, we used a model with variable dosing of the trial medication and by that means 
tried to avoid exposing the patients to additional risk of adverse events (AEs) and to come 
closer to the every day clinical management of agitation. 
 Causes of BPSD in dementia patients are heterogeneous and complex to manage. This 
is something that those administering a drug trial do not usually take into consideration. 
Although we instructed all those who were involved in the recruitment of patients that 
psychosocial interventions had to be tried first and only when it had failed should the patient 
be considered as qualified for inclusion, we believe that this was not always done in the real 
world of screening for inclusion. 
Another problem we faced that posed methodological challenges was, how to react to 
AE. As mentioned, 25% of patients taking OXC experienced sedation. This may have led to 
more apathy, less food and fluid intake, resulting in dehydration and haemoconcentration. 
Herrmann  
563
 mentioned this problem as one of the causes of stroke in antipsychotic trials. 
Although we did not have any incidents of stroke in our trial, we may have exposed our 
patients to a higher risk. Sedation may also have caused a reduction in their quality of life 
(QoL). If we were to do a similar trial again, we would include a scale like CGI as a 
measurement that reflects the clinical state of the patient and a scale measuring QoL, e.g. 
QUALID, in addition to the registration of patients‘ fluid intake.  
After the intervention period of eight weeks in the OBAD trial, both curves, that 
representing the placebo and that for the OXC group respectively, showed a tendency for 
agitation to have increased. We wonder whether this reflects the decreasing influence of the 
Hawthorne effect on the trial, as it represents the decreasing interest of the staff involved in 
the care of the patients or the study nurses. It would be interesting to have a scale that 
measures not only the burden of the carers as the NPI does, but also the satisfaction of the 
carers with the response to the treatment. The OBAD study results showed an impressively 
high placebo effect, which made us curious about the reason for it. 
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8. Future directions for research 
All Cochrane Reviews, ‗Evidence Based Medicine‘-reviews, meta-analyses and expert 
consensus statements in the field of dementia research recommend more research. As recent 
years have showen, there is increasing interest in the research community and from politicians 
in contributitions augmenting knowledge about the aetiology, pathology, prevention and 
treatment of the different forms of dementia and their behavioural and psychological 
symptoms.  
  Until now, the focus has mainly been on psychosocial factors contributing to agitation 
and other behavioural challenges. Concerning drug treatments, it is essential to get more 
insight into the biological processes of dementia, and that is the only way that drug treatments 
can be designed more specifically. This is still a widely unexplored field. 
  The past 30 years have seen many attempts to demonstrate the safety and efficacy of 
drugs for dementia, predominantly those aiming to treat the symptoms 
757
. Most of the benefit 
of the dementia drugs, such as tacrine, donepezil, rivastigmine, galantamine and memantine, 
has been in slowing down the progress of the symptoms rather than producing an 
improvement over the baseline condition of the patient. There have also been attempts at 
arresting the progress of AD, but so far all have failed. Studies treating agitation with 
psychosocial intervention strategies and drugs showed limited effectiveness and a high 
placebo response. Especially in drug trials, there has been quite an alarming number and 
severity of adverse events.  
So far we have only just begun to understand the dementia diseases and persons with 
dementia and are far from treating them properly. Gauthier and Schelters proposed to start      
   ―clinical trials where proof of concept can be done in populations enriched with     
   certain clinical and biological characteristics, including cognitive symptoms, APOE ε4    
  carrier status, CSF AD profile, and hippocampal atrophy. Success in these studies    
   would require a confirmatory follow-up study with more broadly representative    
   populations. These two studies (proof of concept and confirmatory) should satisfy    
    regulatory requirements for efficacy. Designs such as delaying disease milestones  
    should receive equal considerations to fixed endpoint studies, which are currently    
   favoured but not convincing to payers and users.‖  
As the changes in the brain in AD start decades before a dementia diagnosis can be made, 
efforts to find ways to prevent the development of dementia pathology as early as possible 
should be reenforced. Delaying the onset of dementia by treating preclinical states as 
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subjective cognitive impairment and mild cognitive impairment, might make it possible to 
prevent most of the non-cognitive symptoms such as agitation. Could we learn something 
from coronary heart disease prevention and the partly successful strategies there? Prevention 
should always be the primary goal in medicine. 
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